---
document_datetime: 2025-03-20 17:01:00
document_pages: 76
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/darzalex-h-c-004077-ii-0030-epar-assessment-report-variation_en.pdf
document_name: darzalex-h-c-004077-ii-0030-epar-assessment-report-variation_en.pdf
version: success
processing_time: 160.3653727
conversion_datetime: 2025-12-19 05:55:43.092806
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

12 December 2019 EMA/CHMP/22749/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Darzalex

International non-proprietary name: daratumumab

Procedure No. EMEA/H/C/004077/II/0030

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                 | ..............................................5                                                         |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5 |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................5               |                                                                                                         |
| 2. Scientific discussion                                                                                                   | ................................................................................6                       |
| 2.1. Problem statement                                                                                                     | ...............................................................................................6        |
| 2.1.1. Disease or condition...........................................................................................6    |                                                                                                         |
| 2.1.2. Epidemiology and risk factors, screening tools/prevention                                                           | ......................................6                                                                 |
| 2.1.3. Biologic features: Aetiology and pathogenesis                                                                       | .......................................................7                                                |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                | ..............................................7                                                         |
| 2.1.5. Management.....................................................................................................8    |                                                                                                         |
| 2.2. Non-clinical aspects                                                                                                  | ............................................................................................10          |
| 2.3. Clinical aspects                                                                                                      | ..................................................................................................11    |
| 2.3.1. Introduction....................................................................................................11  |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................12     |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................13        |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................14     |                                                                                                         |
| 2.3.5. Discussion on clinical pharmacology...................................................................17            |                                                                                                         |
| 2.3.6. Conclusions on clinical pharmacology.................................................................18             |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                     | ..................................................................................................18    |
| 2.4.1. Dose response study(ies)                                                                                            | .................................................................................18                     |
| 2.4.2. Main study(ies)                                                                                                     | ...............................................................................................19       |
| 2.4.3. Discussion on clinical efficacy............................................................................47       |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................49         |                                                                                                         |
| 2.5. Clinical safety                                                                                                       | ....................................................................................................49  |
| 2.6. Discussion on clinical safety.................................................................................70      |                                                                                                         |
| 2.6.1. Conclusions on clinical safety                                                                                      | ............................................................................70                          |
| 2.6.2. PSUR cycle                                                                                                          | .....................................................................................................70 |
| 2.7. Risk management plan........................................................................................70        |                                                                                                         |
| 2.8. Update of the Product information                                                                                     | ........................................................................72                              |
| 2.8.1. User consultation.............................................................................................72    |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................73                    |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                   | ...........................................................................................73           |
| 3.2. Disease or condition                                                                                                  | ...........................................................................................73           |
| 3.2.1. Available therapies and unmet medical                                                                               | need.......................................................73                                           |
| 3.2.2. Main clinical studies                                                                                               | .........................................................................................73             |
| 3.3. Favourable effects                                                                                                    | ..............................................................................................73        |
| 3.4. Uncertainties and limitations about favourable effects.............................................74                 |                                                                                                         |
| 3.5. Unfavourable effects...........................................................................................74     |                                                                                                         |
| 3.6. Uncertainties and limitations about unfavourable effects                                                              | .........................................74                                                             |
| 3.7. Effects Table......................................................................................................74 |                                                                                                         |
| 3.8. Benefit-risk assessment and discussion.................................................................75             |                                                                                                         |
| 3.8.1. Importance of favourable and unfavourable effects..............................................75                   |                                                                                                         |
| 3.8.2. Balance of benefits and risks.............................................................................75        |                                                                                                         |
| 3.8.3. Additional considerations on the benefit-risk balance                                                               | ...........................................75                                                           |

<div style=\"page-break-after: always\"></div>

3.9. Conclusions .......................................................................................................  75

4. Recommendations .................................................................................  75

5. EPAR changes  ........................................................................................  76

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR

adverse drug reaction

AE

adverse event

ASCT

autologous stem cell transplant

CHMP

Committee for Medicinal Products for Human Use

CI

confidence interval

CMH

Cochran-Mantel-Haenszel

CR

complete response

DVMP

daratumumab + bortezomib (VELCADE) + melphalan + prednisone

DVTd

daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone

ECOG

Eastern Cooperative Oncology Group

EMN

European Myeloma Network

FDA

Food and Drug Administration

G-CSF

granulocyte colony-stimulating factor

HDT

high-dose chemotherapy

HOVON

Dutch-Belgian Cooperative Trial Group for Hematology Oncology

HR

hazard ratio

ICH

International Conference on Harmonisation

IFM

Intergroupe Francophone Du Myelome

IMiD

immunomodulatory drug

IMWG

International Myeloma Working Group

IPW

Inverse Probability Weighting

IRR

infusion-related reaction

ISS

International Staging System

ITT

intent-to-treat

IV

intravenous

MRD

minimal residual disease

NCCN

National Comprehensive Cancer Network

ORR

overall response rate

OS

overall survival

PAD

bortezomib (VELCADE) + doxorubicin + dexamethasone

PFS

progression-free survival

PI

proteasome inhibitor

Rd

lenalidomide + dexamethasone

SC

subcutaneous

sCR

stringent complete response

TEAE

treatment emergent adverse event

US

United States

VCd

bortezomib (VELCADE) + cyclophosphamide + dexamethasone

VMP

bortezomib (VELCADE) + melphalan + prednisone

VRd

bortezomib (VELCADE) + lenalidomide + dexamethasone

VTd

bortezomib (VELCADE) + thalidomide + dexamethasone

VGPR

very good partial response

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International NV submitted to the European Medicines Agency on 27 March 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIA         |

Extension of indication in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT) for Darzalex; as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP (Version 6.4) has also been submitted.

Darzalex was designated as an orphan medicinal product EU/3/13/1153 on 24 May 2016. Darzalex was designated as an orphan medicinal product in the following indication: treatment of plasma cell myeloma.

The new indication, which is the subject of this application, falls within the above mentioned orphan designation.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0264/2017 on the granting of a (product-specific) waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Protocol assistance

The MAH received Protocol Assistance from the CHMP on 24 July 2014 (EMEA/H/SA/2456/4/2014/PA/II). The CHMP agreed to study design, treatment regimens and endpoints for the pivotal study MMY3006.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Jorge Camarero Jiménez

<div style=\"page-break-after: always\"></div>

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 27 March 2019     |
| Start of procedure:                                  | 27 April 2019     |
| CHMP Co-Rapporteur Assessment Report                 | 2 July 2019       |
| CHMP Rapporteur Assessment Report                    | 21 June 2019      |
| PRAC Rapporteur Assessment Report                    | 21 June 2019      |
| PRAC members comments                                | 3 July 2019       |
| Updated PRAC Rapporteur Assessment Report            | 4 July 2019       |
| PRAC Outcome                                         | 11 July 2019      |
| CHMP members comments                                | 15 July 2019      |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 19 July 2019      |
| Request for supplementary information (RSI)          | 25 July 2019      |
| CHMP Rapporteur Assessment Report                    | 30 September 2019 |
| CHMP members comments                                | 05 October 2019   |
| Updated CHMP Rapporteur Assessment Report            | 11 October 2019   |
| 2 nd Request for supplementary information (RSI)     | 17 October 2019   |
| CHMP Rapporteur Assessment Report                    | 28 November 2019  |
| CHMP members comments                                | 02 December 2019  |
| Updated CHMP Rapporteur Assessment Report            | 05 December 2019  |
| Opinion                                              | 12 December 2019  |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

Treatment of adult patients with newly diagnosed multiple myeloma (MM) who are eligible for autologous stem cell transplant.

## 2.1.2. Epidemiology and risk factors, screening tools/prevention

Multiple myeloma is estimated to represent 0.9% of all cancers worldwide (Bray 2018). The incidence of multiple myeloma increases steadily with age, with a median age at diagnosis of approximately 65 to 72 years (Howlader 2017; Merz 2017; Song 2016). The annual number of new cases of multiple myeloma diagnosed is estimated to be approximately 48,297 in Europe (IARC/WHO 2018). The estimated world-wide 5-year prevalence is approximately 230,000 patients (Ruzafa 2016). Major strides have been made in the treatment of multiple myeloma in the last decade. Despite the availability of new therapies, 106,105 deaths were estimated worldwide due to multiple myeloma in 2018 (Bray 2018), and annually, approximately 24,300 deaths are estimated in Europe (Ferlay 2015).

<div style=\"page-break-after: always\"></div>

## 2.1.3. Biologic features: Aetiology and pathogenesis

Multiple  myeloma  is  a  malignant  disorder  of  the  plasma  cells,  characterised  by  uncontrolled  and progressive proliferation of a plasma cell clone. The proliferation of myeloma cells causes displacement of the normal bone marrow leading to dysfunction in normal hematopoietic tissue and destruction of the normal bone marrow architecture (Kyle 2003), resulting in progressive morbidity and eventual mortality.

The precise etiology of MM has not yet been fully established. Roles have been suggested for a variety of factors, including genetic causes, environmental or occupational causes, MGUS, radiation, chronic inflammation and infection. A variety of cytogenetic changes in oncogenes and tumor suppressors have been  associated  with  MM.  This  genetic  heterogeneity  contributes  to  the  rapid  emergence  of  drug resistance in MM (Niels van Nieuwenhuijzen et al   2018). Increasing evidence also suggests that the bone marrow microenvironment of tumor cells plays a pivotal role in the pathogenesis of myelomas. Finally, the  role  of  cytokines  in  the  pathogenesis  of  MM  is  also  considered  as  Interleukin  (IL)-6  is  also  an important factor promoting the in vitro growth of myeloma cells. Other cytokines are tumor necrosis factor and IL-1b (Fairfield H et al., 2016).

Risk factors include the previous development of monoclonal gammopathy of undetermined significance (MGUS), being of male sex, older age, and African American racial background. Secondary risk factors include exposure to chronic, low-grade inflammation, pre-existing and/or chronic immunodeficiency, and, potentially, the presence of known inflammatory diseases or conditions (Fairfield H et al., 2016).

The  pathophysiologic  basis  for  the  clinical  sequelae  of  MM  involves  the  skeletal  (osteolytic  lesions, anemia, and hypercalcemia), hematologic (neutropenia, anemia, and thrombocytopenia), renal (direct tubular injury, amyloidosis, or involvement by plasmacytoma), and nervous system (adiculopathy and/or cord compression).

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

Multiple myeloma is a heterogeneous and genetically complex disease with a course that varies depending on both disease- and host-related factors. Typically, a chronic phase lasting several years is followed by an aggressive terminal phase. The coexistence of different tumour subclones at baseline displaying different drug sensitivities ultimately contributes to the development of drug resistance and disease progression (Barlogie 2014). Multiple myeloma is fatal and incurable, as all patients eventually relapse after treatment.

MM can range from asymptomatic to severely symptomatic with complications requiring emergent treatment. Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anaemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and renal failure.

MM begins as monoclonal gammopathy of undetermined significance (MGUS), progresses to smouldering (or indolent) MM (SMM) and finally becomes overt (symptomatic) myeloma, resulting in BM infiltration and osteolytic lesions. SMM progresses to myeloma at a rate of 10% per year over the first 5 years following diagnosis, 3% per year over the following 5 years, and 1.5% per year thereafter.

The criteria for diagnosis of MM were updated in 2014 by the International Myeloma Working Group (IMWG) (Rajkumar SV et al.,   2014). The diagnosis requires ≥ 10% clonal BM plasma cells or biopsyproven bony or extra-medullary plasmacytoma and any of the following myeloma-defining events. Myeloma-defining events include the following:

- Serum calcium level &gt;0.25 mmol/L (&gt;1 mg/dL) higher than the upper limit of normal or &gt;2.75 mmol/L (&gt;11 mg/dL)

<div style=\"page-break-after: always\"></div>

- Renal insufficiency (creatinine &gt;2 mg/dL [&gt;177 μmol/L] or creatinine clearance &lt; 40 mL/min)
- Ana emia (hemoglobin &lt; 10 g/dL or hemoglobin &gt;2 g/dL below the lower limit of normal)
- One or more osteolytic bone lesions on skeletal radiography, CT, or PET-CT
- Clonal bone marrow plasma cells ≥ 60%
- Abnormal serum free light chain (FLC) ratio ≥ 100 (involved kappa) or &lt; 0.01 (involved lambda)
- One or more focal &gt;5 mm lesions on MRI scans

Active disease may also be indicated by repeated infections, amyloidosis, or hyperviscosity.

MM is a heterogeneous disease, with survival ranging from 1 year to more than 10 years. Median survival in unselected patients with MM is 3 years. The 5-year relative survival rate is 46.6% (SEER Stat Fact Sheets et al., 2019). Survival is higher in younger people and lower in the elderly (Key Statistics About Multiple Myeloma. American Cancer Society    2019). Poor prognostic factors include the following: Tumor mass, Hypercalcemia, Bence Jones proteinemia, Renal impairment (i.e. stage B disease or creatinine level &gt;2 mg/dL at diagnosis).

The International Staging System (PR Greipp    et al., 2005) provides improved prognosis from readily available tests of serum concentrations of β2 -microglobulin and albumin. It has been validated in several clinical trials and is undergoing assessment for prognostic value with additional biological factors.

Table 1 . International Staging System

|           | Concentration of components in serum                                                     |   Median survival (months) |
|-----------|------------------------------------------------------------------------------------------|----------------------------|
| Stage I   | β2 - microglobulin ≤3·5 mg/L and albumin ≥3·5 g/dL                                       |                         62 |
| Stage II  | β2 - microglobulin <3·5 mg/L and albumin <3·5 g/dL, or β2 - microglobulin 3·5 - 5·5 mg/L |                         44 |
| Stage III | β2 - microglobulin >5·5 mg/L                                                             |                         29 |

## 2.1.5. Management

At diagnosis, newly diagnosed patients are categorised into 2 subpopulations defined by age, comorbidity and suitability for high-dose chemotherapy.

- Patients who are younger and considered fit and eligible for ASCT will receive induction therapy followed by high-dose chemotherapy (HDT) with ASCT (Kumar 2018; Gay 2018; Moreau 2017). This is the standard of care worldwide and in agreement with international guidelines: European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN)).
- Patients considered ineligible to HDT and ASCT are usually older, more fragile with comorbidities and will usually receive less intensive and less toxic therapy.

Induction regimens are given with the intention of reducing the plasma cell disease burden before HDT, Triplets  such  as  VTd,  bortezomib  +  cyclophosphamide  +  dexamethasone  (VCd),  bortezomib  + doxorubicin + dexamethasone (PAD) or VRd are the current standard of care for induction therapy. In Europe, VTd and VCd are the most used regimens with 4 to 6 courses typically given before transplant.

<div style=\"page-break-after: always\"></div>

Overall, bortezomib-based induction regimens have demonstrated significant improvements in response, PFS and OS in the induction setting, compared with non-bortezomib-based induction. Bortezomib-based induction  regimens  are  generally  well-tolerated  with  a  higher  rate  of  peripheral  neuropathy  but  no apparent increase in risk of death (Sonneveld 2013). The occurrence of peripheral neuropathy can be decreased substantially with subcutaneous (SC) administration of bortezomib (Gay 2018).

Several trials have shown that consolidation, i.e. a further short intense period of treatment after HDT and ASCT, is improving the depth of response (Lee 2016) and PFS (Sonneveld 2016; Sonneveld 2018). VTd consolidation (2 cycles) improves response rates and PFS (Cavo 2012; Leleu 2013) and induces molecular  remissions  in  up  to  60%  of  patients  (Ladetto 2010;  Terragna 2010).  Guidelines  from  the European Myeloma Network (EMN) and the National Comprehensive Cancer Network (NCCN) suggests different consolidation regimens, including VTd or VRd (Kumar 2018, Gay 2018).

Despite  the  availability  of  new  therapies,  multiple  myeloma  remains  incurable,  characterised  by successive relapses, less and shorter duration of response until the disease becomes refractory. Hence there is a need for further treatment options that can lead to deeper responses pre- and post-transplant, ultimately resulting in improved long-term outcomes for patients, without adding substantially to the toxicity of the regimen.

## About the product

Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to the CD38 protein expressed at a high level on the surface of multiple myeloma tumour cells, as well as other cell types and tissues at various levels. CD38 protein has multiple functions such as receptor mediated adhesion, signalling and enzymatic activity. Daratumumab has been shown to potently inhibit the in vivo growth of CD38expressing tumour cells. In vitro studies suggest that daratumumab can induce tumour cell lysis through complement-dependent  cytotoxicity,  antibody-dependent  cell-mediated  cytotoxicity  and  antibodydependent  cellular  phagocytosis  in  malignancies  expressing  CD38.  A  subset  of  myeloid  derived suppressor  cells  (CD38+MDSCs),  regulatory  T  cells  (CD38+Tregs)  and  B  cells  (CD38+Bregs)  are decreased by daratumumab mediated cell lysis. T cells (CD3+, CD4+, and CD8+) are also known to express CD38 depending on the stage of development and the level of activation. Significant increases in  CD4+  and  CD8+  T  cell  absolute  counts,  and  percentages  of  lymphocytes,  were  observed  with daratumumab treatment in peripheral whole blood and bone marrow. In addition, T-cell receptor DNA sequencing verified that T-cell clonality was increased with daratumumab treatment, indicating immune modulatory effects that may contribute to clinical response.

Daratumumab induced apoptosis in  vitro after  Fc  mediated  cross-linking.  In  addition,  daratumumab modulated CD38 enzymatic activity, inhibiting the cyclase enzyme activity and stimulating the hydrolase activity. The significance of these in vitro effects in a clinical setting, and the implications on tumour growth, are not well-understood.

The recommended dose is DARZALEX 16 mg/kg body weight administered as an intravenous infusion according to the following dosing schedule in Table 3.

Table 2: DARZALEX dosing schedule in combination with bortezomib, thalidomide and dexamethasone ([VTd]; 4-week cycle dosing regimen)

| Treatment phase                          | Weeks                                    | Schedule                                 |
|------------------------------------------|------------------------------------------|------------------------------------------|
| Induction                                | Weeks 1 to 8                             | weekly (total of 8 doses)                |
|                                          | Weeks 9 to 16 a                          | every two weeks (total of 4 doses)       |
| Stop for high dose chemotherapy and ASCT | Stop for high dose chemotherapy and ASCT | Stop for high dose chemotherapy and ASCT |
| Consolidation                            | Weeks 1 to 8 b                           | every two weeks (total of 4 doses)       |

- a First dose of the every-2-week dosing schedule is given at Week 9
- b First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT

<div style=\"page-break-after: always\"></div>

The dose and schedule of medicinal products administered with Darzalex are provided in section 5.1 of the SmPC.

## Type of Application and aspects on development

Daratumumab is approved in the relapsed and refractory setting as monotherapy for the treatment of multiple myeloma patients whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy. It is also approved in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone in the relapse setting and in combination with lenalidomide and dexamethasone, or bortezomib, melphalan and  prednisone  in  newly  diagnosed  multiple  myeloma  patients,  ineligible  for  autologous  stem  cell transplant (ASCT).

This variation application is an extension of indication as follows:

DARZALEX is indicated in combination with bortezomib, thalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

The  current  submission  is  supported  by  the  Phase  3  study  MMY3006,  where  D-VTd  (Daratumumab bortezomib,  thalidomide  and  dexamethasone)  was  compared  with  VTd  alone  as  induction  and consolidation treatment of patients with newly diagnosed multiple myeloma who are eligible for ASCT. Study MMY3006 is being conducted in 2 parts: evaluation of induction/ASCT/consolidation in Part 1 and evaluation  of  maintenance  or  observation  in  Part  2.  Only  results  from  Part 1  are  included  in  this submission. Part 2 of the Study is still ongoing and will be reported separately.

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant

- Tabular overview of clinical studies

<!-- image -->

| Study Iype                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study ID EudraCT Number First Patient First Visit/ Completion date (day Month year) Study Status                                                                                                                                                                                                                           | Country(ies): Number of Centers                                                                                                                                                                                                                                                                                            | Phase Study Description/Design, Study Population Primary Objective(s)                                                                                                                                                                                                                                                          | Total Number of Subjects                                                                                                                                                                                                                                                                                                   | StudyDrug(s):Formulation (Route of Administration) Dose Regimen Durationof Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Number of Subjects Treated (by Treatment Group)                                                                                                                                                                                                                                                                            | Type of Study Report Approved Date CTD Location of Report or Publication                                                                                                                                                                                                                                                   |
| Efficacy andSafety Controlled ClinicalStudies                                                                                                                                                                                                                                                                              | Efficacy andSafety Controlled ClinicalStudies                                                                                                                                                                                                                                                                              | Efficacy andSafety Controlled ClinicalStudies                                                                                                                                                                                                                                                                                  | Efficacy andSafety Controlled ClinicalStudies                                                                                                                                                                                                                                                                              | Efficacy andSafety Controlled ClinicalStudies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Efficacy andSafety Controlled ClinicalStudies                                                                                                                                                                                                                                                                              | Efficacy andSafety Controlled ClinicalStudies                                                                                                                                                                                                                                                                              |
| 54767414MMY3006 2014-004781-15 Synopsis 22 Sep 2015/ 19 Jun 2018 (clinical cutoff for Part 1) Ongoing                                                                                                                                                                                                                      | Belgium:13 France : 70 Luxembourg: 1a Netherlands: 28                                                                                                                                                                                                                                                                      | Phase:3 Randomized,open-label,active- controlled, parallel-group. multicenter study Subjectswithnewly diagnosed multiple myeloma who are eligible for high-dose therapy and ASCT. Todetermineif the additionof daratumumab toVId increased the proportion of subjects achieving sCR 100 days post- ASCT compared withVTd alone | Treated: 1074                                                                                                                                                                                                                                                                                                              | Daratumumab:solution (S) Study has 2 parts: Part 1: Induction/ASCT/Consolidation Phase (1:1 randomization) Part2:MaintenancePhase(1:1Re-randomizationof subjects achieving at least aPR after consolidation) All cycles were 28 days duration Part 1: Arm A: VTd induction therapy (4 cycles), followed by ASCT,followedby2cyclesofVTd consolidation Arm B: DVTd induction therapy (4 cycles), followed byASCT, followed by2 cycles of DVTd consolidation. Daratumumab: (16 mg/kg) IV infusion once every week for8weeks (Induction Cycle1-2),then once every 2 weeks for8weeks (InductionCycle 3-4), and following ASCT once every 2 weeks for 8 weeks (consolidation Cycle 5-6). | DVTd:536 VTd:538                                                                                                                                                                                                                                                                                                           | CSR 20 Feb 2019 Module 5.3.5.1                                                                                                                                                                                                                                                                                             |
| ASCT=autologous stem cell transplant; CSR=Clinical Study Report;DVTd=daratumumab +bortezomib+ thalidomide + dexamethasone IV=intravenous;PO=orally,PR=partial response;SC=subcutaneous; sCR=stringent complete rtesponse; VTd=bortezomib + thalidomide + dexamethasone. Sitereceived study drug,but didnot enroll subjects | ASCT=autologous stem cell transplant; CSR=Clinical Study Report;DVTd=daratumumab +bortezomib+ thalidomide + dexamethasone IV=intravenous;PO=orally,PR=partial response;SC=subcutaneous; sCR=stringent complete rtesponse; VTd=bortezomib + thalidomide + dexamethasone. Sitereceived study drug,but didnot enroll subjects | ASCT=autologous stem cell transplant; CSR=Clinical Study Report;DVTd=daratumumab +bortezomib+ thalidomide + dexamethasone IV=intravenous;PO=orally,PR=partial response;SC=subcutaneous; sCR=stringent complete rtesponse; VTd=bortezomib + thalidomide + dexamethasone. Sitereceived study drug,but didnot enroll subjects     | ASCT=autologous stem cell transplant; CSR=Clinical Study Report;DVTd=daratumumab +bortezomib+ thalidomide + dexamethasone IV=intravenous;PO=orally,PR=partial response;SC=subcutaneous; sCR=stringent complete rtesponse; VTd=bortezomib + thalidomide + dexamethasone. Sitereceived study drug,but didnot enroll subjects | ASCT=autologous stem cell transplant; CSR=Clinical Study Report;DVTd=daratumumab +bortezomib+ thalidomide + dexamethasone IV=intravenous;PO=orally,PR=partial response;SC=subcutaneous; sCR=stringent complete rtesponse; VTd=bortezomib + thalidomide + dexamethasone. Sitereceived study drug,but didnot enroll subjects                                                                                                                                                                                                                                                                                                                                                         | ASCT=autologous stem cell transplant; CSR=Clinical Study Report;DVTd=daratumumab +bortezomib+ thalidomide + dexamethasone IV=intravenous;PO=orally,PR=partial response;SC=subcutaneous; sCR=stringent complete rtesponse; VTd=bortezomib + thalidomide + dexamethasone. Sitereceived study drug,but didnot enroll subjects | ASCT=autologous stem cell transplant; CSR=Clinical Study Report;DVTd=daratumumab +bortezomib+ thalidomide + dexamethasone IV=intravenous;PO=orally,PR=partial response;SC=subcutaneous; sCR=stringent complete rtesponse; VTd=bortezomib + thalidomide + dexamethasone. Sitereceived study drug,but didnot enroll subjects |

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

The clinical pharmacology supporting the present application is based on pharmacokinetic data from Study MMY3006, as well as clinical pharmacologic data from previous studies totally including more than 1,000 patients treated with daratumumab.

## Absorption

Absorption studies have not been conducted considering that daratumumab is administered as an IV infusion.

## Distribution

The mean±SD volume of distribution in subjects who received 16 mg/kg was 90.19±43.40 mL/kg after the  first  dose  and  59.51±54.68  mL/kg  following  repeat  dosing  (Study  GEN501);  Japanese  subjects receiving 16 mg/kg exhibited a similar volume of distribution of 57.97±3.29 mL/kg (Study MMY1002). As described by the monotherapy PPK model, the estimate for the central volume of distribution is 56.98±18.07 mL/kg. Overall, these data suggest that daratumumab is primarily localised to the vascular system with limited extravascular tissue distribution.

## Elimination

As shown previously in the monotherapy studies, daratumumab clearance decreased with increasing dose and with multiple doses. After the first infusion, mean clearance decreased from 1.06 mL/h/kg in the 2 mg/kg group to 0.29 mL/h/kg in the 24 mg/kg group; after repeat dosing, clearance decreased from 0.59 mL/h/kg (n=1) in the 2 mg/kg group to 0.16 mL/h/kg in the 24 mg/kg group (Study GEN501). Following the first administration at the approved dose of 16 mg/kg, clearance was 0.42±0.42 mL/h/kg and  the  T½  was  216±104  hours  (9.0±4.3  days).  Following  repeated  administration  of  16  mg/kg, daratumumab  clearance  decreased  to  0.30±0.12  mL/h/kg  and  T½  increased  to  255±216  hours (10.6±9.0 days) (Study GEN501).

## Dose proportionality and time dependencies

## Dose Proportionality

Following the first administration of daratumumab ranging from 0.005 to 24 mg/kg, Cmax increased in an approximately dose-proportional manner for doses ≥ 1 mg/kg. After repeat dosing, Cmax increased in  a  greater than dose-proportional manner. AUC also increased in a greater than dose-proportional manner after both the first and last dose. Consistent with the monotherapy data, in Study GEN503, Cmax following the first infusion increased in approximate proportion to the increasing daratumumab dose of 2 to 16 mg/kg daratumumab and AUClast increased in a greater than dose-proportional manner after the first dose. These findings are consistent with target-mediated clearance.

As reported for monotherapy, mean clearance following the first dose decreased with increasing dose, from 1.50±0.96 mL/h/kg in the 1 mg/kg cohort to 0.29±0.15 mL/h/kg in the 24 mg/kg cohort. This trend  for  decreasing  clearance  with  increased  dose  was  also  evident  following  repeat  dosing,  from 6.72±6.18 mL/h/kg in the 0.5 mg/kg cohort to 0.16±0.08 mL/h/kg in the 24 mg/kg cohort. Following the first administration at the approved dose of 16 mg/kg, clearance was 0.32±0.13 mL/h/kg and 0.10 mL/h/kg in the 1 subject with the parameter estimated after repeat dosing. Due to the evident nonlinear PK, statistical assessment of dose proportionality was not performed.

## Time Dependency

Clearance of daratumumab also decreased with multiple doses in the monotherapy studies: after the first infusion, mean clearance decreased from 1.06 mL/h/kg in the 2 mg/kg group to 0.29 mL/h/kg in the 24 mg/kg group; after the last infusion, mean clearance decreased from 0.59 mL/h/kg in the 2

<div style=\"page-break-after: always\"></div>

mg/kg group to 0.16 mL/h/kg in the 24 mg/kg group. Following the first administration at the approved dose of 16 mg/kg, clearance was 0.32±0.13 mL/h/kg (mean±SD) and 0.10 mL/h/kg in the 1 subject with  the  parameter  estimated  after  repeat  dosing.  The  trend  of  decreasing  clearance  with  repeated dosing was also evident in Part 2 of Study GEN501 and Study MMY1002.

## Comparison of DVTd Combination in MMY3006 and Previous Monotherapy and Combination Therapies

In Study MMY3006, daratumumab serum concentrations were evaluated pre-dose, on Cycle 1 Day 1 of Part 1 and at the end of induction/ASCT/consolidation treatment in Part 1, just before initiation of the maintenance  phase  at  the  time-points.  A  total  of  302  subjects  were  included  in  the  PK-evaluable population  (subjects  who  received  at  least  1  dose  of  daratumumab  and  had  at  least  1  serum daratumumab concentration value after the first infusion).

When comparing results from the present combination study (Study MMY3006) with the results from the monotherapy  studies,  similar  Ctrough  values  are  observed.  In  the  present  study,  the  pre-dose daratumumab concentration (mean±standard deviation [SD]) at the end of treatment in Part 1, (thus following  multiple  doses  of  daratumumab)  was  219±93.3  μg/mL.  In  the  monotherapy  studies,  the observed  values  at  a  similar  time-point  (every  4-week  dosing  at  Cycle  12,  Day  1  preinfusion)  was 224±169 μg/mL (Study GEN503), and in the combination studies following the first dose of 16 mg/kg of daratumumab in combination studies of D-VMP, mean end of infusion conce ntrations were 266.72 μg/mL (Study  MMY3007)  and  332.16  μg/mL  (Study  MMY1001),  respectively.  In  Study  MMY3003  where daratumumab was combined with lenalidomide and dexamethasone (DRd), Ctrough at Cycle 12, Day 1 was 255±124 μg/mL. Similar C trough values was also confirmed at the PK simulation, where the predicted Ctrough value was 227.54 ±178.57 μg/mL.

## Special populations

No special population studies for hepatic or renal dysfunction with daratumumab have been presented in this application.

## Pharmacokinetic interaction studies

No dedicated clinical drug-drug interaction studies were presented. Since there is no overlapping pathway of elimination, no interactions are expected between daratumumab and small-molecule drugs including bortezomib, thalidomide and dexamethasone.

## 2.3.3. Pharmacodynamics

## Mechanism of action

No new data on the mechanism of action has been presented in this application.

Daratumumab is a human IgG mAb that binds with high affinity to CD38, a transmembrane glycoprotein expressed on tumor cells, and induces tumor cell death through multiple mechanisms of action. These mechanisms of  action  include  several  immune-mediated  activities,  including  complement-dependent cytotoxicity,  antibody-dependent  cellular  cytotoxicity,  antibody-dependent  cellular  phagocytosis,  and direct cytotoxicity by induction of apoptosis by Fc gamma receptor mediated crosslinking of tumor-bound mAbs  (Overdijk  2016).  Translational  biomarker  studies  of  samples  from  subjects  treated  with daratumumab  in  Phase  1  and  Phase  2  studies  (Studies  GEN501  and  MMY2002,  respectively)  have revealed previously unknown immunomodulatory effects of daratumumab (Krejcik 2016). Daratumumab leads to the rapid and sustained elimination of highly immunosuppressive subsets of CD38+ regulatory T  cells,  CD38+  myeloid-derived  suppressor  cells,  and  CD38+  regulatory  B  cells  (Krejcik  2016).  The elimination of these immunosuppressive cells, modulation of CD38 enzymatic activity, and destruction of the malignant myeloma cells are thought to lead to the clonal expansion of CD8+ and CD4+ T cells

<div style=\"page-break-after: always\"></div>

(Chiu  2016).  Altogether,  daratumumab's  converging  mechanisms  of  actions  are  hypothesised  to synergistically lead to the deep responses observed in patients.

## Primary and secondary pharmacology

## Immunogenicity

A summary of anti-daratumumab antibody status for Part 1 of Study MMY3006 is shown inTable 3. None (0%) of the 301 subjects who were treated with DVTd and had 1 or more samples obtained after their first  daratumumab  administration  were  positive  for  anti-daratumumab  antibodies.  The  majority  of immunogenicity-evaluable subjects (n=299) had PK concentrations (at all time-points) below the drug tolerance limit of the assay (630 μg/mL). One of 302 subjects in the PK -evaluable population was not evaluable for anti-daratumumab antibodies because this subject only had a baseline sample and no sample was obtained after the first daratumumab administration when the PK data cut-off occurred.

Table 3 Summary of Anti-daratumumab antibodies status

Table 5: SummaryofAnti-daratumumabAntibodiesStatus;ImmuneResponse-evaluableAnalysisSet (Study 54767414MIMIY3006)

|                                                       | Induction/ASCT/Consolidation DVTd n (%)   |
|-------------------------------------------------------|-------------------------------------------|
| Analysis set: immune response-evaluable               | 302                                       |
| Subjects with appropriate sample a                    | 301                                       |
| Subjects positive for anti-daratumumab antibodies b.c | 0                                         |
| Subjects negative for anti-daratumumab antibodies b   | 301 (100.0%)                              |

a Subjects with appropriate samples had a baseline sample and 1 or more samples obtained after their first daratumumabadministration,based oninformation available at thepharmacokineticdatacutoff date.

Abbreviations: ASCT=autologous stem cell transplantation; DVTd=daratumumab-bortezomib-thalidomidedexamethasone.

' Denominator is subjects with appropriate sample.

Includes all subjects who had at least 1 positive sample at any time after start of treatment and baseline positive subjects who had posttreatment sample titers increase at least 2-fold compared to baseline.

## 2.3.4. PK/PD modelling

## Population Pharmacokinetic Analysis

The pharmacokinetics of daratumumab have been previously well characterised in monotherapy and various combination studies in subjects with multiple myeloma. The PK findings in previous monotherapy and  combination  studies  following  administration  of  multiple  doses  of  daratumumab  are  consistent. Therefore, a sparse PK sampling scheme was utilised in Study MMY3006 and a population PK simulation was conducted using previous population PK model(s) to confirm that the observed daratumumab PK profile  in  MMY3006  population  is  similar  to  the  predicted  pharmacokinetic  profile  based  on  previous models.

## Methods for Population Pharmacokinetic Analysis

A PPK model of daratumumab was developed to describe the PK characteristics of daratumumab in combination with VMP and to evaluate the influence of covariates on the disposition of daratumumab in subjects with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. In  addition,  PK  of  daratumumab  combined  with  VMP  was  compared  with  that  of  daratumumab monotherapy studies and the previous combination therapy studies.

The PPK analysis included combined data from a Phase 3 study (MMY3007) and the D-VMP combination arm of a Phase 1b (MMY1001). Serum concentration-time data of daratumumab were used for nonlinear

<div style=\"page-break-after: always\"></div>

mixed effects modelling using NONMEM (ICON plc, Version 7.3). The first-order conditional estimation with  the  INTERACTION  method  was  used.  Due  to  the  lack  of  overlapping  clearance  mechanism  for daratumumab  and  co-administered  small-molecule  combination  therapies,  no  direct  impact  of  the combination therapies on the PK of daratumumab is expected. Therefore, the previously developed base and final PPK models were used to fit the concentration-time data of daratumumab. To compare the effects  of  covariates  on  exposure to daratumumab, subgroup analyses were conducted on predicted exposure metrics  derived from  simulation  of  daratumumab  PK  profiles  based  on  empirical  Bayesian estimates of individual PK parameters.

Furthermore, daratumumab serum concentrations were planned to be collected from all subjects treated with daratumumab in Study MMY3006 at the timepoints where immunogenicity (i.e. anti-daratumumab antibody) was assessed (i.e., pre-dose of Cycle 1, Day 1 at the end of treatment in Part 1 and when an infusionrelated  reaction  [IRR]  associated  with  daratumumab  administration  occurred)  given  that immunogenicity  assessment  was  a  secondary  endpoint  in  the  study.  The  daratumumab  serum concentration determined from these samples were used for interpreting immunogenicity data and for evaluating the exposure to daratumumab.

## Intrinsic and extrinsic Factors

Body weight, age, sex, race, renal impairment, baseline albumin, hepatic dysfunction categories using the  National  Cancer  In stitute  (NCI)  criteria  (based  on  aspartate  aminotransferase  [AST]  and  total bilirubin [TB]), and type of myeloma at baseline (IgG versus non -IgG) were considered as intrinsic factors to  be  examined for their potential impact on PK of daratumumab. Region of subject enrolment was evaluated as an extrinsic factor in the PPK analysis and Exposure to daratumumab compared between subgroups for baseline disease status (i.e., ECOG status at baseline) was evaluated as 'Other factors'.

Cox proportional hazard regression models, implemented in the 'survival' package in R (Therneau 2000), were used to explore the relationship between exposure metrics and the relative hazard of progression or  death  using  P-splines.  The  control  group  in  Study  MMY3007  was  used  as  the  reference  level  to calculate the relative hazard.

In  addition,  a  matched  case-control  analysis  was  conducted  to  assess  the  influence  of  potential imbalances of risk factors among subjects with different exposure quantiles (Yang 2013). The potential of unbalanced distribution of identified covariates (risk factors) among different exposure quantile was examined.

## Population Pharmacokinetic Analysis

The PPK analysis was based on 1,635 PK samples from 352 PPK-evaluable subjects with at least 1 evaluable  (concentration  above  the  lower  limit  of  quantification)  post-dose  sample.  The  observed concentration time data of daratumumab were adequately described by a 2-compartment PPK model with parallel linear and nonlinear Michaelis-Menten eliminations. The model was parameterised in terms of  non-specific  linear  clearance  (CL),  volume  of  distribution  in  the  central  compartment  (V1),  intercompartmental clearance (Q), volume of distribution in the peripheral compartment (V2), maximum rate of  the  saturable  target-mediated  drug  disposition  clearance  process  (Vmax),  and  daratumumab concentration (Km) associated with half of Vmax. The estimated CL value was similar to the clearance of non-specific endogenous IgG reported in the literature, and the estimated V1 value approached plasma volume.  The  ratio  of  the  steady-state  peak  concentration  after  every-4-week  dosing  and  the  peak concentration after the first dose was 2.06±0.61 (mean±SD).

## Effects of Covariates

A forest plot was constructed to compare the exposure (maximal trough concentration) of daratumumab in subgroups  defined  by  specific  covariates  (Figure  1).  The  preinfusion  serum  daratumumab

<div style=\"page-break-after: always\"></div>

concentration at the end of treatment in Part 1 indicates systemic exposure to daratumumab following multiple  doses  of  daratumumab,  and  is  generally  consistent  with  observations  from  previous monotherapy  and  combination  studies  after  accounting  for  periods  when  daratumumab  was  not administered  during  the  MMY3006  study  (including  ASCT  and  the  lag  time  prior  to  initiation  of  the maintenance phase).

Figure 1 Forest Plot of Subgroup Analyses on Percent Change relative to Reference Value predicted Maximal Trough (pre-infusion) concentrations

<!-- image -->

%changerelativetoreference

ECOG=Eastern Cooperative Oncology Group: IgG=immunoglobulin G.

Key: Solid blue circle represents mean and error bar represents 95% confidence interval. Dashed line represents no change at 0%. Numbers represent percent change, confidence interval, and number of subjects in the comparison groups. Gray shaded region represents ±25% from reference value.

Note: Analyses assumed that all subjects in Studies MMY1001 and MMY3007 received 16 mg/kg weekly for 6 weeks (6 doses). every 3 weeks for 48 weeks (16 doses), and then every 4 weeks thereafter. Maximal trough (preinfusion) concentration was derived as the trough concentration of the first dose of the every 3 dosing period.

The number of subjects in the reference group for each covariate: normal renal fumction (N=62); normal hepatic fumction (N=304); age &lt;65 yr (N=36); female (N=189); Non-white (N=51); other region (N=59); body weight 65.0 to 85.0 kg (N=172); normal albumin concentration (N=209); EC0G=0 (N=83); non-IgG myeloma (N=127).

Only 2 subjects had moderate hepatic impairment, and 2 subjects had severe renal impairment. These subjects are combined with subjects with mild hepatic impairment and moderate renal impairment, respectively, in this analysis.

years ≤ age &lt;75 years, n=214; and age ≥ 75 years, n=102).

<div style=\"page-break-after: always\"></div>

Sex:  No  clinically  important  influence  of  sex  on  the  exposure  to  daratumumab  was  observed.  The difference in exposure was approximately 9% between males (n=163) and females (n=189), although V1 of daratumumab in female subjects was approximately 13% lower than that of male subjects.

Race: Because 85% of subjects were white and there were only limited sample sizes in other race categories,  the  effect  of  race  was  evaluated  as  white  (n=301)  and  non-white  (n=51).  No  clinically important influence of race on the exposure to daratumumab was observed. The difference in exposure was approximately 9% between white and non-white subjects.

Region: The majority (83%) of subjects were from the European Union (EU). The effect of region was evaluated in EU (n=293) and Other (n=59). The difference in exposure was approximately 9% between EU and Other.

Renal Impairment: As only 2 subjects had severe rena l impairment (creatinine clearance [CRCL] &lt;30 mL/min), they were combined with subjects with moderate renal impairment (30 ≤ CRCL &lt;60 mL/min) in this analysis. The effect of renal impairment was evaluated in categories of normal renal function (CRCL ≥ 90 mL/min, n=62), mild renal impairment (60 ≤ CRCL  &lt;90  mL/min,  n=142),  and moderate/severe renal impairment (n=147). No clinically important differences ( ≤ 18%) in the exposure to daratumumab were observed between subjects with renal impairment and those with normal renal function.

Hepatic Impairment: As only 2 subjects had moderate hepatic impairment (TB &gt;1.5× to 3.0× upper limit of normal [ULN] as defined using the NCI criteria of hepatic dysfunction) and no subjects had severe hepatic impairment (TB &gt;3× ULN and any AST), the 2 subjects with moderate hepatic impairment were combined  with  subjects  with  mild  hepatic  impairment  (TB  1.0×  to  1.5×  ULN  or  AST  &gt;ULN)  in  this analysis. The effect of hepatic impairment was evaluated in categories of normal hepatic function (TB and AST ≤ ULN, n=304) and mild/moderate hepatic impairment (n=45). The exposures in subjects with mild/moderate hepatic  impairment  were  similar  with  subjects  who  had  normal  hepatic  function  and consistent with the findings based on previous studies. No clinically important differences in the exposure to  daratumumab  were  observed  between  subjects  with  hepatic  impairment  and  those  with  normal hepatic function as found in the monotherapy or the previous combination therapy study populations.

Baseline Albumin: No clinically important differences in the exposure to daratumumab were observed between  subjects  with  abnormal  albumin  and  those  with  normal  albumin  level.  The  exposure  to daratumumab was 20% lower in subjects with abnormal albumin level (&lt;35 g/L; n=143 ) compared with subjects who had normal albumin level ( ≥ 35 g/L; n=209). The difference in exposure had minimal impact on target saturation.

Type of Myeloma: No clinically important differences in the exposure to daratumumab were observed between  subjects  with  IgG  myeloma  and  non-IgG  myeloma.  The  exposure  to  daratumumab  was approximately 20% lower in the IgG multiple myeloma subjects (n=225) compared to the non-IgG subjects (n=127). The difference in exposure had minimal impact on target saturation.

## 2.3.5. Discussion on clinical pharmacology

The clinical pharmacology of daratumumab used as monotherapy is well established. Likewise, clinical pharmacology data for daratumumab when used in various combination treatments is also extensively described  including  more  than  1,000  patients.  Clinical  pharmacology  data  of  daratumumab  in combination treatment with DVTd derive from a single clinical study (Study MMY3006) with PK data from a total of 302 patients. However, as daratumumab serum concentrations were only collected at the time points where immunogenicity was assessed (pre-dose on Cycle 1 Day 1 and at end of treatment in Part 1), only one post-daratumumab treatment PK sample at the end of treatment in Part 1 was collected.

<div style=\"page-break-after: always\"></div>

None of the patients tested in the present study developed anti-daratumumab neutralising antibodies, which is reassuring.

The MAH has sufficiently justified  this  sparse  PK  data  collection  as  overall,  the  pharmacokinetics  of daratumumab are well-known both as monotherapy and in various combinations. Therefore, the aim was mainly 'to confirm that the observed daratumumab PK profile in MMY3006 population is similar to the predicted pharmacokinetic profile based on previous models.'. Information from a previous population PK analysis has been included in the present assessment report.

Overall,  there  is  no  new  data  with  regard  to  the  basic  pharmacokinetic  properties  of  daratumumab including absorption, distribution, metabolism, elimination and excretion. It is supported that as a mAb, the distribution of daratumumab is primarily localised to the vascular system, and the dose-dependent elimination (nonlinear characteristics) is consistent with target-mediated elimination (where clearance decreases as a function of dose).

The results confirmed, that there were no unexpected findings and that the observed daratumumab PK profile in MMY3006 population shows similar pattern to what has been observed both in the monotherapy and other combination-therapy studies.

It  was  agreed with the MAH that combination treatment with DVTd is not expected to interact with daratumumab. In accordance with this, the measured PK values seems to be similar between Study MMY3006 and the monotherapy studies as well as other combination treatment studies.

The pop-PK analysis reported in the present assessment report derives from the latest extension of indication procedure (Procedure No. EMEA/H/C/004077/II/0011, dated January 2018) and was based on 1,635 PK samples from 353 PK-evaluable patients (all receiving daratumumab at 16 mg/kg). Several covariates were investigated in the pop-PK analysis. Consistent with the results from the initial (monoand combination-therapy) pop-PK analyses, results from this latest pop-PK analysis where daratumumab was given in combination with VMP (thus D-VMP combination treatment) show that albumin level, type of myeloma and body weight were the covariates with the highest impact on the PK values. Numeric differences were also observed for gender and renal function, but these findings were expected to be a random  finding.  Importantly,  none  of  the  findings  from  previous  pop-PK  analyses  are  expected  to influence the recommended dose of daratumumab when given in the applied combination with DVTd.

With regards to the pharmacodynamics, no new data related to mechanism of action or QTc evaluation are presented. This is overall acceptable.

## 2.3.6. Conclusions on clinical pharmacology

The  clinical  pharmacology  of  daratumumab  is  well  characterised  and  was  summarised  in  the  initial monotherapy submission. Further, the clinical pharmacology properties of daratumumab in combination treatment with other agents than the bortezomib-thalidomide-dexamethasone (DVTd) combination has been studied in numerous Phase (1, 2 and) 3 combination treatment studies totally including more than 1,000  patients  treated  with  daratumumabThe  new  analyses  presented  do  not  change  the  current knowledge on PK/PD and immunogenicity of daratumumab.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

In previously reported Phase 1b, open-label, nonrandomized, multicenter study MMY1001 the safety, tolerability, and dose regimen of DVTd were evaluated in subjects with newly diagnosed MM.

<div style=\"page-break-after: always\"></div>

In study MMY3006, Daratumumab was administered at 16 mg/kg by intravenous (IV) infusion. In Arm B (D-VTd), daratumumab was administered once every week for 8 weeks (D-VTd Induction Cycle 1-2), then once every 2 weeks for 8 weeks (D-VTd Induction Cycle 3-4) and following ASCT once every 2 weeks for 8 weeks (D-VTd consolidation Cycle 5-6). Following subsequent re-randomization, subjects assigned to the maintenance Arm B received daratumumab (16 mg/kg) once every 8 weeks until documented disease progression (limited to a maximum duration of 2 years) (Part 2)

## 2.4.2. Main study(ies)

## MMY3006: Study of Daratumumab (JNJ-54767414 [HuMax CD38]) in Combination with Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTd) in the First Line Treatment of Transplant Eligible Subjects with Newly Diagnosed Multiple Myeloma

The Study MMY3006 is a large randomised, open-label, active-control, parallel-group, multicenter, Phase 3 study comparing the efficacy of daratumumab when combined with VTd (D-VTd) to that of VTd in terms of achieving sCR 100 days post-ASCT in subjects at least 18 years up to 65 year of age with newly diagnosed multiple myeloma and who were eligible for ASCT. A target of 1080 subjects were planned to be enrolled in this study, with 540 subjects planned per treatment arm. The treatment phase of Study MMY3006 study consists of 2 stages:

- Part 1 (Induction/ASCT/Consolidation): subjects were randomized in a 1:1 ratio to receive either DVTd or VTd. Planned enrollment was 1080 subjects. The number of planned cycles was 6 overall (4 cycles of induction therapy before ASCT and 2 cycles of consolidation therapy after ASCT). Response was assessed approximately 100 days post-ASCT and eligibility for the second randomization was determined.
- Part 2 (Maintenance): subjects with at least a partial response (PR) by Day 100 post-transplant were re-randomized in a 1:1 ratio to daratumumab maintenance or observation only. Approximately 800 subjects (400/arm) of the initial 1080 subjects were expected to be randomized to maintenance.

The aim of Part 1 was to demonstrate the benefit of adding daratumumab to VTd induction and consolidation therapy and the aim of Part 2 will be to evaluate daratumumab monotherapy as maintenance therapy.

<div style=\"page-break-after: always\"></div>

## Methods

Figure 2 Schematic Overview of Study MMY3006

<!-- image -->

## Study participants

Main inclusion criteria for participation in the study were the following:

- Subjects had to have newly diagnosed Multiple Myeloma and eligible for high dose therapy and ASCT
- Subject must have documented multiple myeloma satisfying the CRAB (calcium elevation, renal insufficiency,  anemia  and  bone  abnormalities),  or  biomarkers  of  malignancy  criteria  (see Attachment 1) and measurable disease as defined by:
- Monoclonal  plasma  cells  in  the  bone  marrow  ≥10%  or  presence  of  a  biopsy  proven plasmacytoma AND any one or more of the following myeloma defining events:
- -Hypercalcemia: serum calcium &gt;0.25 mmol/L (&gt;1 mg/dL) higher than ULN or &gt;2.75 mmol/L (&gt;11 mg/dL)
- -Renal  insufficiency:  creatinine  clearance  &lt;40  mL/min  or  serum  creatinine  &gt;177 μ mol/L (&gt;2 mg/dL)
- -Anemia: hemoglobin &gt;2 g/dL below the lower limit of normal or hemoglobin&lt;10 g/dL.
- -Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT
- -Clonal bone marrow plasma cell percentage ≥60%
- -Involved: uninvolved serum free light chain ratio ≥100
- -&gt;1 focal lesion on MRI studies

<div style=\"page-break-after: always\"></div>

- Measurable  disease  at  screening  as  defined  by  any  of  the  following  by  a  central laboratory:
- -IgG multiple myeloma: Serum monoclonal paraprotein (Mprotein) level ≥1.0 g/dL or urine Mprotein level ≥200 mg/24 hours; or
- -IgA, IgE, IgD, or IgM multiple myeloma: serum Mprotein level ≥0.5 g/dL or urine Mprotein level ≥200 mg/24 hours; or
- -IgD multiple myeloma: serum Mprotein level &lt;0.5 g/dL and Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio; or
- -Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio; or
- Subject must have had an ECOG Performance Status score of 0, 1, or 2.
- Subject must have pretreatment clinical laboratory values meeting the following criteria during the Screening Phase (Lab tests should be repeated if done more than 15 days before C1D1):

a)  hemoglobin ≥7.5  g/dL  (prior  red  blood  cell  [RBC]  transfusion  or recombinant  human erythropoietin use is permitted);

- b) absolute neutrophil count (ANC) ≥ 1.0 x 109/L (GCSF use is permitted);
- c) AST ≤2.5 x upper limit of normal (ULN); ALT ≤2.5 x ULN;

d) total bilirubin ≤ 1.5 x ULN (except in subjects with congenital bilirubinemia, such as Gilbert syndrome, direct bilirubin ≤1.5 x ULN);

e) calculated creatinine clearance ≤ 40 mL/min/1.73 m2 (see Attachment 3);

f) corrected serum calcium ≤14 mg/dL (&lt;3.5 mmo l/L); or free ionized calcium ≤ 6.5 mg/dL (≤ 1.6 mmol/L) (see Attachment 4);

g) platelet count ≥ 70 x 109/L for subjects in whom &lt;50% of bone marrow nucleated cells are plasma cells; otherwise platelet count &gt;50x109/L (transfusions are not permitted to achieve this minimum platelet count).

Main exclusion criteria were:

- Subject has received daratumumab or other anti-CD38 therapies previously.
- Subject  had  a  diagnosis  of  primary  amyloidosis,  monoclonal  gammopathy  of  undetermined significance, smoldering multiple myeloma, or solitary plasmacytoma,
- Subject has a diagnosis of Waldenström's macroglobulinemia, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
- Subject had prior or current systemic therapy or SCT for any plasma cell dyscrasia, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of corticosteroids before treatment.

## Treatments

Treatment Arm A: VTd (Bortezomib, Thalidome dexamethasone)

Treatment Arm B: D-VTd (Daratumab-Bortezomib, Thalidome dexamethasone)

The dosing schedules for VTd in both groups were as follows:

- Bortezomib (SC or intravenous [IV]): 1.3 mg/m2 body surface area twice weekly for 2 weeks (Days 1, 4, 8, and 11) in each cycle.
- Thalidomide (oral): 100 mg daily in each cycle.

<div style=\"page-break-after: always\"></div>

- Dexamethasone (oral or IV): 40 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. Dexamethasone 20 mg was administered on Days 1, 2, 8, 9, 15, 16 in Cycles 5 and 6. If daratumumab was administered on the same day, the dexamethasone dose was administered IV as a pre-infusion medication.
- In the DVTd group, daratumumab 16 mg/kg body weight was administered as an IV infusion according to the dosing schedule in Table 4 .

## Table 4 : Daratumumab Dosing Schedule in Combination with Bortezomib, Thalidomide, and Dexamethasone (VTd; 4-week Cycle Dosing Regimen) in Study MMY3006

| Treatment Phase                          | Weeks                                    | Schedule                                 |
|------------------------------------------|------------------------------------------|------------------------------------------|
| Induction                                | Weeks 1 to 8                             | weekly (total of 8 doses)                |
|                                          | Weeks 9 to 16 a                          | every 2 weeks (total of 4 doses)         |
| Stop for high dose chemotherapy and ASCT | Stop for high dose chemotherapy and ASCT | Stop for high dose chemotherapy and ASCT |
| Consolidation                            | Weeks 1 to 8 b                           | every 2 weeks (total of 4 doses)         |

Key: ASCT = autologous stem cell transplant; VTd = bortezomib (VELCADE) + thalidomide + dexamethasone.

a First dose of the every -2 -week dosing schedule was given at Week 9

b First dose of the every -2 -week dosing schedule was given at Week 1 upon re-initiation of treatment following ASCT

## Objectives

## Primary Objectives:

- The primary objective in Part 1 is to determine if the addition of daratumumab to VTD will increase the proportion of subjects achieving stringent complete response (sCR) post completion of consolidation therapy compared with VTD alone.
- The primary objective in Part 2 is to determine if the use of daratumumab as single agent in maintenance compared to observation only will increase progression-free survival (PFS) when used after autologous stem cell transplant and consolidation therapy.

## Secondary Objectives:

In Part 1, major secondary efficacy objectives are to determine if the addition of daratumumab to VTD will improve:

- Progression-free survival (PFS) from first randomization
- Time to progression (TTP) from first randomization
- Complete response (CR) rate by the end of ASCT/consolidation
- Minimal residual disease (MRD) negative rate by the end of ASCT/consolidation
- Post-induction stringent complete response (sCR) rate
- Progression-free survival after next line of therapy (PFS2)
- Post-induction overall response rate (ORR) and rate of very good partial response (VGPR) or better
- Overall survival (OS)
- Duration of CR and sCR

<div style=\"page-break-after: always\"></div>

In Part 2, major secondary efficacy objectives are to determine if the addition of daratumumab to VTD will improve the assessment during maintenance of:

- Time to progression
- CR rate
- MRD negative rate
- PFS2
- Rate of improved response
- Rate of MRD negative conversion
- ORR
- OS

Other secondary objectives throughout the study are:

- To evaluate quality of life and health economic/resource utilization
- To assess immunogenicity of daratumumab
- To assess safety and tolerability of daratumumab in combination with VTD

Exploratory Objectives:

- To evaluate daratumumab ' s impact on response and resistance to treatment

## Outcomes/endpoints

Primary Endpoints

The primary endpoint is stringent complete response (sCR) by end of consolidation therapy, 100 days post-ASCT, defined as the percentage of subjects achieving CR in addition to having a normal serum FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry. Subjects, who demonstrate all criteria for sCR, but have daratumumab interference on SPEP and IFE and have a NEGATIVE result per DIRA test, will be considered sCR.

Secondary endpoints controlled for multiplicity

- MRD  negativity  rate  100  days  post-ASCT,  defined  as  the  proportion  of  subjects  who  have negative  MRD  at  any  timepoint  after  first  dose  by  bone  marrow  aspirate  by  end  of ASCT/consolidation. An assessment of MRD will be conducted using next generation sequencing (NGS)  and  multiparametric  flow  cytometry  on  bone  marrow  aspirates  for  all  patients  in induction/consolidation phases and for patients who achieve at least VGPR in maintenance phase (array sensitivity 1 cancer cell in the background of &gt;= 100,000 white blood cells).
- Post-consolidation CR or better rate, defined as the proportion of subjects with a response of CR or better (i.e., CR or sCR), according to IMWG response criteria, by the end of ASCT/consolidation among all ITT population in each first randomized treatment arm.
- PFS from first randomization: PFS in Part 1 is defined as the duration from the date of first randomization to either progressive disease, according to the IMWG response criteria, or death, whichever occurs first.

<div style=\"page-break-after: always\"></div>

- OS  from  first  randomization:  OS  in  Part  1  is  defined  as  the  time  from  the  date  of  first randomization to the date of the subject's death.

## Secondary endpoints not controlled for multiplicity (Part 1)

- Time  to  Progression,  defined  similarly  as  the  PFS,  except  that  death  not  due  to  PD  will  be censored.
- Post-induction overall response rate (ORR) and rate of very good partial response (VGPR) or better. Post-induction overall response rate (ORR) is defined as the proportion of subjects with a response of PR or better (i.e., PR, VGPR, CR or sCR), according to IMWG response criteria, by the end of induction.
- Post-induction sCR rate, defined as the proportion of subjects with a response of sCR, according to IMWG response criteria, by the end of induction phase.
- Progression-free  survival  on  next  line  of  therapy  (PFS2),  defined  as  the  time  from  first randomization to progression on the next line of treatment or death, whichever comes first. Disease progression on the next line of treatment will be based on investigator judgment.
- Duration of CR/sCR and Duration of Response: Duration of CR/sCR is defined for a subject with confirmed CR/sCR as the time between the initial documentation of CR or better/sCR and disease progression (PD) per IMWG criteria, or death due to PD, whichever occurs first. Duration of Response is defined for a subject with confirmed response (PR or better) as the time between the initial documentation of response and disease progression per IMWG criteria, or death due to PD, whichever occurs first.
- Functional Status and Well-being: Health-related quality of life (HRQoL), symptoms, functional status and well-being will be assessed using 2 PRO measures, the EORTC-QLQ-C30 and the EQ5D-5L.  The  EORTC  QLQ-C30  includes  30  items  resulting  in  5  functional  scales  (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 Global Health Status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain),  and  6  single  items  (dyspnoea,  insomnia,  appetite  loss,  constipation,  diarrhoea,  and financial difficulties). The recall period is 1 week (the past week). The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including  mobility,  self-care,  usual  activities,  pain/discomfort  and  anxiety/depression  plus  a visual analog scale rating 'health today' with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

## Sample size

The sample size of this study takes into consideration the statistical power for the primary comparisons in both phases of the study. For Part 2 (maintenance phase), it is assumed that median PFS from the second randomization is 45 months for observation, and daratumumab maintenance will decrease the risk of progression or death by 25% (HR=0.75; estimated median PFS of 60 months for daratumumab maintenance). To achieve 80% power with a significance level of 0.05, 390 PFS events are needed. Assuming  a  36-month  accrual  and  45  months  of  additional  follow-up,  approximately  800  subjects (400/arm) will be randomized in the second randomization (daratumumab maintenance vs. observation).

Assuming that 75% of subjects in the induction/consolidation phase are eligible to be randomized for maintenance, which takes into account the expected response rate as well as potential dropouts, 1080 subjects (540/arm) will be randomized in the first randomization (daratumumab in combination with VTD induction/consolidation vs. VTD induction/consolidation). This sample size would provide at least 85% power to detect an improvement in sCR rate from 25% to 35% at a 2sided α of 0.05.

<div style=\"page-break-after: always\"></div>

Simulations have been performed to study the statistical powers in Part1 and Part 2. The simulation shows that the sample size is driven by maintenance stage. With adequate power for the maintenance stage, the induction/consolidation stage will have sufficient power as well. However, if an interaction exists between induction and maintenance, then the testing power for the maintenance effect could be different.

Table 5 : Simulation results for interaction and power of PFS comparison

|                                              |             | Induction   | Induction              | Induction            |
|----------------------------------------------|-------------|-------------|------------------------|----------------------|
| Scenario                                     | Maintenance | Overall     | DVTD-dara vs. VTD-dara | DVTD-obs vs. VTD obs |
| No interaction: HRm(DVTD)=0.75 HRm(VTD)=0.75 | 80.9%       | 98.6%       | 97.5%                  | 97.9%                |
| HRm(DVTD)=0.8 HRm(VTD)=0.75                  | 71.3%       | 97.3%       | 94.3%                  | 97.9%                |
| HRm(DVTD)=0.85                               | 60.4%       | 96.0%       | 89.2%                  | 97.9%                |
| HRm(VTD)=0.75                                |             |             |                        |                      |
| HRm(DVTD)=0.9 HRm(VTD)=0.75                  | 48.5%       | 94.7%       | 81.6%                  | 97.8%                |
| HRm(DVTD)=0.75 HRm(VTD)=0.8                  | 70.5%       | 99.2%       | 99.1%                  | 97.9%                |
| HRm(DVTD)=0.75 HRm(VTD)=0.85                 | 59.1%       | 99.6%       | 99.7%                  | 97.9%                |
| HRm(DVTD)=0.75 HRm(VTD)=0.9                  | 47.4%       | 99.8%       | 99.8%                  | 97.8%                |

## Randomisation

Subjects were assigned in a randomized manner to receive either D- VTD or VTD as induction and consolidation therapy. Subjects who successfully completed consolidation with a response of PR or better according to the IMWG criteria would be assigned a second time in a randomized manner to receive daratumumab alone or observation until documented progression of disease (limited to a maximum duration of 2 years). Permuted block randomization would be implemented in this study.

Subjects were stratified at first randomization by site, International Staging System stage I, II, or III and by cytogenetics.

Subjects were stratified at the second randomization by type of induction treatment and by depth of response to induction/consolidation therapy.

## Blinding (masking)

This is an open-label study. Subjects and sites will not be blinded to treatment assignment.

<div style=\"page-break-after: always\"></div>

## Statistical methods

## Part 1

## Analysis sets

- Intent-to-treat (ITT) analysis set: includes all subjects randomized in the first randomization.
- Maintenance-specific Intent-to-treat (ITT-m) analysis set: includes all subjects randomized in the second randomization.
- Induction-specific Safety analysis set: includes all subjects randomized in the induction/consolidation phase and have received at least 1 administration of any study treatment (daratumumab, bortezomib, thalidomide, or dexamethasone) in the first phase.
- Maintenance-specific  Safety analysis set: includes all  subjects  who  are  randomized  to daratumumab maintenance and have received at least 1 administration o daratumumab in the maintenance phase, and includes all subjects who are randomized to observation.
- Transplant-specific Safety analysis set: includes all subjects randomized in the induction/consolidation phase and have received transplant.

## Primary endpoint: sCR rate

sCR rate is defined as the proportion of patients with sCR among ITT subjects in each first randomized treatment arm. Patients who have progression of disease before ASCT will also be counted in the ITT population for the analyses.

The  primary  comparison  of  the  2  randomized  induction/consolidation  treatments  will  be  made  with respect to sCR rate using the stratified Cochran-Mantel-Haenszel chi-square test in the ITT analysis set. A Mantel-Haenszel odds ratio, along with its 2-sided 95% confidence interval and the p-value from the CMH test will be reported. Stratification factors used in the analysis include site, International Staging System stage I, II, or III and by cytogenetics  at first randomization.

## Secondary endpoints controlled for multiplicity (Part 1)

## 1. Post ASCT/consolidation MRD negative rate

For  analysis  purpose,  subjects  in  the  ITT  population  without  MRD  assessment  will  be  considered  as having positive MRD. The MRD negative rate will be analyzed similarly to the sCR rate.

## 2. Post-ASCT/consolidation CR rate

A similar analysis to that described for post-consolidation sCR is performed.

## 3. Key secondary endpoint 3 Progression-Free survival (PFS) from first randomization

PFS in Part 1 is defined as the duration from the date of first randomization to either progressive disease, according to the IMWG response criteria, or death, whichever occurs first.

Analysis of PFS in Part 1 will be based on the ITT analysis set. Two 'ITT'-type of induction comparisons, one specific to each maintenance treatment, will be conducted:

- DVTD-daratumumab vs. VTD-daratumumab
- DVTD-observation vs. VTD- observation

The weighted Kaplan-Meier method will be used to estimate the distribution of PFS for each of the 4 treatment sequences in the two 'ITT'-type of induction comparisons. Weight 2 is assigned to subjects

<div style=\"page-break-after: always\"></div>

randomized to the specific maintenance treatment and weight 1 is assigned to those subjects who do not respond after the induction/consolidation stage or not consent to participate in the maintenance stage. The median PFS with 95% CI will be provided. The PFS rates will also be summarized at landmarks (e.g., 6 months, 12 months, 18 months, etc). The weighted Kaplan-Meier PFS curve will also be plotted by each induction treatment group for specific maintenance treatment in the 'ITT'-type of induction comparisons. For each of the 2 comparisons, p-value from the log-rank test with risk factor adjusted by inverse probability- weight (IPW) method will be reported for the two 'ITT'-type of induction comparisons. Hazard ratio and its 95% confidence interval will be estimated based on a Cox regression analysis with inverse probability weighting (IPW) (Lokhnygina 2007), in which the weights to be used are the same as the above weighted KM method. Due to the expected small number of PFS events at the end of Part I, unstratified analyses will be used in each of the 2 comparisons.

The overall comparison of induction treatments will be made treating these 2 comparisons as 2 strata with  the  variance  estimated  using  the  robust  variance  estimator  (the  sandwich  estimate).  These  3 comparisons will all be tested with the significance level of 0.05 (2-sided) following the closed testing procedure. Essentially, the statistical significance is established for each of the 2 maintenance-specific comparisons if both itself and the overall induction comparison are significant at the 2-sided level of 0.05.

## Censoring rules for PFS

Subjects who have not achieved a response will enter the Follow-up Phase and will be followed until disease progression or death, even if they receive subsequent treatment.

Determination of dates of PFS event and dates for censoring is summarized in Table 6 .

Table 6: PFS event and censoring method

| Situation                                                                                                                   | DateofProgression or Censoring                   | Outcome   |
|-----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|-----------|
| No postbaseline disease assessment                                                                                          | First randomization                              | Censored  |
| Subjects with 2\" randomization                                                                                              |                                                  |           |
| Disease progression prior to start of subsequent anticancer therapy                                                         | Earliest date that indicates disease progression | PFS event |
| Death prior to start of subsequent anticancer therapy                                                                       | Date of death                                    | PFS event |
| Other (e.g., withdrawal of consent to study participation, lost to follow-up, start of subsequent anticancer therapy) etc.) | Date oflast disease assessment prior to Other    | Censored  |
| Subjects without 2nd randomization                                                                                          |                                                  |           |
| Disease progression                                                                                                         | Earliest date that indicates disease progression | PFS event |
| Death                                                                                                                       | Date of death                                    | PFS event |
| Other (e.g., withdrawal of consent to study participation, lost to follow-up, etc.)                                         | Date of last disease assessment prior to Other   | Censored  |

## 4. Overall survival (OS) from first randomization

OS in Part 1 is defined as the time from the date of first randomization to the date of the subject's death. If the subject is alive or the vital status is unknown, then the subject's data will be censored at the date the subject was last known to be alive. A similar analysis as PFS in Part 1 will be performed.

<div style=\"page-break-after: always\"></div>

## Secondary endpoints not controlled for multiplicity

- Time to progression (TTP): a similar analysis to that described for PFS is performed.
- Post-induction sCR rate: Post-induction sCR rate will be analysed similarly to post-consolidation sCR rate.
- Progression-free survival after next line of therapy (PFS2) from first randomization

PFS2 will be analysed for the ITT population. A similar analysis as PFS described will be performed.

Table 7: PFS2 event and censoring method

| Situation                                                                                                                                                 | Date of Progression or Censoring                                                                                      | Outcome    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|------------|
| No post-baseline disease assessment                                                                                                                       | Randomization                                                                                                         | Censored   |
| Disease progression on the 1\" line of subsequent t  anticancer  therapy o1r death^(prior to start 2nd line of subsequent anticancer therapy)              | Minimum of earliest date that indicates progression on the 1\" line of subsequent anticancer therapy and date of death | PFS2 event |
| No disease progression on study treatment, and no progression on 1 line of subsequent therapy or 1\" line of subsequent anticancer therapy not yet started | Date of last disease assessment prior to start of 1\" line of subsequent anticancer therapy                            | Censored   |
| Other                                                                                                                                                     | Minimum of start date of 2\"d line of subsequent anticancer therapy minus 1 and last date of follow- up                | Censored   |

- Post-induction overall response rate (ORR) and rate of very good partial response (VGPR) or better: they will be analyzed similarly to post-consolidation sCR rate.
- Duration  of  CR  and  sCR:  will  be  presented  descriptively  using  the  weighted  Kaplan-  Meier estimates by for two induction treatment groups with specific maintenance treatment in the 'ITT'type of induction comparisons.

## Sensitivity analysis

## Primary endpoint (sCR)

A sensitivity analysis of sCR by the end of consolidation therapy based on investigator assessment per the IMWG response criteria was performed in a similar manner as described for the primary analysis. sCR rate in the response-evaluable population will be summarized as a sensitivity analysis as well.

## PFS

A sensitivity  analysis  for  the  overall  comparison  of  induction  treatments  regardless  of  response  and second randomization will be performed among the ITT population. This analysis is to compare two treatment policies starting with DVTD or VTD induction/consolidation and responders afterward with half chance to be re-randomized to data maintenance and half chance to no maintenance (observation). The Kaplan-Meier method will be used to estimate the distribution of overall PFS for each treatment group. The p-value for DVTD and VTD induction comparison is based on a log-rank test. Hazard ratio and its 95% confidence interval are to be estimated based on a Cox's model with induction treatment as the

<div style=\"page-break-after: always\"></div>

explanatory variable. Kaplan-Meier PFS curve will also be plotted by DVTD and VTD induction treatment groups regardless of response and second randomization.

Additionally, reasons for PFS and censoring will be summarized for the ITT analysis set.

For the overall comparison, Cox regression model with weights as time-dependent covariate will be used as a sensitivity analysis.

A sensitivity analysis for PFS to evaluate the impact of transplant on the efficacy findings in the induction phase will be evaluated by including transplant as a time-varying covariate in the Cox regression model with inverse probability weighting (IPW) for two 'ITT'-type of induction comparisons.

A sensitivity analysis of PFS, in which progressive disease is based on investigator assessment according to the IMWG response criteria, will be performed in a similar manner as described above.

A similar sensitivity analysis of PFS by not censoring data due to start of subsequent anticancer therapy will be performed in a similar manner as described above.

## Post-ASCT/consolidation MRD negative rate

A sensitivity analysis of MRD negative rate by using threshold of &lt;10 -4, 10-6 will be performed in a similar manner as described for the primary analysis.

## Type I error control

The study has a primary endpoint, sCR. If sCR is statistically significant, then 4 key secondary endpoints will be tested hierarchically: 1) post-consolidation MRD negativity rate 2) post-consolidation CR or better rate 3) PFS from first randomization 4) OS from first randomization. This method strongly controls the family-wise type I error rate at 0.05 (2-sided).

## Interim analysis

An interim analysis was not planned for Part 1 of the study, it was only planned for Part 2 of the study.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 3 : Subject disposition as of clinical cut-off date (19 June 2018); study 54767414MMY30006

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 8 Summary of subject Disposition Intent to Treat Analysis set study MMY3006

|                                                                                                   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|---------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                                                                   | VId (9)                        | DVTd n(%)                      | Total n(%6)                    |
| Analysis set: intent-to-teat                                                                      | 542                            | 543                            | 1085                           |
| Subjecis randomized but not teated                                                                | 4 (0.796)                      | 7 (1.396)                      | 11 (1.0%)                      |
| Subjecis induction/ASC T/consolidation teated                                                     | 538 (99.396)                   | 536 (98.7%6)                   | 1074 (99.096)                  |
| Completed                                                                                         | 437 (80.696)                   | 461 (84.9%6)                   | 898 (82.896)                   |
| Discoutinued                                                                                      | 101 (18.6%6)                   | 75 (13.896)                    | 176 (16.2%6)                   |
| Death                                                                                             | 7 (1.396)                      | 0                              | 7 (0.6%6)                      |
| Disease progression                                                                               | 21 (3.9%6)                     | 19 (3.5%6)                     | 40 (3.796)                     |
| Investigator's judgment                                                                           | 12 (2.296)                     | 4 (0.796)                      | 16 (1.596)                     |
| Lost to follow-up                                                                                 | 0                              | 1 (0.2%6)                      | 1 (0.1%6)                      |
| Participant decision (want to discontinue the dn-molog olrapm oi searae pue jmewnean assessmenis) | 8 (1.596)                      | 0                              | 8 (0.7%6)                      |
| Participant withdrawal of consent                                                                 | 1 (0.296)                      | 3 (0.696)                      | 4 (0.4%6)                      |
| Prohibited medication                                                                             | 1 (0.296)                      | 0                              | 1 (0.1%)                       |
| Treatment delay for toxicity for more than 6 weeks                                                | 1 (0.2%)                       | 2 (0.496)                      | 3 (0.3%6)                      |
| Treatment stopped by sponsor                                                                      | 2 (0.496)                      | 3 (0.696)                      | 5 (0.5%6)                      |
| Unacceptable adverse event(s) / serious adverse events(s)                                         | 55 (10.1%6)                    | 49 (9.0%6)                     | 104 (9.6%6)                    |
| Subjects 2\"randomized                                                                             | 428 (79.0%6)                   | 458 (84.3%)                    | 886 (81.796)                   |
| Subjects who discontinued shudy                                                                   | 43 (7.9%6)                     | 23 (4.2%6)                     | 66 (6.1%6)                     |
| Consent withdrawn                                                                                 | 5 (0.996)                      | 5 (0.996)                      | 10 (0.9%0)                     |
| Death                                                                                             | 32 (5.9%6)                     | 14 (2.6%)                      | 46 (4.296)                     |
| Lost to follow-up                                                                                 | 5 (0.996)                      | 3 (0.696)                      | 8 (0.7%6)                      |
| Sponsor's decision                                                                                | 1 (0.296)                      | 1 (0.296)                      | 2 (0.296)                      |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVId = daratmmumab + bortezomib (VELCADE) + thalidomide+dexamethasone.

Note: Percentages are calculated with the mumber of subjects in each group as denominator.

Note: Subjects may have mmltiple reasons for treatment discourinuation.

## Recruitment

Study Centres : Belgium (13 sites), France (70 sites), Netherlands (28 sites).

Study Period: The study was initiated 22 September 2015 (Date first subject signed informed consent), the data cut-off for Part 1 (induction/consolidation phase) was 19 June 2018 (Date of last observation recorded as part of the database for Part 1 analysis). The study is still ongoing. Updated data was requested for PFS, OS and key secondary points and a new clinical cut-off point of May 1 st  2019 was set providing 10 additional months.

## Conduct of the study

## Protocol amendments

The initial protocol version was dated 14 January 2015, there were 2 amendments to the protocol. The first amendment (24 August 2015) was adopted before any study-related procedures had begun. Details of each amendment are included in the protocol (Appendix 1). The rationale for each amendment is summarized in Table 9 :

<div style=\"page-break-after: always\"></div>

Table 9 Summary of Protocol Amendments for MMY3006

| Amendment 1 (24 August 2015)   | Inclusion/exclusion criteria updated to include specific CRABcriteria,includefreelight chainfor quantification of IgD,and allowfor controlled arrhythmias and vertebroplasty Other changes including alignment with daratumumab standard protocol wording, updated missing text and addingfurther text clarification to allowbetter understandingoftheprotocoldesignandrequirements   |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 2 (21 March 2016)    | Exclusion criteria updated to exclude solitary plasmacytoma Other changes to ensure better differentiation between Part                                                                                                                                                                                                                                                               |

Key: CRAB = calcium elevation, renal insufficiency, anemia and bone abnormalities

## Protocol Deviations

All protocol deviations of eligibility criteria and those deviations that could impact subject safety or study endpoints were considered major protocol deviations. Major protocol deviations were reported for 48 subjects (8.8%) in the DVTd group and 56 subjects (10.3%) in the VTd group ( Table 10 ).

Table 10 Major Protocol Deviations (excluding part 2) ITT set MMY3006

|                                                 | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|-------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                 | VTd n (%)                      | DVTd n (%)                     | Total n (%)                    |
| Analysis set:intent-to-treat                    | 542                            | 543                            | 1085                           |
| Totalnumberofsubjectswithmajorprotocoldeviation | 56 (10.3%)                     | 48 (8.8%)                      | 104 (9.6%)                     |
| Type of major protocol deviation                |                                |                                |                                |
| Developed withdrawal criteriabutnotwithdrawn    | 3 (0.6%)                       | 0                              | 3 (0.3%)                       |
| Efficacy assessment deviation                   | 8 (1.5%)                       | 2 (0.4%)                       | 10 (0.9%)                      |
| Enteredbut didnotsatisfy criteria               | 16 (3.0%)                      | 12 (2.2%)                      | 28 (2.6%)                      |
| Received anexcludedconcomitanttreatment         | 16 (3.0%)                      | 9 (1.7%)                       | 25 (2.3%)                      |
| Received wrong treatment or incorrect dose      | 8 (1.5%)                       | 15 (2.8%)                      | 23 (2.1%)                      |
| Safetyassessmentdeviation                       | 14 (2.6%)                      | 13 (2.4%)                      | 27 (2.5%)                      |

Key: VTd= bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide+dexamethasone.

Note.Percentages are.calcnlated with the mmher of snhiectsineach groun as denominator

<div style=\"page-break-after: always\"></div>

## Baseline data

## Baseline disease characteristics

Table 11 Pre induction Baseline Disease characteristics by Induction/ASCT/Consolidation Treatment Group ITT analysis set MMY3006

|                                                        | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                        | VTd                            | DVTd                           | Total                          |
|                                                        | n(:)                           | (0n                            | n(%)                           |
| Analysis set: intent-to-treat                          | 542                            | 543                            | 1085                           |
| Iype of myeloma by immunofixation, n(%)                |                                |                                |                                |
| N                                                      | 542                            | 543                            | 1085                           |
| IgG                                                    | 333 (61.4%%)                   | 351 (64.6%)                    | 684 (63.0%)                    |
| IgA                                                    | 104 (19.2%)                    | 87 (16.0%%)                    | 191 (17.6%)                    |
| IaM                                                    | 2 (0.4%)                       | 1 (0.2%)                       | 3 (0.3%)                       |
|                                                        | 13 (2.4%)                      | 5 (0.9%6)                      | 18 (1.7%)                      |
| Lizht chain                                            | 66 (12.2%)                     | 83 (15.3%6)                    | 149 (13.7%%)                   |
| Kappa                                                  | 46 (8.5%%)                     | 53 (9.8%6)                     | 99 (9.1%)                      |
| Lambda                                                 | 20 (3.7%4)                     | 30 (5.5%%)                     | 50 (4.6%)                      |
| Biclonal                                               | 19 (3.5%%)                     | 12 (2.2%6)                     | 31(2.9%)                       |
| Negative immunofiwation                                | 5 (0.9%%)                      | 4 (0.7%)                       | 9 (0.8%)                       |
| Type of measurable disease', n (%)                     |                                |                                |                                |
| N                                                      | 542                            | 543                            | 1085                           |
| 1gG                                                    | 314 (57.9%)                    | 331 (61.0%)                    | 645 (59.4%)                    |
| IeA                                                    | (%E81)66                       | 80 (14.7%6)                    | 179 (16.5%%)                   |
| Otherb                                                 | 22 (4.1%)                      | 13 (2.4%)                      | 35 (3.2%)                      |
| Urine only                                             | 67 (12.4%)                     | 70 (12.9%.)                    | 137 (12.6%)                    |
| Senum FLC only                                         | 40 (7.4%)                      | 48 (8.8%6)                     | 88 (8.1%)                      |
| Unknown                                                | 0                              | 1 (0.2%)                       | 1 (0.1%)                       |
| ISS staging. n (%)                                     |                                |                                |                                |
| N                                                      | 542                            | 543                            | 1085                           |
| 1                                                      | 228 (42.1%)                    | 204 (37.6%)                    | 432 (39.8%)                    |
| 11                                                     | 233 (43.0%%)                   | 255 (47.0%)                    | 488 (45.0%)                    |
|                                                        | 81 (14.9%)                     | 84 (15.5%%)                    | 165 (15.2%)                    |
| Time since initial diagiosis to randomization (months) |                                |                                |                                |
| N                                                      | 542                            | 543                            | 1085                           |
| Mean (SD)                                              | 1.37 (2.184)                   | 1.33 (2.984)                   | 1.35 (2.614)                   |
| Median                                                 | 0.95                           | 0.92                           | 0.92                           |
| Ramee                                                  | (0.2; 31.0)                    | (0.2; 66.6)                    | (0.2; 66.6)*                   |
| Number of lytic bone lesions, n (%.)                   |                                |                                |                                |
| N                                                      | 540                            | 540                            | 1080                           |
| None                                                   | 86 (15.9%)                     | 81 (15.0%)                     | 167 (15.5%)                    |
| 1-3                                                    | 153 (28.3%))                   | 176 (32.6%)                    | 329 (30.5%)                    |
| 4-6                                                    | 110 (20.4%6)                   | 98 (18.1%)                     | 208 (19.3%6)                   |
| More Than 7                                            | 191 (35.4%%)                   | 185 (34.3%)                    | 376 (34.8%6)                   |

<div style=\"page-break-after: always\"></div>

|                                                        | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                        | VTd n(%)                       | DVTd                           | Toal n(%)                      |
| Presence of diffuse myeloma-related osteopenia, n (%6) |                                | (%)                            |                                |
| N                                                      | 540                            | 540                            | 1080                           |
| S1                                                     | 49 (9.1%)                      | 53 (9.876)                     | 102 (9.4%)                     |
| No                                                     | 491 (90.9%)                    | 487 (90.2%)                    | 978 (90.6%6)                   |
| Presence of extramedullary                             |                                |                                |                                |
| plasmacytomas, n (%6) N                                | 542                            | 543                            | 1085                           |
| S1                                                     | 2 (0.4%%)                      | 8 (1.5%6)                      | 10 (0.9%)                      |
| No                                                     | 540 (99.6%)                    | 535 (98.5%)                    | 1075 (99.1%)                   |
| Presence ofevalnblebonemarow assessment, n (96)        |                                |                                |                                |
| N                                                      | 542                            | 543                            | 1085                           |
| 1                                                      | 533 (98.3%%)                   | 533 (98.2%)                    | 1066 (98.2%)                   |
| No                                                     | 9 (1.7%)                       | 10 (1.8%4)                     | 19 (1.8%%)                     |
| %Plasma cells, bone mamow biopsy/aspirate, n (%)       |                                |                                |                                |
| N                                                      | 533                            | 533                            | 1066                           |
| 10                                                     | 17 (3.2%%)                     | 20 (3.8%6)                     | 37 (3.59%)                     |
| 10-30                                                  | 249 (46.7%6)                   | 245 (46.0%)                    | 494 (46.396)                   |
| >30                                                    | 267 (50.1%)                    | 268 (50.3%)                    | 535 (50.2%)                    |
| %Plhsma cells, bone marow biopsy. (%]u                 |                                |                                |                                |
| N                                                      | 86                             | 97                             | 183                            |
| c10                                                    | 2 (2.39:)                      | 3 (3.1%)                       | 5 (2.7%%)                      |
| 10-30                                                  | 35 (40.7%6)                    | 32 (33.0%)                     | 67 (36.6%)                     |
| 0Ec                                                    | 49 (57.0%)                     | 62 (63.9%)                     | 111 (60.7%)                    |
| Plasma cells, bone marow aspirate, n (%)               |                                |                                |                                |
| N                                                      | 523                            | 522                            | 1045                           |
| 10                                                     | 37 (7.1%6)                     | 43 (8.2%6)                     | 80 (7.7%6)                     |
| 10-30                                                  | 242 (46.3%)                    | 250 (47.9%)                    | 492 (47.1%)                    |
| >30                                                    | 244 (46.7%6)                   | 229 (43.9%)                    | 473 (45.3%6)                   |
| Bone marow cellularity. n (%)                          |                                |                                |                                |
| N                                                      | 534                            | 531                            | 1065                           |
| Hypercellulkr                                          | 155 (29.0%)                    | 136 (25.6%)                    | 291 (27.3%%)                   |
| Normocellular                                          | 223 (41.8%)                    | 244 (46.0%)                    | 467 (43.8%6)                   |
| Moderately cellular                                    | 116 (21.7%)                    | 107 (20.2%)                    | 223 (20.9%)                    |
| Severely acellular Indeterminate                       | 23 (4.3%) 17 (3.2%)            | 27 (5.1%) 17 (3.2%6)           | 50 (4.7%) 34 (3.2%)            |
| Cytogenetics profile                                   |                                |                                |                                |
| 1(4: 14) Ne                                            | 503                            | 501                            | 1004                           |
| Normal                                                 | 450 (89.5%)                    | 450 (89.8%)                    | (94968)006                     |
| Abnormal                                               | 53 (10.5%6)                    | 51 (10.2%)                     | 104 (10.4%)                    |
| Dell7p                                                 |                                |                                |                                |
| Nd                                                     | 503                            | 501                            | 1004                           |
| Normal                                                 | 464 (92.2%)                    | 459 (91.6%)                    | 923 (91.9%)                    |
| Abnormal                                               |                                |                                |                                |
|                                                        | 39 (7.8%%)                     | 42 (8.4%6)                     | 81 (8.1%)                      |
| Risk result N                                          | n() 540 86 (15.996)            | n(-) 542 82 (15.1%6)           | n(%) 1082 168 (15.5%)          |
| High risk                                              |                                | 460 (84.9%%)                   |                                |
| Standard risk                                          | 454 (84.1%)                    |                                | 914 (84.5%)                    |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone: DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

Note: Percentages are calculated with the number of subjects in each group with available data as denominator.

Includes IgD, IgM, IgE and biclonal.

* Includes subjects without measurable disease in serm and urine.

*Subjects with t(4: 14) measured (normal or abnormal)

* Includes subjects with risk results available.

d Subjects with Dell7p measued (nommal or abnormal).

Incomect *time to initial diagnosis\" data were entered into the database for 4 subjects (see ERRATA). These data erors did not affect the median reported in this analysis

<div style=\"page-break-after: always\"></div>

Table 12 Summary of IMWG Revised ISS staging in Multiple Myeloma, ITT Analysis set MMY3006

|                             | Inductiom/ASCTiConsolidation   | Inductiom/ASCTiConsolidation   | Inductiom/ASCTiConsolidation   |
|-----------------------------|--------------------------------|--------------------------------|--------------------------------|
|                             | VTd                            | DVTd                           | Total                          |
|                             | n()                            | n(%)                           | n(6)                           |
| Amhysis set:intent-to-trent | 542                            | 543                            | 1085                           |
| DMwGRevisedIss Stagine'     |                                |                                |                                |
| N                           | 540                            | 535                            | 1075                           |
|                             | 146 (27.0%6)                   | 103 (19.3%6)                   | 249 (23.2%)                    |
|                             | 344 (63.7%%)                   | 383 (71.6%6)                   | 727 (67.6%)                    |
|                             | 50 (9.3%6)                     | 49 (9.2%6)                     | 99 (9.276)                     |

Key: VTd= bortezomib (VELCADE) + thalidomide + dexamethasone: DVTd =daratumumab + bortezomib (VELCADE) +thalidlomide+dewamethasone.

Key: DMW'G=Intemafional Myeloma Working Group: ISS=Intemational Stnging System

Determinationis based on three factors: Intemational Staging System (IsS): presence of chromosomal abnommalities of I4:14).ordell7pbyFISH testing and serum lactatedehydrogenase(LDH)at Pre-inductionBaseline

Note: Perceniages are calcuwated with the number of subjects in each group with awailable dataas denominator.

The stratification factors for randomization, comprised of site affiliation (IFM vs HOVON), ISS staging (I vs II vs III) and cytogenic risks (normal vs high risk). After initiation of the study, a revised ISS (R-ISS) was published.  In  addition  to  albumin  and β -2-microglobulin,  the  R-ISS  uses  additional  information consisting of lactate dehydrogenase (LDH) and cytogenetic risk ( Table 11 ).

## Numbers analysed

The primary analysis population was the intent-to-treat (ITT) population, which included all randomized subjects. The perprotocol population included ≥94% of the ITT popul ation; therefore, only ITT results are presented in-text for the efficacy endpoints. A summary of all subjects per analysis set is presented in Table 11.

Table 13 Summary of Subjects per Analysis Set MMY3006

|                           | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|---------------------------|--------------------------------|--------------------------------|--------------------------------|
|                           | VTd                            | DVId                           | Total                          |
| Study population          |                                |                                |                                |
| Subiects screened         |                                |                                | 1207                           |
| Intent-to-treat (IT T)    | 542                            | 543                            | 1085                           |
| Safety                    | 538                            | 536                            | 1074                           |
| Per-protocol (PP)         | 502                            | 522                            | 1024                           |
| Response-evaluableb       | 535                            | 536                            | 1071                           |
| Immunogenicity evaluables | 0                              | 302                            | 302                            |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone:DVTd=dhahumwmnb+bortezomib (VELCADE) + thalidomide + dexamethasone.

* Includes subjects who have a confinmed dingiosis of multiple myeloma and measuwable disease at baseline or screening Wisit. In addition, snbjecis must have received at least one component of shudy treatment and have adequate post-baseline disease assessments to allow for the assessment of disease.

Includes subjecis who are randomized and meet all eligibility crileria

* is defined as subjects assianed to DV'Td group who have at least 1 inmunogenicity sample obtained after their first darahmumabadministranion

<div style=\"page-break-after: always\"></div>

## Outcomes and estimation

Primary endpoint: sCR

Table 14: Summary of Post-Consolidation Response Based on Computerized Algorithm; Intent-to-treat Analysis Set (Study 54767414MMY3006)

|                                   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|-----------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                   | VTd                            | VTd                            | DVTd                           | DVTd                           |                                |                                |
|                                   | n (%)                          | 95% CI for%                    | n (%)                          | 95% CI for%                    | Odds Ratio (95% CI) a          | P-value b                      |
| Analysis set: intent -to-treat    | 542                            |                                | 543                            |                                |                                |                                |
| Response category                 |                                |                                |                                |                                |                                |                                |
| Stringent complete response (sCR) | 110 (20.3%)                    | (17.0%, 23.9%)                 | 157 (28.9%)                    | ( 25.1%, 32.9%)                |                                |                                |
| Complete response (CR)            | 31 (5.7%)                      | (3.9%, 8.0%)                   | 54 (9.9%)                      | (7 .6%, 12. 8 %)               |                                |                                |
| Very good partial response (VGPR) | 282 (52.0%)                    | (47.7%, 56.3%)                 | 242 (44.6%)                    | ( 40.3%, 48.9%)                |                                |                                |
| Partial response (PR)             | 64 (11.8%)                     | ( 9.2%, 14.8%)                 | 50 (9.2%)                      | (6.9%, 12.0%)                  |                                |                                |
| Stable disease (SD)               | 15 (2.8%)                      | (1 .6%, 4.5%)                  | 10 ( 1.8%)                     | ( 0.9%, 3.4%)                  |                                |                                |
| Progressive disease (PD)          | 25 (4.6%)                      | ( 3.0%, 6.7%)                  | 2 0 ( 3.7%)                    | ( 2.3%, 5. 6 %)                |                                |                                |
| Not evaluable (NE)                | 15 (2.8%)                      | (1 .6%, 4.5%)                  | 10 (1.8%)                      | (0.9%, 3. 4 %)                 |                                |                                |
| Stringent complete response (sCR) | 110 (20.3%)                    | ( 17.0%, 23.9%)                | 157 (28.9%)                    | ( 25. 1 %, 32.9%)              | 1.6 0 (1.2 1 , 2.12)           | 0.001 0                        |
| CR or better (sCR + CR)           | 141 (26.0%)                    | ( 22.4%, 29.9%)                | 211 (38.9%)                    | ( 34.7%, 43.1%)                | 1.82 (1.4 0 , 2.3 6 )          | <0.0001                        |
| VGPR or better (sCR + CR + VGPR)  | 423 (78.0%)                    | ( 74.3%, 81.5%)                | 4 53 (8 3.4%)                  | (8 0.0%, 8 6 .5%)              | 1. 41 ( 1.04, 1.92)            | 0.0239                         |
| Overall response (sCR+CR+VGPR+PR) | 487 (89.9%)                    | ( 87.0%, 92.3%)                | 503 (92. 6 %)                  | (90.1%, 94.7%)                 | 1. 4 1 (0.92, 2.16)            | 0.1085                         |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

Key: CI = exact confidence interval.

a  MantelHaenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are site affiliation, ISS stage and cytogenetic risks.

b Pvalue from the stratified Cochran MantelHaenszel Chi -Squared test.

Note: Response was assessed by computerized algorithm, based on International Uniform Response Criteria Consensus Recommendations.

Note: Percentages are calculated with the number of subjects in each group as denominator.

[TEFRESP01\\_3006.RTF] [JNJ -54767414 \\ MMY3006 \\ DBR\\_PART1\\_CSR \\ RE\\_PART1\\_CSR \\ PROD \\ TEFRESP01\\_3006.SAS] 01NOV2018, 17:03

<div style=\"page-break-after: always\"></div>

## Major Secondary Endpoints

For key secondary endpoints, pre-specified hierarchical testing order is 1) post-consolidation MRD negativity rate 2) post-consolidation CR or better rate 3) PFS from first randomization 4) OS from first randomization.

Post-consolidation MRD negativity rate

Table 15 Summary of Post-Consolidation MRD Negative Rate by Flow Cytometry at 10 -5  in Bone Marrow; ITT Analysis set MMY3006

|                                            | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------------------|--------------------------------|--------------------------------|
|                                            | VTd                            | DVTd                           |
| Analysis set: intent-to-treat              | 542                            | 543                            |
| MRD negative rate (10-)                    | 236 (43.5%)                    | 346 (63.7%)                    |
| 95% CI of MRD negative rate                | (39.3%, 47.8%)                 | (59.5%, 67.8%)                 |
| Odds ratio with 95% CI                     |                                | 2.27 (1.78,2.90)               |
| P-valuec                                   |                                | <0.0001                        |
| CR or better + MRD negative rate (10-)     | 108 (19.9%)                    | 183 (33.7%)                    |
| 95% CI of CR or better + MRD negative rate | (16.6%, 23.5%)                 | (29.7%, 37.9%)                 |
| Odds ratio with 95% CI                     |                                | 2.06 (1.56, 2.72)              |
| P-valuec                                   |                                | <0.0001                        |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE)

+ thalidomide + dexamethasone.

b Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are site affiliation, ISS stage and cytogenetics.

Exact 95% confidence interval.

p-value from the stratified Cochran Mantel-Haenszel Chi-Squared test.

Note: Percentages are calculated with the number of subjects in each group as denominator.

For patients with PD/death by post-consolidation, MRD is imputed as positive

Table 16 Summary of Post-Consolidation VGRD or better MRD Negative Rate by Flow Cytometry at 10 -5  in Bone Marrow; ITT Analysis set MMY3006

|                                                | Induction/ASC T/Consolidation   | Induction/ASC T/Consolidation   |
|------------------------------------------------|---------------------------------|---------------------------------|
|                                                | PLA                             | DVTd                            |
| Analysis set. intent-to-teat                   | 542                             | 543                             |
| VGPR or better + MRD negative rate(10°)        | 231 (42.6%6)                    | 338 (62.296)                    |
| g5y6 CT of VGPR. or better + MRD negative rate | (38.4%6, 46.996)                | (58.0%6, 66.396)                |
| Odds rmatio with 95%6 CI                       |                                 | 2.21 (1.74, 2.82)               |
| P-value\"                                       |                                 | -0.0001                         |

Key: VTd =bortezomib (VELCADE) +thalidomide + dexamethasone; DVTd= darahmumab +bortezomib (VELCADE) + thalidomide + dexamethnsone.

*Exact 95%6 confidence intenval.

Mantel-Haenszel estimate of the comumon odds ratio for statified tables is used.The stratification factors are site affiliation, Iss stage and cytogenetics.

\"P-value from the stratified Cochran Mantel-Haenszel Chi-Squared test

Note: Percentages are calculated with the nuumber of subjects in each group as denominator.

For patients with PD/death by post-consolidation, MRD is imputed as positive.

Table 17 Forest Plot of Subgroup Analyses on Post-consolidation MRD negative Rate by Flow Cytometry at 10 -5  in Bone Marrow; ITT Analysis set MMY3006

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                           |       | VTd                             | DVTd                            |                                     |
|-------------------------------------------|-------|---------------------------------|---------------------------------|-------------------------------------|
| Sex                                       |       |                                 |                                 |                                     |
| Male                                      | H     | 131/319 (41.1%)                 | 192/316 (60.8%)                 | 2.22 (1.62, 3.05)                   |
| Fulllake                                  |       | 105/223 (47.1%)                 | 154/227 (57.8%)                 | 2.37 (1.62, 3.45)                   |
| Age 50 years =50 ycara                    |       | 30/90 (42.2%) 198/952 (43.8%)   | 56/83 (67.5%) 2904460 (83.0%)   | 2.84 (1.53, 5.28) 2.19 (1.68, 2.89) |
| Site IFM Hovem ISS taging                 |       | 204/457 (44.6%) (sc0\"2c) c0/30  | 287/452 (63.5%) 4%/01-0] 16/86  | 2.16 (1.65, 2.81) 0.05 (1.05, 5.05) |
| IIII                                      | H+ T+ | 103/228 (45.2%) 06/223 (41.294) | 137/204 (67.2%)                 | 2.48 (1.68, 3.67) 2.21 (1.64, 9.19) |
| III                                       | +     | 37,81 (45.7%)                   | 165/265 (60.8%) 54/84 (64.3%)   | 2.14 (1.15, 4.00)                   |
| Cytogenetic risk Hich Risk Standard Risk  |       | (sc pF) stne 197,0454 (43.4%)   | (ve oal Csnor                   | 1.88 (1.02, 3.65)                   |
| Baseline renal function (CrCI) >90 mL/min | H+H   | 139:316 (44.0%)                 | 296/460 (64.3%)                 | 2.35 (1.80, 3.07)                   |
| c=90 mL/min                               | T     | 97/226 (42.9%)                  | 205/331 (61.9%)                 | 2.07 (1.51. 2.84)                   |
| Baseline hepatic function                 | H+    | 216/500 (43.2%)                 | 141/212 (66.5%)                 | 2.64 (1.79, 3.89)                   |
| Normal Impained                           |       | 2042 (47.6%)                    | 310/480 (64.6%) 36/63 (57.1%)   | 2.40 (1.85, 3.10) 1.47 (0.67, 3.21) |
| Type of MM                                | H+    | 59′121 (48.8%)                  |                                 |                                     |
| IgG Non-lgG                               |       | 122.314 (38.6%)                 | 201/331 (60.7%) 61/99 (65.6%)   | 2.43 (1.77, 3.34) 2.00 (1.15, 3.50) |
| ECOG performance soore Q                  | H+    | 112/257 (43.6%)                 |                                 |                                     |
| =                                         |       |                                 |                                 |                                     |
|                                           |       | 124/285 (43.5%)                 | 172/265 (64.9%) 174/278 (52.6%) | 2.39 (1.68, 3.41)                   |
|                                           |       |                                 |                                 | 2.17 (1.55, 3.04)                   |

For patients with PD/death by post-consolidation, MRD is imputed as positive

Key:VTd=bortezomib (VELCADE) +thnlidomide +dexamethnsone: DVTd=daratumumnb +bortezomib (VELCADE) + thalidomide + dewamethnsone. Note: Impaired baseline hepatic fimction include mild (total bilirubin≤ ULN and AST &gt; ULN) or (ULN ≤ total

bilinubin S 1.5.ULN: moderate (1.5.ULN c total bilinubin s 3.ULN: and severe (tothl bilinubin &gt; 3.ULN))

## Post-consolidation CR or better rate

The Number of patients who achieved CR or better was significantly higher in the DVTd group compared with the VTd group, 38.9% vs. 26.0%, (odds ratio=1.82, 95% CI: 1.40, 2.36; pvalue&lt;0.0001) (Table 12).

## PFS from first randomization

The PFS events (PD or death) may include those that occur in the maintenance phase.

<div style=\"page-break-after: always\"></div>

Table 18: Progression-Free Survival by Induction/ASCT/Consolidation Treatment Group from First Randomization for Overall Comparison Regardless of Second Randomization Based on Computerized Algorithm; Intent-to-treat Analysis Set (Study 54767414MMY3006)

|                                  | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|----------------------------------|--------------------------------|--------------------------------|
|                                  | VTd                            | DVTd                           |
| Analysis set: intent-to-treata   | 542                            | 543                            |
| Progression-free survival (days) |                                |                                |
| Number of events (%)a            | 91 (16.8%)                     | 45 (8.3%)                      |
| Number of censored (%)a          | 451 (83.2%)                    | 498 (91.7%)                    |
| 25% quantile (95% CI)            | 768.00 (633.00, 941.00)        | NE (NE, NE)                    |
| Median (95% C1)b                 | NE (941.00, NE)                | NE (NE, NE)                    |
| 75% quantile (95% CI)b           | NE (NE, NE)                    | NE (NE, NE)                    |
| P-valuec                         |                                | <0.0001                        |
| Hazard ratio (95% CI)*           |                                | 0.47 (0.33, 0.67)              |
| 6-month PFS rate % (95% CI)b     | 95.8 (93.7, 97.2)              | 96.6 (94.6, 97.8)              |
| 12-month PFS rate % (95% CI)     | 92.4 (89.8, 94.4)              | 95.6 (93.5, 97.1)              |
| 18-month PFS rate % (95% CI)     | 84.6 (80.7, 87.7)              | 92.7 (89.8, 94.7)              |
| 24-month PFS rate % (95% CI)     | 76.9 (71.5, 81.3)              | 89.4 (85.6, 92.3)              |

Including all subjects randomized in Part I regardless of second randomization p-value is based on the log-rank test.

Based on Kaplan-Meier product limit estimates.

Hazard ratio and 95% CI from a Cox regression analysis with treatment as the sole explanatory variable.

Figure 4: Kaplan-Meier Plot of Progression-Free Survival by Induction/ASCT/Consolidation Treatment Group from First Randomization for Overall Comparison Regardless of Second Randomization Based on Computerized Algorithm; Intentto-treat Analysis Set (Study 54767414MMY3006)

<!-- image -->

VTd---G---DVTd

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

<div style=\"page-break-after: always\"></div>

Figure 5: Forest Plot of Subgroup Analyses on Progression-Free Survival by Induction/ASCT/Consolidation Treatment Group from First Randomization for Overall Comparison Regardless of Second Randomization Based on Computerized Algorithm; Intent-to-Treat Analysis Set (Study 54767414MMY3006)

<!-- image -->

|                                |                         | PIA     | PIA         | DVTd   | DVTd   | Hazard Ratio      |
|--------------------------------|-------------------------|---------|-------------|--------|--------|-------------------|
|                                | Hazard Ratio and 95% CI |         | EVT/NMedian | EVT/N  | Median | (95% CI)          |
| Sex                            |                         |         |             |        |        |                   |
| Male                           |                         | 98/319  | NE          | 49/316 | NE     | 0.46 (0.33, 0.65) |
| Female                         |                         | 53/223  | NE          | 34/227 | NE     | 0.55 (0.36, 0.85) |
| Age                            |                         |         |             |        |        |                   |
| <50 years                      |                         | 28/90   | NE          | 9/83   | NE     | 0.31 (0.15, 0.66) |
| >=50 years                     |                         | 123/452 | NE          | 74/460 | NE     | 0.53 (0.40, 0.71) |
| Site                           |                         |         |             |        |        |                   |
| IFM                            | TI                      | 133/457 | NE          | 72/452 | NE     | 0.50 (0.37, 0.66) |
| Hovon                          |                         | 18/85   | NE          | 11/91  | NE     | 0.46 (0.22, 0.98) |
| ISS staging                    |                         |         |             |        |        |                   |
| 1                              |                         | 48/228  | NE          | 21/204 | NE     | 0.45 (0.27, 0.75) |
| II                             | T                       | 74/233  | NE          | 44/255 | NE     | 0.47 (0.32, 0.68) |
| III                            |                         | 29/81   | NE          | 18/84  | NE     | 0.56 (0.31,1.01)  |
| Cytogenetic risk               |                         |         |             |        |        |                   |
| High Risk                      |                         | 34/86   | 33.3        | 24/82  | NE     | 0.69 (0.41, 1.16) |
| Standard Risk                  | TI                      | 117/454 | NE          | 59/460 | NE     | 0.45 (0.33, 0.61) |
| Baseline renal function (CrCI) |                         |         |             |        |        |                   |
| >90 mL/min                     | T⊥                      | 88/315  | NE          | 50/331 | NE     | 0.48 (0.34,0.68)  |
| <=90 mL/min                    | T1                      | 63/227  | NE          | 33/212 | NE     | 0.52 (0.34, 0.79) |
| Baselinehepaticfunction        |                         |         |             |        |        |                   |
| Normal                         | TI                      | 137/499 | NE          | 71/480 | NE     | 0.49 (0.37, 0.65) |
| Impaired                       |                         | 14/43   | NE          | 12/63  | NE     | 0.51 (0.24, 1.11) |
| Type of MM                     |                         |         |             |        |        |                   |
| IgG                            | T                       | 90/314  | NE          | 61/331 | NE     | 0.56 (0.41, 0.78) |
| Non-lgG                        |                         | 24/121  | NE          | 12/93  | NE     | 0.63 (0.32, 1.27) |
| ECOG performance score         |                         |         |             |        |        |                   |
| 0                              | T·                      | 64/257  | NE          | 38/265 | NE     | 0.53 (0.35, 0.79) |
| >=1                            | T                       | 87/285  | NE          | 45/278 | NE     | 0.47 (0.33, 0.68) |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

Note: Impaired baseline hepatic function include mild (total bilirubin ≤ ULN and AST &gt; ULN) or (ULN &lt; total bilirubin ≤ 1.5×ULN); moderate (1.5×ULN &lt; total bilirubin ≤ 3×ULN); and severe (total bilirubin &gt; 3×ULN).

## OS from first randomization.

Table 19: Overall Survival by Induction/ASCT/Consolidation Treatment Group from First Randomization for Overall Comparison Regardless of Second Randomization; Intent-to-treat Analysis Set (Study 54767414MMY3006)

|                                  | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|----------------------------------|--------------------------------|--------------------------------|
|                                  | VTd                            | DVTd                           |
| Analysis set: intent -to-treat a | 542                            | 543                            |
| Overall survival (days)          |                                |                                |
| Number of events (%) a           | 48 (8.9%)                      | 26 (4.8%)                      |
| Number of censored (%) a         | 494 (91.1%)                    | 517 (95.2%)                    |
| 25% quantile (95% CI) b          | NE (NE, NE)                    | NE (NE, NE)                    |
| Median (95% CI) b                | NE (NE, NE)                    | NE (NE, NE)                    |
| 75% quantile (95% CI) b          | NE (NE, NE)                    | NE (NE, NE)                    |
| P-value c                        |                                | 0.0070                         |
| Hazard ratio (95% CI) d          |                                | 0.52 (0.33, 0.85)              |

<div style=\"page-break-after: always\"></div>

Table 19: Overall Survival by Induction/ASCT/Consolidation Treatment Group from First Randomization for Overall Comparison Regardless of Second Randomization; Intent-to-treat Analysis Set (Study 54767414MMY3006)

|                                      | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------------|--------------------------------|--------------------------------|
|                                      | VTd                            | DVTd                           |
| 6- month Survival rate %(95% CI) b   | 98.9 (97.5, 99.5)              | 99.6 (98.5, 99.9)              |
| 12 - month Survival rate %(95% CI) b | 97.8 (96.1, 98.7)              | 98.1 (96.6, 99.0)              |
| 18- month Survival rate %(95% CI) b  | 95.1 (92.9, 96.7)              | 97.2 (95.4, 98.3)              |
| 24 - month Survival rate %(95% CI) b | 93.2 (90.6, 95.0)              | 96.6 (94.7, 97.9)              |

a Including all subjects randomized in Part I regardless of second randomization.

b Based on Kaplan -Meier product limit estimates.

c pvalue is based on the log -rank test.

d Hazard ratio and 95% CI from a Cox regression analysis with treatment as the sole explanatory variable.

Figure 6: Kaplan-Meier Plot of Overall Survival by Induction/ASCT/Consolidation Treatment Group from First Randomization for Overall Comparison Regardless of Second Randomization; Intent-to-treat Analysis Set (Study 54767414MMY3006)

<!-- image -->

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

[GEFOS01E\\_3006.RTF] [JNJ -54767414 \\ MMY3006 \\ DBR\\_EMA\\_UPDATE \\ RE\\_EMA\\_UPDATE \\ PROD \\ GEFOS01E\\_3006.SAS] 24JUL2019, 21:13

<div style=\"page-break-after: always\"></div>

## Additional Analysis Requested by CHMP

An  additional  analysis  was  requested  by  CHMP  for  PFS  censoring  subjects  randomized  to  Daratumab Maintenance at 2 nd  Randomization. Results are shown in Table 20

Table 20 Progression Free Survival by Induction/ASCT/Consolidation Treatment Group from first randomization for overall comparison by censoring subjects randomized to Daratumumab Maintenance at Second randomization based on computerized algorithm.

|                                        | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|----------------------------------------|--------------------------------|--------------------------------|
|                                        | VId                            | DVTd                           |
| Analysis set: intent-to-treat subjects | 542                            | 543                            |
| P-valueb                               |                                | 0.0005                         |
| Hazard ratio (95% CI)                  |                                | 0.50 (0.34, 0.75)              |

Including all subjects randomized in Induction/ASCT/Consolidation

p-value is based on the log-rank test.

Hazard ratio and 95% CI from a Cox regression analysis with treatment as the sole explanatory variable.

Subjects randomized to daratumumab maintenance at the second randomization were censored at the date of the second randomization.

## Other Secondary Endpoints not controlled for multiplicity

## Post-consolidation VGPR or better and ORR and Post-induction Response Rate Time to progression

At the time of clinical cutoff, 42 subjects (7.7%) in the DVTd group and 76 subjects (14.0%) in the VTd group had progressive disease or were reported to have died due to progressive disease throughout the entire study. The analysis showed an improvement for subjects in the DVTd group compared with subjects in the VTd group (HR=0.52; 95% CI: 0.36, 0.76, p=0.0006).

## Time to Response

The median time to response was approximately 1 month of treatment. Similar median time to VGPR or better (2.14 vs 2.83 months), and median time to CR or better (7.2 vs 7.4 months) were observed for the DVTd group versus the VTd group, respectively. Median durations of response were not reached.

## Stem cell-related procedures and Transplant

Mobilizing and collecting stem cells was feasible in both treatment arms, the proportion of treated subjects proceeding to stem cell transplantation did not differ between the treatment groups (DVTd: 91.2%, VTD: 90.0%).

<div style=\"page-break-after: always\"></div>

Table 21 Stem Cell Mobilization and Harvesting; Safety Analysis Set (MMY3006)

|                                                                                                  | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------------------------------------------------------------------------|--------------------------------|--------------------------------|
|                                                                                                  | PIA                            | DVId                           |
| Analysis set. safety                                                                             | 538                            | 536                            |
| PBSC Mobilization agents (several possible by patient)                                           |                                |                                |
| N                                                                                                | 492                            | 506                            |
| Cyclophosphamide/G-CSF                                                                           | 492 (100.0%6)                  | 506 (100.0%)                   |
| Mlozobil                                                                                         | 39 (7.9%)                      | 110 (21.7%)                    |
| PBSC apheresis perfonmed                                                                         |                                |                                |
| Number of days of apheresis                                                                      |                                |                                |
| N                                                                                                | 490                            | t05                            |
| Mean (SD)                                                                                        | 1.4 (0.67)                     | 1.9 (0.92)                     |
| Median                                                                                           | 1.0                            | 2.0                            |
| Total mumber of CD34+ stem cells collected (10*/kg) among subjects with PBSC apheresis perfonmed |                                |                                |
| N                                                                                                | 490                            | t05                            |
| Meam (SD)                                                                                        | 10.041 (5.2495)                | 6.716 (2.6299)                 |
| Median                                                                                           | 8.900                          | 6.340                          |
| If < 2 x 10°/kg collected:                                                                       |                                |                                |
| Total mumber of CD34+ stem cells collected (10f/kg)                                              |                                |                                |
| N                                                                                                | 0                              | 3                              |
| Mean (SD)                                                                                        |                                | 1.147 (0.6918)                 |
| Median                                                                                           |                                | 1.000                          |
| Subsequent autologous stem cell tramsplant?                                                      |                                |                                |
| N                                                                                                | 0                              | 3                              |
| No                                                                                               |                                | 2 (66.796)                     |
|                                                                                                  |                                | 1 (33.396)                     |
| If=2x 10°/kg collected:                                                                          |                                |                                |
| Total mmber of CD34+ stem cells collected (10°/kg)                                               |                                |                                |
| N                                                                                                | 490                            | 501                            |
| Mean (SD)                                                                                        | 10.041 (5.2495)                | 6.750 (2.6017)                 |
| Median                                                                                           | 8.900                          | 6.350                          |
| Subsequent autologous stem cell transplant?                                                      |                                |                                |
| N                                                                                                | 490                            | 501                            |
| No                                                                                               | 6 (1.296)                      | 13 (2.6%)                      |
|                                                                                                  | 484 (98.8%)                    | 488 (97.49)                    |
| Transplant, n (%6)                                                                               | 484 (90.0%)                    | 489 (91.296)                   |
| Number of CD34+ tausplanted (10°/kg)*                                                            |                                |                                |
| N                                                                                                | 483                            | 489                            |
| Mean (SD)                                                                                        | 4.982 (2.8003)                 | 3.636 (1.5883)                 |
| Median                                                                                           | 4.280                          | 3.300                          |
| Q1,Q3 Range                                                                                      | (3.180; 5.920) (1.18; 23.34)   | (2.600; 4.240) (0.47; 12.60)   |
| Transplanted subjecis with hematopoietic reconstihution', n (%6)                                 |                                |                                |
| N                                                                                                | 484                            | 489                            |
|                                                                                                  |                                | 488 (99.896)                   |
|                                                                                                  | 482 (99.6%6)                   |                                |
| No                                                                                               | 2 (0.496)                      | 1 (0.2%)                       |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone:DVTd=darahumumab+bortezomib(VELCADE)+ thalidomide + dexamethasone; PBSC = peripheral blood stem cell.

According to the information provided by the investigator, 1 subject (006-03) had a successfil collection of 5.4*10 9/kg CD34 positive cells from peripheral blood in 2 consecutive days of apheresis without any prior mobilization treatment; high dose therapy with stem cell tansplant with engrafhment was done. One subject (074-02) received a stem cell collection from bone marrow in addition to apheresis from peripheral blood. Here both mumbers are suwmmed up as a total of CD34+ cells collected from this subject.

Note: Percentages are calculated with *N* in each group as denominator.

One subject (l66-04) received ASCT with successfiul engrafiment but the mumber of CD34+ cells used for tansplantation are umkuowm. Prior transplantation this subject collected 14.27x10 */kg CD34+ from peripheral blood in a one day diring apheresis.

Hematopoietic reconstitution requires: neutrophils=0.5x10 °/L, leucocytes&gt;1.0x10*/L, andplatelets&gt;50x10°/L (without transfision)

## Patient-reported Outcomes (Functional Status and Well-being)

The functional status and well-being results from patient-reported outcome (PRO) endpoints, including the cancer-specific European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - Core Questionnaire (EORTC-QLQ-C30) and the general health EuroQol 5-dimension Questionnaire (EQ5D-5L), indicated improvements in health-related quality of life (HRQOL) in subjects who remained in the study in both the DVTd and VTd groups.

Most  scores  showed  numerical  improvement  in  both  arms  (pain,  physical,  role  and  emotional).  An improvement in the Global health Status Subscale (GHS) was observed from baseline to 100 days post-

<div style=\"page-break-after: always\"></div>

ASCT, but no statistically significant difference was noted between the two treatment groups. Cognitive functioning showed less deterioration in the DVTd group compared with the VTd group from baseline to day 100  post-ASCT  (DVTd:  -5.0  [95%  CI:  -7.6,  2.4];  VTd: -7.9  [95%  CI:  -10.6,  5.3],  p=0.0358). An improvement in emotional functioning was observed from baseline to 100 days post-ASCT in the DVTd group (DVTd: 13.0 [95% CI: 10.4, 15.5]; VTd: 9.5 [95% CI: 6.9, 12.1]; p=0.0131). A reduction in pain was observed in both groups, with a greater reduction in pain symptoms from baseline to 100 days postASCT in the DVTd group (-23.3 [95% CI: -26.6, 20.0]) compared with VTd ( -19.7 [95% CI: -23.0, 16.3]) (p=0.0416).

No statistically significant differences in the EQ-5D-5L LS utility value and theEQ-5D-5L visual analog scale (VAS) was observed for the two treatment groups, improvements in VAS and utility were comparable

## Ancillary analyses

Subgroup Analyses

Figure 7: Forest Plot of Subgroup Analyses on Best Response sCR Based on Computerized Algorithm; Intent-to-treat Analysis Set (Study 54767414MMY3006)

<!-- image -->

|                                |            | VTd             | DVTd            |                   |
|--------------------------------|------------|-----------------|-----------------|-------------------|
| Sex                            |            |                 |                 |                   |
| Male                           |            | 123/319 (38.6%) | 162/316 (51.3%) | 1.68 (1.22, 2.30) |
| Female                         |            | 105/223 (47.1%) | 133/227 (58.6%) | 1.59 (1.10, 2.31) |
| Age                            |            |                 |                 |                   |
| <50 years                      |            | 39/90 (43.3%)   | 49/83 (59.0%)   | 1.88 (1.03, 3.45) |
| >=50 years                     |            | 189/452 (41.8%) | 246/460 (53.5%) | 1.60 (1.23, 2.08) |
| Site                           |            |                 |                 |                   |
| IFM                            |            | 199/457 (43.5%) | 255/452 (56.4%) | 1.68 (1.29, 2.18) |
| Hovon                          |            | 29/85 (34.1%)   | 40/91 (44.0%)   | 1.51 (0.82, 2.79) |
| ISS staging                    |            |                 |                 |                   |
|                                |            | 102/228 (44.7%) | 120/204 (58.8%) | 1.76 (1.20, 2.59) |
| I                              |            | 89/233 (38.2%)  | 128/255 (50.2%) | 1.63 (1.14, 2.34) |
| I1I                            |            | 37/81 (45.7%)   | 47/84 (56.0%)   | 1.51 (0.82, 2.79) |
| Cytogenetic risk               |            |                 |                 |                   |
| High Risk                      |            | 34/86 (39.5%)   | 46/82 (56.1%)   | 1.95 (1.06, 3.61) |
| Standard Risk                  | TI         | 193/454 (42.5%) | 248/460 (53.9%) | 1.58 (1.22, 2.05) |
| Baseline renal function (CrCl) |            |                 |                 |                   |
| >90 mL/min                     | TI         | 133/315 (42.2%) | 182/331 (55.0%) | 1.67 (1.22, 2.28) |
| <=90 mL/min                    | 1          | 95/227 (41.9%)  | 113/212 (53.3%) | 1.59 (1.09, 2.31) |
| Baseline hepatic function      |            |                 |                 |                   |
| Normal                         | T1         | 211/499 (42.3%) | 262/480 (54.6%) | 1.64 (1.27, 2.11) |
| Impaired                       |            | 17/43 (39.5%)   | 33/63 (52.4%)   | 1.68 (0.77, 3.69) |
| Type of MM                     |            |                 |                 |                   |
| IgG                            |            | 104/314 (33.1%) | 148/331 (44.7%) | 1.63 (1.19, 2.25) |
| Non-lgG                        |            | 70/121 (57.9%)  | 62/93 (66.7%)   | 1.46 (0.83, 2.56) |
| ECOGperformancescore           |            |                 |                 |                   |
| 0                              |            | 109/257 (42.4%) | 143/265 (54.0%) | 1.59 (1.13, 2.25) |
| >=1                            |            | 119/285 (41.8%) | 152/278 (54.7%) | 1.68 (1.21, 2.35) |
|                                | 1 10       | 100             |                 |                   |
|                                | ←Favor VTd | Favor DVTd→     |                 |                   |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

Note: Impaired baseline hepatic function include mild (total bilirubin ≤ ULN and AST &gt; ULN) or (ULN &lt; total bilirubin ≤ 1.5×ULN); moderate (1.5×ULN &lt; total bilirubin ≤ 3×ULN); and severe (total bilirubin &gt; 3×ULN).

<div style=\"page-break-after: always\"></div>

Table 22 Rate of sCR in MRD negative and MRD positive subjects in ITT regardless treatment arm

| Daratumumab Study   | Subject Population   | Numberof Subjects: ITT/MRD negative/MIRD positive   | Background Therapy   | sCR Ratein MIRD Negative Subjects n (%)   | sCR Rate^in MIRD Positive Subjects n (%)   |
|---------------------|----------------------|-----------------------------------------------------|----------------------|-------------------------------------------|--------------------------------------------|
| MMY3003*            | RRMM                 | 569/112/457                                         | Rd                   | 70 (62.5)                                 | 42 (9.2)                                   |
| MMY3004?            | RRMM                 | 498/42/456                                          | Vd                   | 16 (38.1)                                 | 13 (2.9)                                   |
| MMY3007*            | NDMMb                | 706/124/582                                         | VMP                  | 64 (51.6)                                 | 45 (7.7)                                   |
| MMY3008*            | NDMMb                | 737/140/597                                         | Rd                   | 103 (73.6)                                | 68 (11.4)                                  |

KEY:ITT:intent-to-treat;MRD:minimal

1 residual disease; NDMM:newly diagnosed multiple myeloma;

Rd: lenalidomide, dexamethasone; RRMM relapsed/refractory multiple myeloma; sCR: stringent complete response;

Vd: bortezomib, dexamethasone; VlMP: bortezomib, melphalan, prednisone.

*MRD was assessed using next-generation sequencing and only for subjects meeting CR or better by IMWG criteria. Transplant ineligible

sCR rate based on best response during follow up time.

Table 23 Summary of post-consolidation MRD negative rate by flow cytometry at 10 -5  in bone marrow; ITT analysis set (MMY3006)

|                                            | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------------------|--------------------------------|--------------------------------|
|                                            | VId                            | DVTd                           |
| Analysis set: intent-to-treat              | 542                            | 543                            |
| MRD negative rate (10-5)                   | 236 (43.5%)                    | 346 (63.7%)                    |
| 95% CI of MRD negative rate                | (39.3%, 47.8%)                 | (59.5%, 67.8%)                 |
| Odds ratio with b5% CIb                    |                                | 2.27 (1.78, 2.90)              |
| P-valuec                                   |                                | <0.0001                        |
| CR or better + MRD negative rate (10-5)    | 108 (19.9%)                    | 183 (33.7%)                    |
| 95% CI of CR or better + MRD negative rate | (16.6%, 23.5%)                 | (29.7%, 37.9%)                 |
| Odds ratio with 95% CIb                    |                                | 2.06 (1.56, 2.72)              |
| P-valuec                                   |                                | <0.0001                        |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE)

+ thalidomide + dexamethasone.

b Mantel-Haenszel estimate of the common odds ratio for stratified tables is used. The stratification factors are site affiliation, ISS stage and cytogenetics.

Exact 95% confidence interval.

p-value from the stratified Cochran Mantel-Haenszel Chi-Squared test.

Note: Percentages are calculated with the number of subjects in each group as denominator.

For patients with PD/death by post-consolidation, MRD is imputed as positive

## Summary of main study

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Summary of Efficacy for trial MMY 3006

Title: Open-label, Multi-center, randomized Study of Darzalex (daratumumab) in combination with bortezomib,  thalidomide  and  dexamethasone  (D-VTd)  versus  VTd  alone  for  patients  with  newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

| Study identifier   | MMY 3006                                            | MMY 3006                                                                    |
|--------------------|-----------------------------------------------------|-----------------------------------------------------------------------------|
| Design             | Phase 3, open-label, multi-center, randomised trial | Phase 3, open-label, multi-center, randomised trial                         |
|                    | Duration of main phase:                             | study initiation date 22 September 2015, data cut off 19 June 2018, ongoing |

<div style=\"page-break-after: always\"></div>

| Hypothesis Treatments groups                    | Superiority D-VTd          | Superiority D-VTd          | Superiority D-VTd          | Induction phase: 4 cycles Daratumumab 16 mcg/kg IV, Q week for 8 weeks (total of 8 doses), weeks 9-16: q2 week (total of 4 doses)                                                                                                                                                                                                                                                                                                | Induction phase: 4 cycles Daratumumab 16 mcg/kg IV, Q week for 8 weeks (total of 8 doses), weeks 9-16: q2 week (total of 4 doses)                                                                                                                                                                                                                                                                                                | Induction phase: 4 cycles Daratumumab 16 mcg/kg IV, Q week for 8 weeks (total of 8 doses), weeks 9-16: q2 week (total of 4 doses)                                                                                                                                                                                                                                                                                                |
|-------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | VTd                        | VTd                        | VTd                        | VTd, as below Induction phase: 4 cycles Consolidation phase: 2 cycles Bortezomib (SC or intravenous [IV]): 1.3 mg/m 2 twice weekly for 2 weeks (Days 1, 4, 8, and 11) in each cycle. Thalidomide (oral): 100 mg daily in each cycle. Dexamethasone (oral or IV): 40 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. | VTd, as below Induction phase: 4 cycles Consolidation phase: 2 cycles Bortezomib (SC or intravenous [IV]): 1.3 mg/m 2 twice weekly for 2 weeks (Days 1, 4, 8, and 11) in each cycle. Thalidomide (oral): 100 mg daily in each cycle. Dexamethasone (oral or IV): 40 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. | VTd, as below Induction phase: 4 cycles Consolidation phase: 2 cycles Bortezomib (SC or intravenous [IV]): 1.3 mg/m 2 twice weekly for 2 weeks (Days 1, 4, 8, and 11) in each cycle. Thalidomide (oral): 100 mg daily in each cycle. Dexamethasone (oral or IV): 40 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of Cycles 1 and 2, and at 40 mg on Days 1-2 and 20 mg on subsequent dosing days (Days 8, 9, 15, 16) of Cycles 3-4. |
| Endpoints and definitions                       | Primary endpoint           | sCR                        | sCR                        | The percentage of subjects achieving CR in addition to having a normal serum FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.                                                                                                                                                                                                                | The percentage of subjects achieving CR in addition to having a normal serum FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.                                                                                                                                                                                                                | The percentage of subjects achieving CR in addition to having a normal serum FLC ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.                                                                                                                                                                                                                |
|                                                 | Secondary                  | MRD negativity             | MRD negativity             | The proportion of subjects who have negative MRD.                                                                                                                                                                                                                                                                                                                                                                                | The proportion of subjects who have negative MRD.                                                                                                                                                                                                                                                                                                                                                                                | The proportion of subjects who have negative MRD.                                                                                                                                                                                                                                                                                                                                                                                |
|                                                 | Secondary                  | CR or better               | CR or better               | The proportion of subjects with a response of CR or better (i.e., CR or sCR), according to                                                                                                                                                                                                                                                                                                                                       | The proportion of subjects with a response of CR or better (i.e., CR or sCR), according to                                                                                                                                                                                                                                                                                                                                       | The proportion of subjects with a response of CR or better (i.e., CR or sCR), according to                                                                                                                                                                                                                                                                                                                                       |
| Database lock 19 June 2018                      | Database lock 19 June 2018 | Database lock 19 June 2018 | Database lock 19 June 2018 | Database lock 19 June 2018                                                                                                                                                                                                                                                                                                                                                                                                       | Database lock 19 June 2018                                                                                                                                                                                                                                                                                                                                                                                                       | Database lock 19 June 2018                                                                                                                                                                                                                                                                                                                                                                                                       |
| Results and Analysis                            | Results and Analysis       | Results and Analysis       | Results and Analysis       | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                             |
| Analysis description                            | Primary Analysis           | Primary Analysis           | Primary Analysis           | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Analysis population and time point description  | Intent to treat Treatment  | Intent to treat Treatment  | VTd                        | VTd                                                                                                                                                                                                                                                                                                                                                                                                                              | D-VTd                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Descriptive statistics and estimate variability | Number of subject          | Number of subject          | 542                        | 542                                                                                                                                                                                                                                                                                                                                                                                                                              | 543                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                 | sCR                        | sCR                        | 20.3%                      | 20.3%                                                                                                                                                                                                                                                                                                                                                                                                                            | 28.9%                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                 | 95% CI                     | 95% CI                     | (17.0%, 23.9%)             | (17.0%, 23.9%)                                                                                                                                                                                                                                                                                                                                                                                                                   | (25.1%, 32.9%)                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                 | MRD                        | MRD                        | 43.5%                      | 43.5%                                                                                                                                                                                                                                                                                                                                                                                                                            | 63.7%                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                 | 95% CI                     | 95% CI                     | (39.3%, 47.8%)             | (39.3%, 47.8%)                                                                                                                                                                                                                                                                                                                                                                                                                   | (59.7%, 67.8%)                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                 | CR or better 95% CI        | CR or better 95% CI        | 26.0% (22.4%, 29.9%)       | 26.0% (22.4%, 29.9%)                                                                                                                                                                                                                                                                                                                                                                                                             | 38.9% (34.7%, 43.1%)                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  | Primary endpoint           | Primary endpoint           | VTd                        | VTd                                                                                                                                                                                                                                                                                                                                                                                                                              | D-VTd                                                                                                                                                                                                                                                                                                                                                                                                                            | D-VTd                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                 | sCR                        | sCR                        | Odds ratio                 | Odds ratio                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.60                                                                                                                                                                                                                                                                                                                                                                                                                             | 1.60                                                                                                                                                                                                                                                                                                                                                                                                                             |
|                                                 |                            |                            | 95% CI                     | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                           | (1.21, 2.12)                                                                                                                                                                                                                                                                                                                                                                                                                     | (1.21, 2.12)                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                 | Secondary endpoint         | Secondary endpoint         | P-value VTd                | P-value VTd                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.0010 D-VTd                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.0010 D-VTd                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| MRD negativity     | Odds ratio   | 2.27         |
|--------------------|--------------|--------------|
|                    | 95% CI       | (1.78, 2.90) |
|                    | P-value      | <0.0001      |
| Secondary endpoint | VTd          | D-VTd        |
| CR or better       | Odds ratio   | 1.82         |
|                    | 95% CI       | (1.40, 2.36) |
|                    | P-value      | <0.0001      |

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The MAH has provided a randomised phase 3, open label multicentre study, MMY3006 in patients 18-65 years newly diagnosed with multiple myeloma and eligible for HDT and ASCT.

The  study  MMY3006  consists  of  2  stages:  In  Part  1  (Induction/ASCT/Consolidation)  subjects  were randomized in a 1:1 ratio to receive either D-VTd or VTd (4 cycles of induction therapy before ASCT and 2 cycles of consolidation therapy after ASCT). Response was assessed approximately 100 days post-ASCT and eligibility for the second randomization was determined. In Part 2 (Maintenance) subjects with at least a partial response (PR) by Day 100 post-transplant were re-randomized in a 1:1 ratio to daratumumab maintenance or observation only (not included in this submission). The goal of Part 1 was aimed to show a higher rate of sCR with the fact of adding daratumumab to VTd induction and consolidation therapy.

The objectives are clearly described and the primary endpoint sCR is acceptable, clinically meaningful and important for long term follow-up. The secondary endpoints are acceptable and relevant from a clinical point of view.

The proposed statistical methods are, in general, endorsed. The sample size calculations were based on both the induction and the maintenance phases, the power for the current study, Part 1, is considered acceptable. The MAH acknowledged the CHMP's concern that the power for the maintenance phase may be decreased when interaction between maintenance and induction treatments exists. Simulations have been performed to understand the impact of the interaction on the power for Part 2.

The randomization stratification factors, i.e. site affiliation, ISS category (I, II, or III), and cytogenetics (standard risk or high risk) were agreed and considered important prognostic factors in MM.

It was agreed that the different age groups of the study should be reflected in Section 5.1, as age is not the only parameter defining eligibility for HDT and ASCT.

The baseline characteristics are well balanced. The majority of patients had IgG myeloma and measurable disease in IgG and IgA, ISS stage I and II, most patients had normal cytogenetics and were considered standard risk (85.5% vs. 15.5%). The median time from diagnosis of multiple myeloma to randomization was approximately 1 month, but the range for 'time since initial diagnoses to randomisation' was up to 31 -  and 66 months respectively in the VTd and the DVTd group. Minor protocol violations were considered non-significant to the overall result.

Overall the study was well conducted, however the MAH was requested to provide additional analyses in order to obtain more information about the difference observed in PFS given only by the induction/consolidation treatment This is because the treatment effect for PFS for Part 1 is affected by the second part of the study, since patients with PR or better after the consolidation phase were offered to be randomized to daratumumab maintenance or observation.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

The study met its  primary  endpoint  (part  1)  results  using  a  clinical  cut-off  of  19  June  2018showed  a statistically significant improvement in the sCR rate post-consolidation (100 days post-ASCT) in favour of D-VTd arm  (DVTd 28.9% vs. VTd 20.3%, odds ratio 95%CI: 1.60 (1.21, 2.12), p=0.0010).

Further data was provided from an updated clinical data cut-off of 1 May 2019, i.e. 10 months after the original cut-off. The updated data continue to show a statistically significant improvement in the sCR rate in favour of the D-VTd arm (DVTd 54.3% vs. VTd 42.1%, odds rati o 95%CI: 1.64, 2.09, p&lt;0.0001). The updated results were consistent in the pre-specified subgroups. both ISS Stage III and cytogenetic highrisk  subgroups  did  benefit  in  the  DVTd  treatment  group  compared  with  the  VTd  group.  The  updated investigator assessment was consistent with the computerised algorithm results with an odds ratio 95%CI: 1.66 (1.30, 2.11), p&lt;0.0001. Nevertheless, the clinical relevance of gaining this difference in sCR is not entirely clear. Ideally, a quantitative correlation between sCR and PFS should be shown in order to achieve a  positive  conclusion  from  this  part  1  of  the  study.  However,  the  correlation  of  between-arm differences/odds ratios for sCR and HR for PFS and OS in the present treatment setting is not established. Further, due to the study design, including eligibility for randomisation to part 2 being contingent on a postbaseline event impacted by initial therapy, there appears to be no straightforward way within this study to isolate the impact of the induction/consolidation regimen alone on PFS in the ITT population for study part 1. It is agreed that the depth of response after ASCT in MM, especially achievement of CR is an important predictor of a positive long-term outcome by means of PFS and OS. The MAH refers to previous published trials showing that patients who achieved sCR, had better PFS (Chakraborty, 2017, Van de Velde, 2017). Despite  several  confounding  factors  and  bias,  pooling  of  previous  studies  MMY3003,  MMY3004  and MMY3007 indicated an association between sCR and PFS. The MAH has updated the efficacy analyses for the MMY3006 study as of clinical cut-off of 1 May 2019, adding 10 months to the follow-up period with a median of 29.2 months of follow-up. The updated data were consistent with the primary analyses, by the means of sCR, CR or better, PFS, MRD negativity and TTP, with and without adjustment for the second randomization. The MAH performed an analysis for PFS where patients who received maintenance therapy at the second randomization were censored. The results are in line with those presented in the primary analysis, with a HR (95% CI) of 0.50 (0.34, 0.75), p-value = 0.0005. This analysis did not take into account the contribution of daratumumab maintenance on PFS. Part of the contribution of induction effect is also removed since patients are censored at the start of maintenance therapy. Therefore, it seems reasonable to  conclude  that  the  addition  of  daratumumab  on top  of  VTd  induction/consolidation  regimen  leads  to significantly prolong the PFS over the VTd arm for study part 1

The updated prespecified subgroup analyses of PFS were consistent across subgroups, but OS data were however still immature, as expected.

Secondary endpoints, MRD negativity, CR or better and PFS were consistent and confirmed the primary analysis. The effect on MRD negativity was significant and consistent throughout all subgroups, also the high-risk and ISS Stage III subgroups. However, not all patients who were MRD negative had a sCR/CR response.  The MAH speculated whether the discrepancy of MRD and CR may be related to the kinetics of clearance of plasma cells in the bone marrow compared with clearance of paraprotein in blood or urine. An analysis of why MRD negative subjects did not meet CR or sCR according to the IMWG criteria at post consolidation was performed. The main reasons for not having CR/sCR was that a negative immunofixation on the serum or urine could not be established, either due to missing confirmation of the clearance of paraprotein from serum/urine or due to remaining traces of the paraprotein, further sampling error in patient not in CR could not be ruled out. It is acknowledged that clinical trials in MM include measurements of MRD, and future studies can hopefully clarify how MRD pfs be used in clinical practice.

HDT and ASCT was performed in a similar proportion of patients in the two treatment groups. Mobilizing and collecting cells was feasible in both treatment groups. However, more patients in the DVTd group

<div style=\"page-break-after: always\"></div>

received  Mozobil  for  mobilization  compared  with  the  VTd  group  (21.7%vs.  7.9%)  and  the  number  of collected cells was lower in the D-VTd group compared with the VTd group.  This could indicate that patients in the DVTd group were poor mobiliser compared with the VTd group. The MAH performed analyses to identify potential factors that could explain the low yield of CD34+ cells in the DVTd arm. No relationship could be established between neutropenia before start of mobilisation and stem cell output or between the overall response to the treatment and stem cell yield.

It has been stated that subjects who did not achieve a response (i.e. PR or better) entered the Follow-up Phase and were followed until disease progression or death, even if they received subsequent treatment. In this regard

OS and PFS data are still immature. The MAH has committed (letter of recommendation) to provide postapproval  updated  part  1  PFS  results  (including  the  analysis  censoring  patients  in  each  arm  who  were randomised to daratumumab maintenance in the second randomisation) and updated part 1 OS data in 2021 based on the data cut of the planned interim analysis.

## 2.4.4. Conclusions on the clinical efficacy

The Study MMY3006 in the part 1 met its primary endpoint and showed statistically significant results. Based on the whole PFS data, it seems reasonable to expect that the addition of daratumumab on top of VTd in the induction/consolidation regimen provides a longer PFS than VTd.

## 2.5. Clinical safety

## Introduction

Summaries of adverse events and other safety data are based on 1074 subjects (DVTd: 536 subjects, VTd: 538 subjects) who The analysis includes all subjects that were randomized and treated in induction and consolidation (Part 1) or had discontinued study treatment by the time of the data cut-off and contributed any safety data after the start of study treatment, i.e. the Safety Population.

## Patient exposure

The median duration of induction/ASCT/consolidation treatment was 8.9 months for the DVTd group and 8.7 months for the VTd group (Table 25). The median number of treatment cycles was 6 (range 1-6) for both DVTd group and VTd group (Table 24).

<div style=\"page-break-after: always\"></div>

Table 24 Induction/ASCT/Consolidation Treatment Cycles During Induction/ASCT/Consolidation Phase; Safety Analysis Set (Study 54767414MMY3006)

|                            | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|----------------------------|--------------------------------|--------------------------------|
|                            | VTd                            | DVTd                           |
| Analysisset:safety         | 538                            | 536                            |
| Number of treatment cycles |                                |                                |
| Induction                  |                                |                                |
| N                          | 538                            | 536                            |
| At least 1 cycle           | 538 (100.0%)                   | 536 (100.0%)                   |
| At least 2 cycles          | 530 (98.5%)                    | 530 (98.9%)                    |
| At least 3 cycles          | 526 (97.8%)                    | 525 (97.9%)                    |
| 4 cycles                   | 512 (95.2%)                    | 518 (96.6%)                    |
| Mean (SD)                  | 3.9 (0.43)                     | 3.9 (0.38)                     |
| Median                     | 4.0                            | 4.0                            |
| Range                      | (1; 4)                         | (1; 4)                         |
| Consolidation              |                                |                                |
| N                          | 448                            | 466                            |
| At least 1 cycle           | 448 (83.3%)                    | 466 (86.9%)                    |
| 2 cycles                   | 437 (81.2%)                    | 464 (86.6%)                    |
| Mean (SD)                  | 2.0 (0.15)                     | 2.0 (0.07)                     |
| Median                     | 2.0                            | 2.0                            |
| Range                      | (1; 2)                         | (1; 2)                         |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide+dexamethasone.

Note: Percentages are calculated with the number of subjects in each group as denominator.

<div style=\"page-break-after: always\"></div>

Table 25 Summary of Duration of Induction/ASCT/Consolidation Treatment and Gaps Between Treatment Phases; Safety Analysis Set (Study 54767414MMY3006)

|                                                                      | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|----------------------------------------------------------------------|--------------------------------|--------------------------------|
|                                                                      | VTd                            | DVTd                           |
| Analysis set: safety                                                 | 538                            | 536                            |
| Treatment duration (months)                                          |                                |                                |
| Inductiona                                                           |                                |                                |
| N                                                                    | 538                            | 536                            |
| Mean (SD)                                                            | 3.57 (0.493)                   | 3.60 (0.469)                   |
| Median                                                               | 3.68                           | 3.68                           |
| Range                                                                | (0.1; 4.5)                     | (0.0; 4.7)                     |
| ASCTb                                                                |                                |                                |
| N                                                                    | 448                            | 466                            |
| Mean (SD)                                                            | 1.81 (0.399)                   | 1.82 (0.384)                   |
| Median                                                               | 1.81                           | 1.81                           |
| Range                                                                | (1.0; 3.7)                     | (1.0; 4.8)                     |
| Consolidation                                                        |                                |                                |
| N                                                                    | 448                            | 466                            |
| Mean (SD)                                                            | 1.78 (0.272)                   | 1.81 (0.222)                   |
| Median                                                               | 1.84                           | 1.84                           |
| Range                                                                | (0.0; 2.8)                     | (0.3; 3.0)                     |
| Induction/ASCT/Consolidation                                         |                                |                                |
| N                                                                    | 448                            | 466                            |
| Mean (SD)                                                            | 8.81 (0.723)                   | 8.91 (0.694)                   |
| Median                                                               | 8.74                           | 8.87                           |
| Range                                                                | (6.4; 11.5)                    | (7.0; 12.0)                    |
| Gaps between treatment phases (months)                               |                                |                                |
| Time from last dose of induction till start of                       |                                |                                |
| ASCT                                                                 |                                |                                |
| N                                                                    | 484                            | 489                            |
| Mean (SD)                                                            | 1.64 (0.605)                   | 1.69 (0.584)                   |
| Median                                                               | 1.53                           | 1.61                           |
| Range                                                                | (0.1; 5.2)                     | (0.5; 4.2)                     |
| Time from last dose of induction till first                          |                                |                                |
| dose of consolidation                                                |                                |                                |
| N                                                                    | 448                            | 466                            |
| Mean (SD)                                                            | 3.42 (0.673)                   | 3.49 (0.661)                   |
| Median                                                               | 3.29                           | 3.48                           |
| Range                                                                | (1.9; 6.3)                     | (2.0; 6.5)                     |
| Timefromlastdoseof daratumumab induction tillfirstdoseof daratumumab |                                |                                |
| consolidation                                                        |                                |                                |
| N                                                                    | 0                              | 466                            |
| Mean (SD)                                                            |                                | 3.88 (0.653)                   |
| Median                                                               |                                | 3.75                           |
| Range                                                                |                                | (2.4; 6.9)                     |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

*Duration of Induction Treatment: from 1 \" induction dose date to the last induction dose date.

bDuration of ASCT phase: time in between transplantation and start of consolidation treatment. Patients who never started consolidation after having received transplantation were not taken into account for this calculation.

Duration of Consolidation Treatment: from 1 consolidation dose date to the last consolidation dose date.

[TSIEXP03\\_3006.RTF] [JNJ-54767414MMY3006DBR\\_PART1\\_CSRIRE\\_PART1\\_CSR PROD\\TSIEXP03\\_3006.SAS]17JAN2019,

<div style=\"page-break-after: always\"></div>

The mean relative dose intensities were similar between the treatment groups (Table 26):

Table 26 Overview of Relative Dose Intensity During Induction/ASCT/Consolidation Phase; Safety Analysis Set (Study 54767414MMY3006)

|                             | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|-----------------------------|--------------------------------|--------------------------------|
|                             | VTd                            | DVTd                           |
| Analysis set: safety        | 538                            | 536                            |
| Relative dose intensity (%) |                                |                                |
| Daratumumab                 |                                |                                |
| Induction Cycles 1-2        |                                |                                |
| N                           | 0                              | 536                            |
| Mean (SD)                   |                                | 98.30 (7.103)                  |
| Median                      |                                | 100.00                         |
| Q1,Q3                       |                                | (98.49; 100.57)                |
| Range                       |                                | (7.3; 122.0)                   |
| Induction Cycles 3-4        |                                |                                |
| N                           | 0                              | 525                            |
| Mean (SD)                   |                                | 98.35 (5.669)                  |
| Median                      |                                | 99.48                          |
| Q1, Q3                      |                                | (96.88; 100.65)                |
| Range                       |                                | (71.3; 112.5)                  |
| Consolidation               |                                |                                |
| N                           | 0                              | 466                            |
| Mean (SD)                   |                                | 99.89 (7.214)                  |
| Median                      |                                | 100.00                         |
| Q1, Q3                      |                                | (98.39;102.78)                 |
| Range                       |                                | (31.5; 131.2)                  |
| Induction/Consolidation     |                                |                                |
| N                           | 0                              | 536                            |
| Mean (SD)                   |                                | 98.38 (6.306)                  |
| Median                      |                                | 99.72                          |
| Q1, Q3                      |                                | (97.76; 100.78)                |
| Range                       |                                | (7.3; 113.1)                   |
| Bortezomib                  |                                |                                |
| Induction/Consolidation     |                                |                                |
| N                           | 538                            | 536                            |
| Mean (SD)                   | 91.31 (11.211)                 | 91.50 (12.057)                 |
| Median                      | 96.30                          | 96.77                          |
| Q1, Q3                      | (84.73; 99.17)                 | (87.02; 99.45)                 |
| Range                       | (49.2; 106.7)                  | (24.5;105.7)                   |
| Thalidomide                 |                                |                                |
| Induction/Consolidation     |                                |                                |
| N                           | 538                            | 536                            |
| Mean (SD)                   | 86.1 (18.36)                   | 86.6 (19.30)                   |
| Median                      | 95.4                           | 96.4                           |
| Q1, Q3                      | (78.0; 100.0)                  | (79.2; 100.0)                  |
| Range                       | (0; 104)                       | (2; 150)                       |
| Dexamethasone               |                                |                                |
| Induction/Consolidation     |                                |                                |
| N                           | 538                            | 536                            |
| Mean (SD)                   | 96.2 (11.84)                   | 96.8 (10.14)                   |
| Median                      | 100.0                          | 100.0                          |
| Q1, Q3                      | (96.7; 100.0)                  | (96.7; 100.0)                  |
| Range                       | (0; 125)                       | (13; 120)                      |

Key:VTd=bortezomib (VELCADE)+ thalidomide + dexamethasone;DVTd=daratumumab +bortezomib (VELCADE)+ thalidomide+dexamethasone.

<div style=\"page-break-after: always\"></div>

## Adverse events

In the DVTd and VTd groups, 99.6% and 99.8% of subjects, respectively, experienced at least 1 treatmentemergent adverse event (TEAE) during induction/ASCT/consolidation.

Table 27 Overview of Treatment-Emergent Adverse Events During Induction/ASCT/Consolidation Phase; Safety Analysis Set (Study 54767414MMY3006)

|                                                | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                | VTd                            | VTd                            | VTd                            | VTd                            |                                |                                |                                |                                |
|                                                | Induction/AS CT/Consolida tion | Induction                      | ASCT                           | Consolidation                  | Induction/AS CT/Consolida tion | Induction                      | ASCT                           | Consolidation                  |
| Analysis set: safety                           | 538                            | 538                            | 484                            | 448                            | 536                            | 536                            | 489                            | 466                            |
| Any TEAE                                       | 536 (99.6%)                    | 529 (98.3%)                    | 299 (61.8%)                    | 346 (77.2%)                    | 535 (99.8%)                    | 530 (98.9%)                    | 292 (59.7%)                    | 394 (84.5%)                    |
| At least one relateda                          | 518 (96.3%)                    | 494 (91.8%)                    | 89 (18.4%)                     | 269 (60.0%)                    | 523 (97.6%)                    | 510 (95.1%)                    | 92 (18.8%)                     | 321 (68.9%)                    |
| Maximum severity of any TEAEb                  |                                |                                |                                |                                |                                |                                |                                |                                |
| Grade 1                                        | 15 (2.8%)                      | 41 (7.6%)                      | 37 (7.6%)                      | 93 (20.8%)                     | 13 (2.4%)                      | 35 (6.5%)                      | 42 (8.6%)                      | 86 (18.5%)                     |
| Grade 2                                        | 112 (20.8%)                    | 180 (33.5%)                    | 90 (18.6%)                     | 167 (37.3%)                    | 90 (16.8%)                     | 182 (34.0%)                    | 68 (13.9%)                     | 157 (33.7%)                    |
| Grade 3                                        | 298 (55.4%)                    | 232 (43.1%)                    | 165 (34.1%)                    | 81 (18.1%)                     | 287 (53.5%)                    | 220 (41.0%)                    | 159 (32.5%)                    | 129 (27.7%)                    |
| Grade 4                                        | 102 (19.0%)                    | 71 (13.2%)                     | 17 (3.5%)                      | 22 (4.9%)                      | 144 (26.9%)                    | 93 (17.4%)                     | 35 (7.2%)                      | 39 (8.4%)                      |
| Grade 5                                        | 9 (1.7%)                       | 5 (0.9%)                       | 1 (0.2%)                       | 3 (0.7%)                       | 1 (0.2%)                       | 0                              | 0                              | 1 (0.2%)                       |
| Any serious TEAE                               | 255 (47.4%)                    | 192 (35.7%)                    | 60 (12.4%)                     | 46 (10.3%)                     | 251 (46.8%)                    | 180 (33.6%)                    | 65 (13.3%)                     | 56 (12.0%)                     |
| At least one related?                          | 114 (21.2%)                    | 88 (16.4%)                     | 10 (2.1%)                      | 24 (5.4%)                      | 148 (27.6%)                    | 103 (19.2%)                    | 15 (3.1%)                      | 44 (9.4%)                      |
| TEAEleading todiscontinuation of daratumumabin |                                |                                |                                |                                |                                |                                |                                |                                |
| Induction/ASCT/Consolidation                   | 0                              | 0                              | 0                              | 0                              | 46 (8.6%)                      | 33 (6.2%)                      | 10 (2.0%)                      | 3 (0.6%)                       |
| Atleastonerelatedtodaratumumab                 | 0                              | 0                              | 0                              | 0                              | 11 (2.1%)                      | 9 (1.7%)                       | 1 (0.2%)                       | 1 (0.2%)                       |
| TEAEleadingtodiscontinuationof                 |                                |                                |                                |                                |                                |                                |                                |                                |
| bortezomibc                                    | 56 (10.4%)                     | 33 (6.1%)                      | 11 (2.3%)                      | 12 (2.7%)                      | 74 (13.8%)                     | 44 (8.2%)                      | 13 (2.7%)                      | 17 (3.6%)                      |
| Atleastonerelatedtobortezomib                  | 45 (8.4%)                      | 27 (5.0%)                      | 10 (2.1%)                      | 8 (1.8%)                       | 48 (9.0%)                      | 27 (5.0%)                      | 8 (1.6%)                       | 13 (2.8%)                      |
| TEAE leading todiscontinuation of              |                                |                                |                                |                                |                                |                                |                                |                                |
| thalidomidec                                   | 97 (18.0%)                     | 67 (12.5%)                     | 16 (3.3%)                      | 17 (3.8%)                      | 114 (21.3%)                    | 69 (12.9%)                     | 15 (3.1%)                      | 31 (6.7%)                      |
| At least one related to thalidomide            | 85 (15.8%)                     | 59 (11.0%)                     | 15 (3.1%)                      | 13 (2.9%)                      | 87 (16.2%)                     | 50 (9.3%)                      | 9 (1.8%)                       | 28 (6.0%)                      |
| TEAEleadingtodiscontinuation of                |                                |                                |                                |                                |                                |                                |                                |                                |
| dexamethasonec                                 | 55 (10.2%)                     | 35 (6.5%)                      | 10 (2.1%)                      | 10 (2.2%)                      | 49 (9.1%)                      | 32 (6.0%)                      | 11 (2.2%)                      | 6 (1.3%)                       |
| At least one related todexamethasone           | 10 (1.9%)                      | 5 (0.9%)                       | 0                              | 5 (1.1%)                       | 8 (1.5%)                       | 6 (1.1%)                       | 1 (0.2%)                       | 1 (0.2%)                       |
| TEAEleadingtodiscontinuationofstudy treatmentd | 45 (8.4%)                      | 29 (5.4%)                      | 10 (2.1%)                      | 6 (1.3%)                       | 40 (7.5%)                      | 28 (5.2%)                      | 10 (2.0%)                      | 2 (0.4%)                       |

Key:VTd=bortezomib (VELCADE)+ thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE)+ thalidomide + dexamethasone.

Key: TEAE = treatment-emergent adverse event.

Maximum severity of any TEAE is based on Part I for each patient for the Part I columns and maximum severity of TEAE is based on period for the period columns.

a TEAE Related to at least one of the four components of any study treatment, drug bortezomib, thalidomide, dexamethasone or daratumumab.

Include those subjects indicated as having discontinued treatment due to an adverse event on the end of treatment CRF page.

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

d Include those subjects indicated as having discontinued all study treatments due to adverse events or treatment delay for toxicity for more than 6 weeks on the end of treatment CRF page.

Note: Percentages are calculated with the number of subjects in each phase/group as denominator.

During the transplant period, according to protocol, only limited AE were collected.

The overall incidences of TEAEs during induction/ASCT/consolidation were similar in both treatment groups (DVTd: 99.6%; VTd: 99.8%). Treatment-emergent adverse events classified by SOC and preferred term that occurred in ≥ 10% of subjects from either treatment group are presented in Table 28.

TEAEs that occurred at a ≥ 5% higher frequency in the DVTd treatment group compared with the VTd treatment group, respectively, included

- Nausea (DVTd: 30.2%; VTd: 24.2%)
- Neutropenia (DVTd: 29.3%; VTd: 16.5%)
- Thrombocytopenia (DVTd: 20.3%; VTd: 13.6%)
- Lymphopenia (DVTd: 18.5%; VTd: 12.5%)
- Cough (DVTd: 17.2%; VTd: 10.4%)

<div style=\"page-break-after: always\"></div>

Table 28 Overview of Treatment-Emergent Adverse Events During Induction/ASCT/Consolidation Phase; Safety Analysis Set (Study 54767414MMY3006)

Table 21 MostCommon(AtLeast1o%)Treatment-EmergentAdverseEventsDuringInduction/ASCT/ConsolidationPhasebySystemOrgan Class,PreferredTerm;SafetyAnalysisSet(Study54767414MIMY3006)

|                                        | Induction/ASCT/Consolidation       | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation       | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|----------------------------------------|------------------------------------|--------------------------------|--------------------------------|--------------------------------|------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Analysis set:safety                    | Induction/AS CT/Consolida tion 538 | Induction 538                  | VTd ASCT 484                   | Consolidation 448              | Induction/AS CT/Consolida tion 536 | Induction 536                  | DVTd ASCT 489                  | Consolidation 466              |
| TotalnumberofsubjectswithTEAE          | 536 (99.6%)                        | 529 (98.3%)                    | 299 (61.8%)                    | 346 (77.2%)                    | 535 (99.8%)                        | 530 (98.9%)                    | 292 (59.7%)                    | 394 (84.5%)                    |
| MedDRAsystemorganclass/preferredterm   |                                    |                                |                                |                                |                                    |                                |                                |                                |
| Nervoussystem disorders                | 456 (84.8%)                        | 398 (74.0%)                    | 59 (12.2%)                     | 135 (30.1%)                    | 437 (81.5%)                        | 381 (71.1%)                    | 53 (10.8%)                     | 140 (30.0%)                    |
| Peripheralsensoryneuropathy            | 340 (63.2%)                        | 273 (50.7%)                    | 34 (7.0%)                      | 81 (18.1%)                     | 314 (58.6%)                        | 251 (46.8%)                    | 28 (5.7%)                      | 78 (16.7%)                     |
| Paraesthesia                           | 108 (20.1%)                        | 88 (16.4%)                     | 7 (1.4%)                       | 21 (4.7%)                      | 118 (22.0%)                        | 101 (18.8%)                    | 8 (1.6%)                       | 25 (5.4%)                      |
| Tremor                                 | 58 (10.8%)                         | 54 (10.0%)                     | 1 (0.2%)                       | 3 (0.7%)                       | 71 (13.2%)                         | 69 (12.9%)                     | 0                              | 8 (1.7%)                       |
| Gastrointestinaldisorders              | 416 (77.3%)                        | 372 (69.1%)                    | 138 (28.5%)                    | 65 (14.5%)                     | 431 (80.4%)                        | 385 (71.8%)                    | 117 (23.9%)                    | 118 (25.3%)                    |
| Constipation                           | 262 (48.7%)                        | 253 (47.0%)                    | 1 (0.2%)                       | 21 (4.7%)                      | 272 (50.7%)                        | 261 (48.7%)                    | 1 (0.2%)                       | 26 (5.6%)                      |
| Nausea                                 | 130 (24.2%)                        | 104 (19.3%)                    | 22 (4.5%)                      | 11 (2.5%)                      | 162 (30.2%)                        | 140 (26.1%)                    | 26 (5.3%)                      | 20 (4.3%)                      |
| Diarrhoea                              | 89 (16.5%)                         | 55 (10.2%)                     | 25 (5.2%)                      | 11 (2.5%)                      | 103 (19.2%)                        | 58 (10.8%)                     | 23 (4.7%)                      | 29 (6.2%)                      |
| Vomiting                               | 52 (9.7%)                          | 40 (7.4%)                      | 11 (2.3%)                      | 5 (1.1%)                       | 87 (16.2%)                         | 60 (11.2%)                     | 9 (1.8%)                       | 27 (5.8%)                      |
| Stomatitis                             | 104 (19.3%)                        | 19 (3.5%)                      | 85 (17.6%)                     | 3 (0.7%)                       | 86 (16.0%)                         | 18 (3.4%)                      | 69 (14.1%)                     | 6 (1.3%)                       |
| Generaldisordersandadministrationsite  |                                    |                                |                                |                                |                                    |                                |                                |                                |
| conditions                             | 398 (74.0%)                        | 359 (66.7%)                    | 39 (8.1%)                      | 104 (23.2%)                    | 414 (77.2%)                        | 378 (70.5%)                    | 57 (11.7%)                     | 112 (24.0%)                    |
| Asthenia                               | 155 (28.8%)                        | 129 (24.0%)                    | 5 (1.0%)                       | 29 (6.5%)                      | 171 (31.9%)                        | 142 (26.5%)                    | 20 (4.1%)                      | 31 (6.7%)                      |
| Oedema peripheral                      | 148 (27.5%)                        | 131 (24.3%)                    | 5 (1.0%)                       | 28 (6.3%)                      | 162 (30.2%)                        | 151 (28.2%)                    | 4 (0.8%)                       | 22 (4.7%)                      |
| Pyrexia                                | 114 (21.2%)                        | 94 (17.5%)                     | 20 (4.1%)                      | 13 (2.9%)                      | 140 (26.1%)                        | 114 (21.3%)                    | 21 (4.3%)                      | 21 (4.5%)                      |
| Fatigue                                | 86 (16.0%)                         | 75 (13.9%)                     | 3 (0.6%)                       | 12 (2.7%)                      | 70 (13.1%)                         | 58 (10.8%)                     | 6 (1.2%)                       | 12 (2.6%)                      |
| Infections andinfestations             | 306 (56.9%)                        | 202 (37.5%)                    | 93 (19.2%)                     | 114 (25.4%)                    | 351 (65.5%)                        | 238 (44.4%)                    | 102 (20.9%)                    | 163 (35.0%)                    |
| Bronchitis                             | 66 (12.3%)                         | 30 (5.6%)                      | 5 (1.0%)                       | 35 (7.8%)                      | 102 (19.0%)                        | 44 (8.2%)                      | 7 (1.4%)                       | 59 (12.7%)                     |
| Blood and lymphatic system disorders   | 253 (47.0%)                        | 191 (35.5%)                    | 41 (8.5%)                      | 96 (21.4%)                     | 303 (56.5%)                        | 228 (42.5%)                    | 47 (9.6%)                      | 148 (31.8%)                    |
| Neutropenia                            | 89 (16.5%)                         | 67 (12.5%)                     | 6 (1.2%)                       | 26 (5.8%)                      | 157 (29.3%)                        | 100 (18.7%)                    | 9 (1.8%)                       | 76 (16.3%)                     |
| Thrombocytopenia                       | 73 (13.6%)                         | 45 (8.4%)                      | 4 (0.8%)                       | 35 (7.8%)                      | 109 (20.3%)                        | 56 (10.4%)                     | 12 (2.5%)                      | 60 (12.9%)                     |
| Lymphopenia                            | 67 (12.5%)                         | 53 (9.9%)                      | 5 (1.0%)                       | 36 (8.0%)                      | 99 (18.5%)                         | 83 (15.5%)                     | 6 (1.2%)                       | 43 (9.2%)                      |
| Anaemia                                | 81 (15.1%)                         | 66 (12.3%)                     | 7 (1.4%)                       | 15 (3.3%)                      | 73 (13.6%)                         | 62 (11.6%)                     | 6 (1.2%)                       | 11 (2.4%)                      |
| Respiratory, thoracic and mediastinal  |                                    |                                |                                |                                |                                    |                                |                                |                                |
| disorders                              | 185 (34.4%)                        | 152 (28.3%)                    | 16 (3.3%)                      | 46 (10.3%)                     | 259 (48.3%)                        | 197 (36.8%)                    | 21 (4.3%)                      | 91 (19.5%)                     |
| Cough                                  | 49 (9.1%)                          | 33 (6.1%)                      | 3 (0.6%)                       | 15 (3.3%)                      | 90 (16.8%)                         | 58 (10.8%)                     | 4 (0.8%)                       | 34 (7.3%)                      |
| Dyspnoea                               | 66 (12.3%)                         | 59 (11.0%)                     | 0                              | 7 (1.6%)                       | 77 (14.4%)                         | 55 (10.3%)                     | 6 (1.2%)                       | 19 (4.1%)                      |
| Skin and subcutaneous tissue disorders | 222 (41.3%)                        | 179 (33.3%)                    | 33 (6.8%)                      | 45 (10.0%)                     | 255 (47.6%)                        | 221 (41.2%)                    | 21 (4.3%)                      | 51 (10.9%)                     |
| Rash                                   | 67 (12.5%)                         | 52 (9.7%)                      | 7 (1.4%)                       | 13 (2.9%)                      | 86 (16.0%)                         | 72 (13.4%)                     | 3 (0.6%)                       | 15 (3.2%)                      |
| Erythema                               | 47 (8.7%)                          | 39 (7.2%)                      | 4 (0.8%)                       | 6 (1.3%)                       | 61 (11.4%)                         | 54 (10.1%)                     | 2 (0.4%)                       | 6 (1.3%)                       |
| Musculoskeletalandconnectivetissue     |                                    |                                |                                |                                |                                    |                                |                                |                                |
| disorders                              | 252 (46.8%)                        | 232 (43.1%)                    | 12 (2.5%)                      | 52 (11.6%)                     | 245 (45.7%)                        | 212 (39.6%)                    | 13 (2.7%)                      | 56 (12.0%)                     |
| Bone pain                              | 82 (15.2%)                         | 76 (14.1%)                     | 2 (0.4%)                       | 8 (1.8%)                       | 70 (13.1%)                         | 62 (11.6%)                     | 1 (0.2%)                       | 10 (2.1%)                      |
| Back pain                              | 55 (10.2%)                         | 51 (9.5%)                      | 2 (0.4%)                       | 6 (1.3%)                       | 59 (11.0%)                         | 50 (9.3%)                      | 4 (0.8%)                       | 7 (1.5%)                       |
| Psychiatricdisorders                   | 153 (28.4%)                        | 122 (22.7%)                    | 20 (4.1%)                      | 23 (5.1%)                      | 141 (26.3%)                        | 121 (22.6%)                    | 15 (3.1%)                      | 22 (4.7%)                      |
| Insomnia                               | 78 (14.5%)                         | 59 (11.0%)                     | 12 (2.5%)                      | 12 (2.7%)                      | 61 (11.4%)                         | 51 (9.5%)                      | 6 (1.2%)                       | 6 (1.3%)                       |
| Anxiety                                | 46 (8.6%)                          | 41 (7.6%)                      | 2 (0.4%)                       | 3 (0.7%)                       | 58 (10.8%)                         | 46 (8.6%)                      | 5 (1.0%)                       | 8 (1.7%)                       |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone;DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone.

Key:TEAE=treatment-emergent adverse event.

Note: Adverse events are reported using MedDRA version 20.0.

During the transplant period, according to protocol, only limited AE were collected.

Note:Percentagesarecalculatedwiththenumberofsubjectsineachphase/groupasdenominator.

## Grade 3 or 4 Treatment-emergent Adverse Events

The incidences of Grade 3 and Grade 4 TEAEs reported during induction/ASCT/consolidation were 80.6% in the DVTd group and 75.8% in the VTd group (Table 29).

<div style=\"page-break-after: always\"></div>

Table 29 Most Common (at least 5%) Grade 3 or 4 Treatment-emergent Adverse Events During Induction/ASCT/Consolidation Phase by MedDRA System Organ Class, Preferred Term and Maximum Toxicity Grade; Safety Analysis Set (Study 54767414MMY3006)

|                                                          | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|----------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                          | VTd                            | VTd                            | VTd                            | DVTd                           | DVTd                           | DVTd                           |
| Analysis set: safety                                     | Total 538                      | Grade 3                        | Grade 4                        | Total 536                      | Grade 3                        | Grade 4                        |
| Total number of subjects with toxicity grade 3 or 4 TEAE | 408 (75.8%)                    | 301 (55.9%)                    | 107 (19.9%)                    | 432 (80.6%)                    | 287 (53.5%)                    | 145 (27.1%)                    |
| MedDRA system organ class/ preferred term                |                                |                                |                                |                                |                                |                                |
| Blood and lymphatic system disorders                     | 196 (36.4%)                    | 128 (23.8%)                    | 68 (12.6%)                     | 249 (46.5%)                    | 146 (27.2%)                    | 103 (19.2%)                    |
| Neutropenia                                              | 79 (14.7%)                     | 40 (7.4%)                      | 39 (7.2%)                      | 148 (27.6%)                    | 86 (16.0%)                     | 62 (11.6%)                     |
| Lymphopenia                                              | 52 (9.7%)                      | 38 (7.1%)                      | 14 (2.6%)                      | 91 (17.0%)                     | 60 (11.2%)                     | 31 (5.8%)                      |
| Thrombocytopenia                                         | 40 (7.4%)                      | 29 (5.4%)                      | 11 (2.0%)                      | 59 (11.0%)                     | 41 (7.6%)                      | 18 (3.4%)                      |
| Febrile neutropenia                                      | 28 (5.2%)                      | 26 (4.8%)                      | 2 (0.4%)                       | 36 (6.7%)                      | 31 (5.8%)                      | 5 (0.9%)                       |
| Gastrointestinaldisorders                                | 131 (24.3%)                    | 120 (22.3%)                    | 11 (2.0%)                      | 124 (23.1%)                    | 114 (21.3%)                    | 10 (1.9%)                      |
| Stomatitis                                               | 88 (16.4%)                     | 83 (15.4%)                     | 5 (0.9%)                       | 68 (12.7%)                     | 60 (11.2%)                     | 8 (1.5%)                       |
| Nervous system disorders                                 | 73 (13.6%)                     | 72 (13.4%)                     | 1 (0.2%)                       | 73 (13.6%)                     | 67 (12.5%)                     | 6 (1.1%)                       |
| Peripheralsensoryneuropathy                              | 46 (8.6%)                      | 46 (8.6%)                      | 0                              | 47 (8.8%)                      | 46 (8.6%)                      | 1 (0.2%)                       |

Key:VTd=bortezomib (VELCADE)+ thalidomide + dexamethasone;DVTd =daratumumab +bortezomib(VELCADE)+ thalidomide + dexamethasone.

Key:TEAE=treatment-emergent adverse event.

Note: Adverse events are reported using MedDRA version 20.0.

During the transplant period,according toprotocol, only limited AEwere collected.

Note:Percentages are calculated with the number of subjects in each group as denominator.

## Adverse Drug Reactions

1. All  TEAEs  reported  in ≥ 10% subjects  in  the  DVTd  treatment  group  and  occurred  at  a  higher incidence ( ≥ 5% difference) in the DVTd treatment group compared with the VTd treatment group were considered ADRs (Table 30). A comparative incidence of TEAEs between the 2 treatment groups was completed after rounding incidences to whole numbers for all events (i.e., 4.9% is rounded to 5%).

Table 30 Adverse Drug reactions (Study 54767414MMY3006)

| Table 8:                                               | Adverse Drug Reactions (Study 54767414MMY3006)   | Adverse Drug Reactions (Study 54767414MMY3006)   | Adverse Drug Reactions (Study 54767414MMY3006)   | Adverse Drug Reactions (Study 54767414MMY3006)   | Adverse Drug Reactions (Study 54767414MMY3006)   | Adverse Drug Reactions (Study 54767414MMY3006)   |
|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                                                        | Any Grade 538                                    | VTd Grade 3                                      | Grade 4                                          | Any Grade 536                                    | DVTd Grade 3                                     | Grade 4                                          |
| Analysis set: safety Infusion reactionsa               | 0                                                | 0                                                | 0                                                | 190 (35.4%)                                      | 17 (3.2%)                                        | 2 (0.4%)                                         |
| Gastrointestinaldisorders                              |                                                  |                                                  |                                                  |                                                  |                                                  |                                                  |
| Nausea                                                 | 130 (24.2%)                                      | 11 (2.0%)                                        | 1 (0.2%)                                         | 162 (30.2%)                                      | 21 (3.9%)                                        | 0                                                |
| Vomiting                                               | 52 (9.7%)                                        | 9 (1.7%)                                         | 0                                                | 87 (16.2%)                                       | 12 (2.2%)                                        | 0                                                |
| General disorders and administrationsiteconditions     |                                                  |                                                  |                                                  |                                                  |                                                  |                                                  |
| Pyrexia                                                | 114 (21.2%)                                      | 12 (2.2%)                                        | 0                                                | 140 (26.1%)                                      | 12 (2.2%)                                        | 2 (0.4%)                                         |
| Infections andinfestations                             |                                                  |                                                  |                                                  |                                                  |                                                  |                                                  |
| Upper respiratory tract infectionb                     | 91 (16.9%)                                       | 3 (0.6%)                                         | 0                                                | 147 (27.4%)                                      | 3 (0.6%)                                         | 0                                                |
| Bronchitisc                                            | 68 (12.6%)                                       | 6 (1.1%)                                         | 0                                                | 105 (19.6%)                                      | 8 (1.5%)                                         | 0                                                |
| Respiratory, thoracic and mediastinal disorders Coughd | 49 (9.1%)                                        | 0                                                | 0                                                | 91 (17.0%)                                       | 0                                                | 0                                                |
| Vascular disorders Hypertension                        | 29 (5.4%)                                        | 12 (2.2%)                                        | 0                                                | 51 (9.5%)                                        | 22 (4.1%)                                        | 0                                                |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone:DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone. Includes terms determined by investigators toberelated toinfusion.

tract inectionviral,RhinitisRhinovirusinfection,Sinusitis,Tonsillitis,TracheitisUpperrespiratory tractinfectionViralpharyngitis,ViralrhinitisViralupperrespiratory tractinfection Bronchiolitis, Bronchitis, Bronchitis chronic, Respiratory syncytial virus bronchitis, Tracheobronchitis

Note:Based on Part 1 of theMMY3006 study.

dCough,Productive cough

Adverse events are reported using MedDRA version 20.0.

Percentages arecalculatedwithN asthe denominator,thenumber of safety subjectsineach treatment arm.

2. All  laboratory  parameters in Study MMY3006 were reviewed. No laboratory parameters had an incidence of Grade 3 or 4 values ≥ 10% except for haematology parameters (Table 31).
3. Thrombocytopenia, neutropenia, lymphopenia, leukopenia, and anaemia are listed in a separate haematology  laboratory  table  based  on  haematology  laboratory  parameters  regardless  of  the incidence and difference between treatment groups (Table 31).

<div style=\"page-break-after: always\"></div>

Table 31 Treatment-emergent Hematology Lab Abnormalities; Safety Analysis Set (Study 54767414MMY3006)

| Table 9:                  | Treatment-emergentHematologyLabAbnormalities;SafetyAnalysisSet(Study54767414MMY3006)   | Treatment-emergentHematologyLabAbnormalities;SafetyAnalysisSet(Study54767414MMY3006)   | Treatment-emergentHematologyLabAbnormalities;SafetyAnalysisSet(Study54767414MMY3006)   | Treatment-emergentHematologyLabAbnormalities;SafetyAnalysisSet(Study54767414MMY3006)   | Treatment-emergentHematologyLabAbnormalities;SafetyAnalysisSet(Study54767414MMY3006)   |            |
|---------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------|
|                           | VTd                                                                                    | VTd                                                                                    | VTd                                                                                    | DVTd                                                                                   | DVTd                                                                                   | DVTd       |
|                           | AllGrade                                                                               | Grade 3                                                                                | Grade 4                                                                                | All Grade                                                                              | Grade 3                                                                                | Grade 4    |
| Analysisset:safety Anemia | 538 187 (34.8%)                                                                        | 25 (4.6%)                                                                              | 0                                                                                      | 536 191 (35.6%)                                                                        | 22 (4.1%)                                                                              | 0          |
| Thrombocytopenia          | 314 (58.4%)                                                                            | 43 (8.0%)                                                                              | 15 (2.8%)                                                                              | 436 (81.3%)                                                                            | 46 (8.6%)                                                                              | 26 (4.9%)  |
| Leukopenia                | 304 (56.5%)                                                                            | 31 (5.8%)                                                                              | 51 (9.5%)                                                                              | 438 (81.7%)                                                                            | 74 (13.8%)                                                                             | 54 (10.1%) |
| Neutropenia               | 223 (41.4%)                                                                            | 53 (9.9%)                                                                              | 49 (9.1%)                                                                              | 337 (62.9%)                                                                            | 100 (18.7%)                                                                            | 73 (13.6%) |
| Lymphopenia               | 492 (91.4%)                                                                            | 201 (37.4%)                                                                            | 54 (10.0%)                                                                             | 510 (95.1%)                                                                            | 237 (44.2%)                                                                            | 78 (14.6%) |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone:DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone. Note:Thelaboratory toxicitygrades arederivedbasedontheNCICTCAE(National CancerInstituteCommonTerminologyCriteriaforAdverseEvents)Version 4.03.Foreachparameter,the percentageof subjectsrepresentsthosesubjectsforwhom thetoxicitygradeworsened duringtreatment compared tobaseline:percentages arecalculatedwith thenumber ofsafetysubjectsin each treatment arm.Foreachsubjectandeachparameter,theworsttoxicitygradeisselected. BasedonPart1oftheMMY3006study.

4. Serious TEAEs that occurred at a higher incidence ( ≥ 2% difference) in the DVTd group compared with  the  VTd  treatment  group  were  considered  ADRs  (Table  32).  A  comparative  incidence  was completed after rounding to whole numbers for all events.

Table 32 Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)

| Table 10:                                                           | Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)   | Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)   | Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)   | Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)   | Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)   | Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)   | Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)   | Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DVTd Than VTd During Induction/ASCT/consolidation Phase by System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)   |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                     | VTd                                                                                                                                                                                                                          | VTd                                                                                                                                                                                                                          | VTd                                                                                                                                                                                                                          | VTd                                                                                                                                                                                                                          | DVTd                                                                                                                                                                                                                         | DVTd                                                                                                                                                                                                                         | DVTd                                                                                                                                                                                                                         | DVTd                                                                                                                                                                                                                         |
|                                                                     | Induction/AS CT/Consolida tion                                                                                                                                                                                               | Induction                                                                                                                                                                                                                    | ASCT                                                                                                                                                                                                                         | Consolidation                                                                                                                                                                                                                | Induction/AS CT/Consolida tion                                                                                                                                                                                               | Induction                                                                                                                                                                                                                    | ASCT                                                                                                                                                                                                                         | Consolidation                                                                                                                                                                                                                |
| Analysis set: safety                                                | 538                                                                                                                                                                                                                          | 538                                                                                                                                                                                                                          | 484                                                                                                                                                                                                                          | 448                                                                                                                                                                                                                          | 536                                                                                                                                                                                                                          | 536                                                                                                                                                                                                                          | 489                                                                                                                                                                                                                          | 466                                                                                                                                                                                                                          |
| MedDRA system organ class/preferred term Infections andinfestations |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |                                                                                                                                                                                                                              |
| Pneumoniaa                                                          | 19 (4%)                                                                                                                                                                                                                      | 12 (2%)                                                                                                                                                                                                                      | 4 (1%)                                                                                                                                                                                                                       | 3 (1%)                                                                                                                                                                                                                       | 30 (6%)                                                                                                                                                                                                                      | 16 (3%)                                                                                                                                                                                                                      | 4 (1%)                                                                                                                                                                                                                       | 13 (3%)                                                                                                                                                                                                                      |
| Bronchitisb                                                         | 2 (<1%)                                                                                                                                                                                                                      | 2 (<1%)                                                                                                                                                                                                                      | 0                                                                                                                                                                                                                            | 0                                                                                                                                                                                                                            | 9 (2%)                                                                                                                                                                                                                       | 7 (1%)                                                                                                                                                                                                                       | 0                                                                                                                                                                                                                            | 2 (<1%)                                                                                                                                                                                                                      |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone;DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone. Idiopathic interstitial pneumonia, Lung infection, Pneumocystis jirovecii infection, Pneumocystis jirovecii pneumonia, Pneumonia, Pneumonia aspiration, Pneumonia bacterial,Pneumoniahaemophilus,Pneumonialegionella,Pneumoniaparainfluenzae viral,Pneumonia pseudomonal,Pneumonia respiratory syncytialviral,Pneumonia viral,Pulmonary mycosis,Pulmonary sepsis bBronchiolitis,Bronchitis

Note: Adverse events are reported using MedDRA version 20.0.

Percentages are calculated with the number of subjects in each phase/group as denominator.

## Pooled ADR Safety Data Set

Frequencies of ADRs from the pooled safety data set are included in the Summary of Product Characteristics (SmPC). The pooled safety data set reflects exposure to daratumumab (16 mg/kg) in 2,066 subjects with multiple myeloma including 536 subjects from Study MMY3006 and 1,530 subjects from 4 Phase 3 active controlled studies in which subjects received daratumumab in combination with either lenalidomide and dexamethasone (DRd, n=283 [Study MMY3003] and n=364 [Study MMY3008]), bortezomib and dexamethasone (DVd, n=243 [Study MMY3004]), or bortezomib, melphalan, and prednisone (DVMP, n=346 [Study MMY3007]); and 5 non -randomized, clinical studies in which subjects received daratumumab either in combination with pomalidomide and dexamethasone (DPd, n=103) or lenalidomide and dexamethasone (DRd, n=35), or daratumumab as monotherapy (n=156).

<div style=\"page-break-after: always\"></div>

Table 33 Adverse reactions in multiple myeloma patients treated with DARZALEX 16 mg/kg

| TSFAE42 SMIPC 01: mg/kg                                                                                                                    | Adverse reactions in multiple myeloma patients treated with DARZALEX 16                                                                    | Adverse reactions in multiple myeloma patients treated with DARZALEX 16                                                                    | Adverse reactions in multiple myeloma patients treated with DARZALEX 16                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                            | Any Grade                                                                                                                                  | Any Grade                                                                                                                                  | Grade 3-4                                                                                                                                  |
| Infections and infestations                                                                                                                | Infections and infestations                                                                                                                | Infections and infestations                                                                                                                | Infections and infestations                                                                                                                |
| Upperrespiratory tract infection                                                                                                           | Very Common                                                                                                                                | 41%                                                                                                                                        | 3%                                                                                                                                         |
| Bronchitisa                                                                                                                                | Very Common                                                                                                                                | 17%                                                                                                                                        | 2%                                                                                                                                         |
| Pneumoniaa                                                                                                                                 | Very Common                                                                                                                                | 16%                                                                                                                                        | 10%                                                                                                                                        |
| Urinary tract infection                                                                                                                    | Common                                                                                                                                     | 8%                                                                                                                                         | 1%                                                                                                                                         |
| Influenza                                                                                                                                  | Common                                                                                                                                     | 5%                                                                                                                                         | 1%                                                                                                                                         |
| Blood and lymphatic system                                                                                                                 | Blood and lymphatic system                                                                                                                 | Blood and lymphatic system                                                                                                                 | Blood and lymphatic system                                                                                                                 |
| disorders                                                                                                                                  | disorders                                                                                                                                  | disorders                                                                                                                                  | disorders                                                                                                                                  |
| Neutropeniaa                                                                                                                               | Very Common                                                                                                                                | 45%                                                                                                                                        | 39%                                                                                                                                        |
| Thrombocytopeniaa                                                                                                                          | Very Common                                                                                                                                | 31%                                                                                                                                        | 19%                                                                                                                                        |
| Anaemiaa                                                                                                                                   | Very Common                                                                                                                                | 27%                                                                                                                                        | 12%                                                                                                                                        |
| Lymphopenia                                                                                                                                | Very Common                                                                                                                                | 14%                                                                                                                                        | 11%                                                                                                                                        |
| Leukopeniaa                                                                                                                                | Very Common                                                                                                                                | 12%                                                                                                                                        | 6%                                                                                                                                         |
| Immune system disorders                                                                                                                    | Immune system disorders                                                                                                                    | Immune system disorders                                                                                                                    | Immune system disorders                                                                                                                    |
| Anaphylactic reaction                                                                                                                      | Rare                                                                                                                                       |                                                                                                                                            |                                                                                                                                            |
| Metabolism and nutrition disorders                                                                                                         | Metabolism and nutrition disorders                                                                                                         | Metabolism and nutrition disorders                                                                                                         | Metabolism and nutrition disorders                                                                                                         |
| Decreased appetite                                                                                                                         | Very Common                                                                                                                                | 12%                                                                                                                                        | 1%                                                                                                                                         |
| Hyperglycaemia                                                                                                                             | Common                                                                                                                                     | 7%                                                                                                                                         | 3%                                                                                                                                         |
| Hypocalcaemia                                                                                                                              | Common                                                                                                                                     | 6%                                                                                                                                         | 1%                                                                                                                                         |
| Dehydration                                                                                                                                | Common                                                                                                                                     | 3%                                                                                                                                         | 1%                                                                                                                                         |
| Nervous system disorders                                                                                                                   | Nervous system disorders                                                                                                                   | Nervous system disorders                                                                                                                   | Nervous system disorders                                                                                                                   |
| Peripheral sensory neuropathy                                                                                                              | Very Common                                                                                                                                | 32%                                                                                                                                        | 3%                                                                                                                                         |
| Headache                                                                                                                                   | Very Common                                                                                                                                | 12%                                                                                                                                        | ≤1%                                                                                                                                        |
| Paraesthesia                                                                                                                               | Very Common                                                                                                                                | 11%                                                                                                                                        | ≤1%                                                                                                                                        |
| Cardiac disorders                                                                                                                          | Cardiac disorders                                                                                                                          | Cardiac disorders                                                                                                                          | Cardiac disorders                                                                                                                          |
| Atrial fibrillation                                                                                                                        | Common                                                                                                                                     | 4%                                                                                                                                         | 1%                                                                                                                                         |
| Vascular disorders Hypertensiona                                                                                                           | Very Common                                                                                                                                | 10%                                                                                                                                        | 5%                                                                                                                                         |
| Respiratory, thoracic and mediastinal                                                                                                      | Respiratory, thoracic and mediastinal                                                                                                      | Respiratory, thoracic and mediastinal                                                                                                      | Respiratory, thoracic and mediastinal                                                                                                      |
| disorders                                                                                                                                  | disorders                                                                                                                                  | disorders                                                                                                                                  | disorders                                                                                                                                  |
| Cougha                                                                                                                                     | Very Common                                                                                                                                | 25%                                                                                                                                        | %I>                                                                                                                                        |
| Dyspnoeaa                                                                                                                                  | Very Common                                                                                                                                | 21%                                                                                                                                        | 3%                                                                                                                                         |
| Pulmonary oedema?                                                                                                                          | Common                                                                                                                                     | 1%                                                                                                                                         | ≤1%                                                                                                                                        |
| Gastrointestinal disorders                                                                                                                 | Gastrointestinal disorders                                                                                                                 | Gastrointestinal disorders                                                                                                                 | Gastrointestinal disorders                                                                                                                 |
| Constipation                                                                                                                               | Very Common                                                                                                                                | 33%                                                                                                                                        | 1%                                                                                                                                         |
| Diarrhoea                                                                                                                                  | Very Common                                                                                                                                | 32%                                                                                                                                        | 4%                                                                                                                                         |
| Nausea                                                                                                                                     | Very Common                                                                                                                                | 26%                                                                                                                                        | 2%#                                                                                                                                        |
| Vomiting                                                                                                                                   | Very Common                                                                                                                                | 16%                                                                                                                                        | 1%                                                                                                                                         |
| Musculoskeletal and connective                                                                                                             | Musculoskeletal and connective                                                                                                             | Musculoskeletal and connective                                                                                                             | Musculoskeletal and connective                                                                                                             |
| tissue disorders                                                                                                                           | tissue disorders                                                                                                                           | tissue disorders                                                                                                                           | tissue disorders                                                                                                                           |
| Muscle spasms                                                                                                                              | Very Common                                                                                                                                | 14%                                                                                                                                        | <1%                                                                                                                                        |
| General disorders and administration                                                                                                       | General disorders and administration                                                                                                       | General disorders and administration                                                                                                       | General disorders and administration                                                                                                       |
| site conditions Oedema peripheral                                                                                                          | Very Common                                                                                                                                | 26%                                                                                                                                        | 1%                                                                                                                                         |
| Fatigue                                                                                                                                    | Very Common                                                                                                                                | 26%                                                                                                                                        | 4%                                                                                                                                         |
| Pyrexia                                                                                                                                    | Very Common                                                                                                                                | 23%                                                                                                                                        | 2%                                                                                                                                         |
| Asthenia                                                                                                                                   | Very Common                                                                                                                                | 21%                                                                                                                                        | 2%                                                                                                                                         |
| Back pain                                                                                                                                  | Very Common                                                                                                                                | 19%                                                                                                                                        | 2%                                                                                                                                         |
| Chills                                                                                                                                     | Common                                                                                                                                     | 9%                                                                                                                                         | <1%                                                                                                                                        |
| Injury, poisoning and procedural                                                                                                           | Injury, poisoning and procedural                                                                                                           | Injury, poisoning and procedural                                                                                                           | Injury, poisoning and procedural                                                                                                           |
| complications                                                                                                                              | complications                                                                                                                              | complications                                                                                                                              | complications                                                                                                                              |
| Infusion related reactions                                                                                                                 | Very Common                                                                                                                                | 40%                                                                                                                                        |                                                                                                                                            |
| \"No grade 4                                                                                                                                | \"No grade 4                                                                                                                                | \"No grade 4                                                                                                                                | \"No grade 4                                                                                                                                |
| Indicates a grouping of terms.                                                                                                             | Indicates a grouping of terms.                                                                                                             | Indicates a grouping of terms.                                                                                                             | Indicates a grouping of terms.                                                                                                             |
| Based on post-marketing adverse reactions. Infusion-related reaction includes terms determined by investigators to be related to infusion. | Based on post-marketing adverse reactions. Infusion-related reaction includes terms determined by investigators to be related to infusion. | Based on post-marketing adverse reactions. Infusion-related reaction includes terms determined by investigators to be related to infusion. | Based on post-marketing adverse reactions. Infusion-related reaction includes terms determined by investigators to be related to infusion. |
| Note: Based on 2066 multiple myeloma patients treated with DARZALEX 16 mg/kg.                                                              | Note: Based on 2066 multiple myeloma patients treated with DARZALEX 16 mg/kg.                                                              | Note: Based on 2066 multiple myeloma patients treated with DARZALEX 16 mg/kg.                                                              | Note: Based on 2066 multiple myeloma patients treated with DARZALEX 16 mg/kg.                                                              |

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

Table 34 presents a summary of deaths that occurred up to the clinical cut-off for this analysis.

Table 34 Death and Primary Cause of Death by Treatment Group; Safety Analysis Set (Study 54767414MMY3006)

|                                                           | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|-----------------------------------------------------------|--------------------------------|--------------------------------|
|                                                           | VTd                            | DVTd                           |
|                                                           | n (%)                          | n (%)                          |
| Analysis set: safety                                      | 538                            | 536                            |
| Total number of subjects who died during study            | 32 (5.9%)                      | 14 (2.6%)                      |
| Adverse events                                            | 14 (2.6%)                      | 3 (0.6%)                       |
| At least one related?                                     | 5 (0.9%)                       | 0                              |
| AE(s)umrelated                                            | 9 (1.7%)                       | 3 (0.6%)                       |
| Progressive disease                                       | 15 (2.8%)                      | 10 (1.9%)                      |
| Other                                                     | 3 (0.6%)                       | 1 (0.2%)                       |
| Total number of subjects that died within 30 days of last |                                |                                |
| dose of studyinduction/ASCT/consolidation                 | 7 (1.3%)                       | 1 (0.2%)                       |
| Adverse events                                            | 6 (1.1%)                       | 1 (0.2%)                       |
| At least one related?                                     | 3 (0.6%)                       | 0                              |
| AE(s) umrelated                                           | 3 (0.6%)                       | 1 (0.2%)                       |
| Progressive disease                                       | 0                              | 0                              |
| Other                                                     | 1 (0.2%)                       | 0                              |
| Deaths duringinduction phase                              | 5 (0.9%)                       | 0                              |
| Adverse events                                            | 4 (0.7%)                       | 0                              |
| At least one related?                                     | 2 (0.4%)                       | 0                              |
| AE(s) umrelated                                           | 2 (0.4%)                       | 0                              |
| Progressive disease                                       | 0                              | 0                              |
| Other                                                     | 1 (0.2%)                       | 0                              |
| Deaths during ASCT phase                                  | 1 (0.2%)                       | 0                              |
| Adverse events                                            | 1 (0.2%)                       | 0                              |
| At least one related?                                     | 0                              | 0                              |
| AE(s)umrelated                                            | 1 (0.2%)                       | 0                              |
| Progressive disease                                       | 0                              | 0                              |
| Other                                                     | 0                              | 0                              |
| Deaths during consolidation phase                         | 1 (0.2%)                       | 1 (0.2%)                       |
| Adverse events                                            | 1 (0.2%)                       | 1 (0.2%)                       |
| At least one related?                                     | 1 (0.2%)                       | 0                              |
| AE(s) umrelated                                           | 0                              | 1 (0.2%)                       |
| Progressive disease                                       | 0                              | 0                              |
| Other                                                     | 0                              | 0                              |
| Deathswithin60 days of first induction dose               | 1 (0.2%)                       | 0                              |
| Adverse events                                            | 1 (0.2%)                       | 0                              |
| At least one related?                                     | 0                              | 0                              |
| AE(s) umrelated                                           | 1 (0.2%)                       | 0                              |
| Progressive disease                                       | 0                              | 0                              |
| Other                                                     | 0                              | 0                              |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

Last dose in induction or consolidation phase is defined as last dose of VTd or DVTd and within ASCT defined as last

Includes adverse events that were related to at least 1 of study treatments.

application of one of the following: mobilization treatment, conditioning therapy or transplantation

Note: Percentages are calculated with the number of subjects in each group as denominator.

During induction/ASCT/consolidation phase of the study, TEAEs with an outcome of death (toxicity Grade 5) were reported in 1 subject in the DVTd group (cardiac arrest; unrelated to study treatment) and 9 subjects (1.7%) in the VTd group (Table 27, Table 29). Of the 9 subjects with a TEAE outcome of death in the VTd group, only 7 subject deaths occurred within 30 days of last dose (Table 29). With the exception of the general term 'death' (3 subjects), each fatal AE was reported in only 1 subject each.

<div style=\"page-break-after: always\"></div>

Table 35 Treatment-Emergent Adverse Events with Outcome of Death During Induction/ASCT/Consolidation Phase by System Organ Class, Preferred Term and Relationship; Safety Analysis Set (Study 54767414MMY3006)

|                                                            | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                            |                                | VTd                            |                                |                                |                                |                                | DVTd n (%)                     |                                |                                |
|                                                            |                                | n (%)                          |                                |                                |                                |                                |                                |                                |                                |
|                                                            |                                | Related to                     | Related to                     | Related to                     |                                | Related to                     | Related to                     | Related to                     | Related to                     |
|                                                            | Total                          |                                |                                |                                | Total                          |                                |                                |                                |                                |
|                                                            |                                | Bor                            | Tha                            | Dex                            |                                | Dara                           | Bor                            | Tha                            | Dex                            |
| Analysis set: safety                                       | 538                            |                                |                                |                                | 536                            |                                |                                |                                |                                |
| Total number of subjects with TEAE with outcome death      | 9 (1.7%)                       | 2 (0.4%)                       | 3 (0.6%)                       | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              |
| MedDRA system organ class / preferred term                 |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Cardiac disorders                                          | 2 (0.4%)                       | 1 (0.2%)                       | 0                              | 0                              | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              |
| Cardiac arrest                                             | 1 (0.2%)                       | 0                              | 0                              | 0                              | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              |
| Myocarditis                                                | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |
| Gastrointestinal disorders                                 | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |
| Large intestine perforation                                | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |
| General disorders and                                      |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| administrationsite conditions                              | 3 (0.6%)                       | 0                              | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |
| Death                                                      | 3 (0.6%)                       | 0                              | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |
| Neoplasms benign,malignant and unspecified (incl cysts and |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| polyps)                                                    | 2 (0.4%)                       | 1 (0.2%)                       | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              |
| Lung adenocarcinoma                                        | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              |                                | 0                              | 0                              |
| Naturalkiller-cell lymphoblastic lymphoma                  | 1 (0.2%)                       | 1 (0.2%)                       | 1 (0.2%)                       | 1 (0.2%)                       | 0                              |                                | 0                              | 0                              | 0                              |
| Respiratory, thoracic and mediastinal disorders            | 1 (0.2%)                       | 0                              | 1 (0.2%)                       | 0 0                            | 0 0                            | 0                              | 0                              | 0                              | 0                              |
| Pulmonary embolism                                         | 1 (0.2%)                       | 0                              | 1 (0.2%)                       |                                |                                | 0                              | 0                              | 0                              | 0                              |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone;DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone.

Note: Adverse events are reported using MedDRA version 20.0.

Note: Percentages are calculated with the number of subjects in each group as denominator.

During the transplant period, according to protocol. only limited AE were collected.

The overall incidence of serious TEAEs was similar for both treatment groups (DVTd: 46.8%; VTd: 47.4%) (Table 13/SCS). Serious TEAEs that occurred at a ≥ 3% frequency in either treatment group were:

- Neutropenia (DVTd: 3.9%; VTd: 1.5%)
- Pneumonia (DVTd: 3.5%; VTd: 1.7%)
- Pyrexia (DVTd: 2.8%; VTd: 4.3%)
- Pulmonary embolism (DVTd: 1.5%; VTd: 3.7%)

Table 36 Most Common (At Least 2%) Treatment-Emergent Serious Adverse Events During Induction/ASCT/Consolidation Phase by System Organ Class, Preferred Term; Safety Analysis Set (Study 54767414MMY3006)

|                                                      | VTd                               |               |            | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation      | DVTd          |            |                   |
|------------------------------------------------------|-----------------------------------|---------------|------------|--------------------------------|-----------------------------------|---------------|------------|-------------------|
| Analysis set: safety                                 | Induction/ASCT /Consolidation 538 | Induction 538 | ASCT 484   | Consolidation 448              | Induction/ASCT/ Consolidation 536 | Induction 536 | ASCT 489   | Consolidation 466 |
| Total number of subjects with Serious Adverse Events | 255 (47.4%)                       | 192 (35.7%)   | 60 (12.4%) | 46 (10.3%)                     | 251 (46.8%)                       | 180 (33.6%)   | 65 (13.3%) | 56 (12.0%)        |
| MedDRA system organ class/preferred term             |                                   |               |            |                                |                                   |               |            |                   |
| Infections and infestations                          | 67 (12.5%)                        | 37 (6.9%)     | 20 (4.1%)  | 15 (3.3%)                      | 80 (14.9%)                        | 43 (8.0%)     | 26 (5.3%)  | 22 (4.7%)         |
| Pneumonia                                            | 9 (1.7%)                          | 7 (1.3%)      | 1 (0.2%)   | 1 (0.2%)                       | 19 (3.5%)                         | 9 (1.7%)      | 2 (0.4%)   | 9 (1.9%)          |
| Sepsis                                               | 11 (2.0%)                         | 5 (0.9%)      | 4 (0.8%)   | 2 (0.4%)                       | 7 (1.3%)                          | 3 (0.6%)      | 2 (0.4%)   | 2 (0.4%)          |
| Blood and lymphatic system disorders                 | 44 (8.2%)                         | 31 (5.8%)     | 5 (1.0%)   | 10 (2.2%)                      | 57 (10.6%)                        | 35 (6.5%)     | 8 (1.6%)   | 16 (3.4%)         |
| Neutropenia                                          | 8 (1.5%)                          | 5 (0.9%)      | 0          | 4 (0.9%)                       | 21 (3.9%)                         | 10 (1.9%)     | 2 (0.4%)   | (%6'1) 6          |
| Febrile neutropenia                                  | 15 (2.8%)                         | 10 (1.9%)     | 4 (0.8%)   | 1 (0.2%)                       | 12 (2.2%)                         | 8 (1.5%)      | 2 (0.4%)   | 2 (0.4%)          |
| Thrombocytopenia                                     | 4 (0.7%)                          | 2 (0.4%)      | 0          | 2 (0.4%)                       | 12 (2.2%)                         | 4 (0.7%)      | 4 (0.8%)   | 4 (0.9%)          |
| Febrile bone marrow aplasia                          | 11 (2.0%)                         | 11 (2.0%)     | 0          | 0                              | 7 (1.3%)                          | 7 (1.3%)      | 0          | 0                 |
| Respiratory, thoracic and mediastinal                |                                   |               |            |                                |                                   |               |            |                   |
| disorders                                            | 38 (7.1%)                         | 26 (4.8%)     | 5 (1.0%)   | 7 (1.6%)                       | 38 (7.1%)                         | 27 (5.0%)     | 6 (1.2%)   | 7 (1.5%)          |
| Lung disorder                                        | 6 (1.1%)                          | 3 (0.6%)      | 0          | 3 (0.7%)                       | 11 (2.1%)                         | 6 (1.1%)      | 2 (0.4%)   | 3 (0.6%)          |
| Pulmonary embolism                                   | 20 (3.7%)                         | 17 (3.2%)     | 2 (0.4%)   | 1 (0.2%)                       | 8 (1.5%)                          | 6 (1.1%)      | 1 (0.2%)   | 1 (0.2%)          |
| General disordersandadministration                   |                                   |               |            |                                |                                   |               |            |                   |
| site conditions                                      | 37 (6.9%)                         | 32 (5.9%)     | 4 (0.8%)   | 3 (0.7%)                       | 33 (6.2%)                         | 19 (3.5%)     | 11 (2.2%)  | 3 (0.6%)          |
| Pyrexia                                              | 23 (4.3%)                         | 19 (3.5%)     | 4 (0.8%)   | 0                              | 15 (2.8%)                         | 11 (2.1%)     | 3 (0.6%)   | 1 (0.2%)          |
| Nervous system disorders                             | 44 (8.2%)                         | 30 (5.6%)     | 10 (2.1%)  | 5 (1.1%)                       | 33 (6.2%)                         | 23 (4.3%)     | 7 (1.4%)   | 3 (0.6%)          |
| Peripheral sensory neuropathy                        | 15 (2.8%)                         | 7 (1.3%)      | 6 (1.2%)   | 2 (0.4%)                       | 11 (2.1%)                         | 7 (1.3%)      | 3 (0.6%)   | 1 (0.2%)          |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone;DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone.

Key:TEAE=treatment-emergent adverse event.

Note:Period (induction,ASCT, consolidation) of serious TEAE are assigned by the start date of linked serious TEAE.

Note: Adverse events are reported using MedDRA version 20.0.

Note:Percentages are calculatedwith the number of subjects in each phase/group as denominator.

During the transplant period, according to protocol, only limited AE were collected.

Source:Mod5.3.5.1/MMY3006/Tab25

<div style=\"page-break-after: always\"></div>

Neutropenia was the only serious TEAEs that occurred at a ≥ 2% higher frequency in the DVTd treatment group  compared  with  the  VTd  treatment  group.  Pulmonary  embolism  was  the  only  serious  TEAE  that occurred at a ≥ 2% higher frequency in the VTd treatment group compared with the DVTd treatment group.

## Adverse Events of Special Interest (AESI)

## Infusion-Related Reactions (IRRs)

Of the 536 subjects who received daratumumab, 190 subjects (35.4%) experienced an IRR associated with daratumumab administration (Mod5.3.5.1/MMY3006/AttTSFAE06A). Of these 190 subjects with an IRR, 90.0% (n=171) were Grade 1 or 2 IRRs; 3.2% (n=17) were Grade 3 IRRs; 0.4% (n=2) were Grade 4 IRRs; no Grade 5 IRR was reported. The most frequently reported TEAE term (reported in ≥ 5% of subjects) used to describe IRRs was chills (5.6%).

## Cytopenias

## Neutropenia-Related Events

The incidence of neutropenia-related events (preferred term grouping of neutropenia, febrile neutropenia, neutropenic sepsis, and neutropenic infection) was higher in the DVTd treatment group (34.9% [Grade 3 or 4: 33.0%]) than in the VTd treatment group (24.5% [Grade 3 or 4: 21.9%]) ( Table 37 and Table 38). The higher rate of neutropenia-related events did not translate into a higher rate of neutropenic fever, which was similar between the 2 treatment groups (DVTd: 6.9%; VTd: 5.2%). Neutropenia was managed with the use of growth factors (DVTd: 13.8%; VTd: 7.7%). There were no neutropenia-related events that led to the discontinuation of study treatment in either treatment group.

Table 37 Treatment-emergent Neutropenia During Induction/ASCT/Consolidation Phase by Phase (First Onset), MedDRA System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)

|                                      | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                      | VTd                            | VTd                            | VTd                            | VTd                            | DVTd                           | DVTd                           | DVTd                           | DVTd                           |
|                                      | Induction/AS CT/Consolida tion | Induction                      | ASCT                           | Consolidation                  | Induction/AS CT/Consolida tion | Induction                      | ASCT                           | Consolidation                  |
| Analysis set: safety                 | 538                            | 538                            | 484                            | 448                            | 536                            | 536                            | 489                            | 466                            |
| Total number of subjects withTEAE    | 132 (24.5%)                    | 88 (16.4%)                     | 26 (5.4%)                      | 19 (4.2%)                      | 187 (34.9%)                    | 113 (21.1%)                    | 32 (6.5%)                      | 55 (11.8%)                     |
| MedDRAsystemorganclass/preferredterm |                                |                                |                                |                                |                                |                                |                                |                                |
| Blood andlymphaticsystemdisorders    | 131 (24.3%)                    | 87 (16.2%)                     | 26 (5.4%)                      | 19 (4.2%)                      | 184 (34.3%)                    | 113 (21.1%)                    | 28 (5.7%)                      | 55 (11.8%)                     |
| Neutropenia                          | 89 (16.5%)                     | 67 (12.5%)                     | 4 (0.8%)                       | 18 (4.0%)                      | 157 (29.3%)                    | 100 (18.7%)                    | 4 (0.8%)                       | 53 (11.4%)                     |
| Febrile neutropenia                  | 28 (5.2%)                      | 10 (1.9%)                      | 17 (3.5%)                      | 1 (0.2%)                       | 37 (6.9%)                      | 13 (2.4%)                      | 22 (4.5%)                      | 2 (0.4%)                       |
| Febrile bonemarrow aplasia           | 17 (3.2%)                      | 12 (2.2%)                      | 5 (1.0%)                       | 0                              | 9 (1.7%)                       | 7 (1.3%)                       | 2 (0.4%)                       | 0                              |
| Agranulocytosis                      | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              |
| Gastrointestinaldisorders            | 0                              | 0                              | 0                              | 0                              | 5 (0.9%)                       | 1 (0.2%)                       | 4 (0.8%)                       | 0                              |
| Neutropenic colitis                  | 0                              | 0                              | 0                              | 0                              | 5 (0.9%)                       | 1 (0.2%)                       | 4 (0.8%)                       | 0                              |
| Infections andinfestations           | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |
| Neutropenic infection                | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone;DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone.

Key:TEAE=treatment-emergent adverseevent.

Note:Adverse events arereported usingMedDRAversion 20.0.

During the transplant period, according to protocol, only limited AE were collected.

Note:Percentages are calculatedwith thenumber of subjectsin eachphase/group as denominator.

<div style=\"page-break-after: always\"></div>

Table 38 Treatment-emergent Neutropenia During Induction/ASCT/Consolidation Phase by Phase (First Onset), MedDRA System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)

|                                      | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                      | PLA                            | PLA                            | PLA                            | PLA                            | DVTd                           | DVTd                           | DVTd                           | DVTd                           |
|                                      | Induction/AS CT/Consolida tion | Induction                      | ASCT                           | Consolidation                  | Induction/AS CT/Consolida tion | Induction                      | ASCT                           | Consolidation                  |
| Analysis set: safety                 | 538                            | 538                            | 484                            | 448                            | 536                            | 536                            | 489                            | 466                            |
| Total number of subjects with TEAE   | 132 (24.5%)                    | 88 (16.4%)                     | 26 (5.4%)                      | 19 (4.2%)                      | 187 (34.9%)                    | 113 (21.1%)                    | 32 (6.5%)                      | 55 (11.8%)                     |
| MedDRAsystemorganclass/preferredterm |                                |                                |                                |                                |                                |                                |                                |                                |
| Bloodandlymphaticsystemdisorders     | 131 (24.3%)                    | 87 (16.2%)                     | 26 (5.4%)                      | 19 (4.2%)                      | 184 (34.3%)                    | 113 (21.1%)                    | 28 (5.7%)                      | 55 (11.8%)                     |
| Neutropenia                          | 89 (16.5%)                     | 67 (12.5%)                     | 4 (0.8%)                       | 18 (4.0%)                      | 157 (29.3%)                    | 100 (18.7%)                    | 4 (0.8%)                       | 53 (11.4%)                     |
| Febrile neutropenia                  | 28 (5.2%)                      | 10 (1.9%)                      | 17 (3.5%)                      | 1 (0.2%)                       | 37 (6.9%)                      | 13 (2.4%)                      | 22 (4.5%)                      | 2 (0.4%)                       |
| Febrile bone marrow aplasia          | 17 (3.2%)                      | 12 (2.2%)                      | 5 (1.0%)                       | 0                              | 9 (1.7%)                       | 7 (1.3%)                       | 2 (0.4%)                       | 0                              |
| Agranulocytosis                      | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              |
| Gastrointestinaldisorders            | 0                              | 0                              | 0                              | 0                              | 5 (0.9%)                       | 1 (0.2%)                       | 4 (0.8%)                       | 0                              |
| Neutropenic colitis                  | 0                              | 0                              | 0                              | 0                              | 5 (0.9%)                       | 1 (0.2%)                       | 4 (0.8%)                       | 0                              |
| Infections andinfestations           | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |
| Neutropenicinfection                 | 1 (0.2%)                       | 1 (0.2%)                       | 0                              | 0                              | 0                              | 0                              | 0                              | 0                              |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone;DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone.

Key:TEAE=treatment-emergent adverseevent.

Note:Adverseevents arereported usingMedDRAversion 20.0.

During the transplant period, according to protocol, only limited AE were collected.

Note:Percentagesarecalculatedwiththenumberof subjectsineachphase/groupasdenominator.

## Thrombocytopenia

The incidence of thrombocytopenia was higher in the DVTd treatment group (20.3% [Grade 3 or 4: 11.0%]) compared with the VTd treatment group (13.6% [Grade 3 or 4: 7.4%]) .

Table 39 Treatment-emergent Thrombocytopenia During Induction/ASCT/Consolidation Phase by Phase (First Onset), MedDRA System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)

|                                                                         | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|-------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                                         | VTd                            | VTd                            | VTd                            |                                |                                |                                |                                |                                |
|                                                                         | Induction/AS CT/Consolida tion | Induction                      | ASCT                           | Consolidation                  | Induction/AS CT/Consolida tion | Induction                      | ASCT                           | Consolidation                  |
| Analysis set: safety                                                    | 538                            | 538                            | 484                            | 448                            | 536                            | 536                            | 489                            | 466                            |
| TotalnumberofsubjectswithTEAE                                           | 73 (13.6%)                     | 45 (8.4%)                      | 2 (0.4%)                       | 26 (5.8%)                      | 109 (20.3%)                    | 56 (10.4%)                     | 9 (1.8%)                       | 44 (9.4%)                      |
| MedDRAsystemorganclass/preferredterm Blood andlymphaticsystem disorders | 73 (13.6%)                     | 45 (8.4%)                      | 2 (0.4%)                       | 26 (5.8%)                      | 109 (20.3%)                    | 56 (10.4%)                     | 9 (1.8%)                       | 44 (9.4%)                      |
| Thrombocytopenia                                                        | 73 (13.6%)                     | 45 (8.4%)                      | 2 (0.4%)                       | 26 (5.8%)                      | 109 (20.3%)                    | 56 (10.4%)                     | 9 (1.8%)                       | 44 (9.4%)                      |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone:DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone.

Key:TEAE=treatment-emergent adverseevent.

Note:Adverse events are reported usingMedDRA version 20.0.

Duringthetransplantperiod,accordingtoprotocol,onlylimitedAEwerecollected.

Note:Percentagesarecalculatedwiththenumberofsubjectsineachphase/groupasdenominator.

The incidence of treatment-emergent haemorrhage events was low for both treatment groups (DVTd: 7.5% [Grade 3 or 4: 1.1%]; VTd: 6.7% [Grade 3 or 4: 0.7%]).

## Viral infections

A total of 21 subjects reported a medical history of HBV infection (10 in the DVTd group and 11 in the VTd group). No subjects were reported with HBV reactivation in either treatment group.

## Opportunistic infections

Opportunistic infections were defined as a subpopulation of the SOC 'infections and infestations' by clinical review.

The incidence of treatment-emergent opportunistic infections was numerically higher in the DVTd treatment group compared to the VTd treatment group (DVTd: 13.1%; VTd: 8.2%). Grade 3 or 4 TEAEs opportunistic infections were low in both treatment groups (DVTd: 3.0%; VTd: 1.7%). There was no overall pattern regarding the type of opportunistic infection associated with the use of daratumumab.

<div style=\"page-break-after: always\"></div>

Table 40 Grade 3 or 4 Treatment-emergent Opportunistic Infections During Induction/ASCT/Consolidation Phase by Phase (First Onset), MedDRA System Organ Class and Preferred Term; Safety Analysis Set (Study 54767414MMY3006)

TSFAE25B\\_3006: Grade 3 or 4Treatment-emergent OpportunisticInfections During Induction/ASCT/ConsolidationPhase byPhase (First Onset),MedDRASystemOrganClassandPreferredTerm;SafetyAnalysisSet(Study54767414MIMY3006)

|                                            | Induction/AsCT/Consolidation DVTd   | Induction/AsCT/Consolidation DVTd   | Induction/AsCT/Consolidation DVTd   | Induction/AsCT/Consolidation DVTd   | Induction/AsCT/Consolidation DVTd   | Induction/AsCT/Consolidation DVTd   | Induction/AsCT/Consolidation DVTd   | Induction/AsCT/Consolidation DVTd   |
|--------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
|                                            | Induction/AS CT/Consolida tion      | Induction                           | ASCT                                | Consolidation                       | Induction/AS CT/Consolida tion      | Induction                           | ASCT                                | Consolidation                       |
| Analysis set: safety                       | 538                                 | 538                                 | 484                                 | 448                                 | 536                                 | 536                                 | 489                                 | 466                                 |
| Total number of subjects with TEAE         | 9 (1.7%)                            | 2 (0.4%)                            | 4 (0.8%)                            | 3 (0.7%)                            | 16 (3.0%)                           | 1 (0.2%)                            | 11 (2.2%)                           | 4 (0.9%)                            |
| MedDRA system organ class / preferred term |                                     |                                     |                                     |                                     |                                     |                                     |                                     |                                     |
| Infections and infestations                | 9 (1.7%)                            | 2 (0.4%)                            | 4 (0.8%)                            | 3 (0.7%)                            | 16 (3.0%)                           | 1 (0.2%)                            | 11 (2.2%)                           | 4 (0.9%)                            |
| Cytomegalovirus infection                  | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   | 3 (0.6%)                            | 0                                   | 3 (0.6%)                            | 0                                   |
| Pseudomonal sepsis                         | 0                                   | 0                                   | 0                                   | 0                                   | 3 (0.6%)                            | 0                                   | 3 (0.6%)                            | 0                                   |
| Herpes zoster                              | 1 (0.2%)                            | 0                                   | 0                                   | 1 (0.2%)                            | 2 (0.4%)                            | 0                                   | 0                                   | 2 (0.4%)                            |
| Cytomegalovirusgastroenteritis             | 0                                   | 0                                   | 0                                   | 0                                   | 1 (0.2%)                            | 0                                   | 0                                   | 1 (0.2%)                            |
| Cytomegalovirus oesophagitis               | 0                                   | 0                                   | 0                                   | 0                                   | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   |
| Fungal oesophagitis                        | 1 (0.2%)                            | 1 (0.2%)                            | 0                                   | 0                                   | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   |
| Hepatosplenic candidiasis                  | 0                                   | 0                                   | 0                                   | 0                                   | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   |
| Human herpesvirus 6infection               | 0                                   | 0                                   | 0                                   | 0                                   | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   |
| Oral candidiasis                           | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   |
| Pseudomonas infection                      | 0                                   | 0                                   | 0                                   | 0                                   | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   |
| Scedosporium infection                     | 0                                   | 0                                   | 0                                   | 0                                   | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   |
| Varicella                                  | 0                                   | 0                                   | 0                                   | 0                                   | 1 (0.2%)                            | 1 (0.2%)                            | 0                                   | 0                                   |
| Varicella zoster virus infection           | 0                                   | 0                                   | 0                                   | 0                                   | 1 (0.2%)                            | 0                                   | 0                                   | 1 (0.2%)                            |
| Cytomegalovirus colitis                    | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   | 0                                   | 0                                   | 0                                   | 0                                   |
| Oral fungal infection                      | 1 (0.2%)                            | 1 (0.2%)                            | 0                                   | 0                                   | 0                                   | 0                                   | 0                                   | 0                                   |
| Pneumocystis jirovecii infection           | 1 (0.2%)                            | 0                                   | 1 (0.2%)                            | 0                                   | 0                                   | 0                                   | 0                                   | 0                                   |
| Pneumocystis jirovecii pneumonia           | 2 (0.4%)                            | 0                                   | 0                                   | 2 (0.4%)                            | 0                                   | 0                                   | 0                                   | 0                                   |

Key:VTd =bortezomib (VELCADE)+ thalidomide + dexamethasone;DVTd = daratumumab + bortezomib (VELCADE)+ thalidomide+ dexamethasone.

Key:TEAE=treatment-emergent adverseevent.

Note: Adverse events are reported using MedDRA version 20.0.

During the transplant period, according to protocol, only limited AE were collected.

Note: Percentages are calculated with the number of subjects in each phase/group as denominator.

## Tumor lysis syndrome

Tumor lysis syndrome was reported for no subject in the DVTd group and 1 subject in the VTd treatment group (Grade 3).

## Treatment-emergent Interferences for Blood Typing

No subject had treatment-emergent interference for blood typing reported during the induction/ASCT/consolidation phase of the study.

## Secondary Primary Malignancies

With a median follow-up of 18.8 months, the incidence of SPMs was balanced between both treatment groups (DVTd: 10 subjects [1.9%]; VTd: 12 subjects [2.2%]).

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Haematology

A summary of worst toxicity grade haematology laboratory values during treatment is presented in Table 41.

Table 41 Summary of Worst toxicity grade during treatment in Heamatology; Safety Analysis Set (Study MMY3006)

|                                | VTd Toxicity Grade, n (%)   | VTd Toxicity Grade, n (%)   | VTd Toxicity Grade, n (%)   | VTd Toxicity Grade, n (%)   | VTd Toxicity Grade, n (%)   | VTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   |
|--------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                | Total                       | 0                           | 1                           | 2                           | 3                           | 4                           | Total                        | 0                            | 1                            | 2                            | 3                            |                              |
| Analysis set: safety           | 538                         |                             |                             |                             |                             |                             | 536                          |                              |                              |                              |                              |                              |
| Hematology                     |                             |                             |                             |                             |                             |                             |                              |                              |                              |                              |                              |                              |
| WBC low (Leukopenia)           | 538 (100.0%)                | 324 (60.2%)                 | 241 (44.8%)                 | 123 (22.9%)                 | 34 (6.3%)                   | 52                          | 535 (99.8%)                  | 339 (63.4%)                  | 230 (43.0%)                  | 190                          | 80 (15.0%)                   | 54 (10.1%)                   |
| Hemoglobinlow(Anemia)          | 538                         | 194                         | 423                         | 157                         | 29                          | (9.7%)                      | 536                          | 225                          | 416                          | (35.5%) 182                  | 27                           |                              |
| Plateletslow(Thrombocytopenia) | (100.0%) 538                | (36.1%) 366                 | (78.6%) 276                 | (29.2%) 59                  | (5.4%) 44                   | 0 17                        | (100.0%) 535                 | (42.0%) 342                  | (77.6%) 356                  | (34.0%) 97                   | (5.0%) 47                    | 0 26                         |
| Neutrophilslow(Neutropenia)    | (100.0%) 536                | (68.0%) 450 (84.0%)         | (51.3%) 63 (11.8%)          | (11.0%) 110                 | (8.2%) 58 (10.8%)           | (3.2%) 49 (9.1%)            | (99.8%) 535                  | (63.9%) 439                  | (66.5%) 51                   | (18.1%) 151                  | (8.8%) 108 (20.2%)           | (4.9%) 74                    |
| Lymphocyteslow (Lymphopenia)   | (99.6%) 532                 | 55                          | 257                         | (20.5%) 235                 | 220                         | 55                          | (99.8%) 534                  | (82.1%) 96                   | (9.5%) 231                   | (28.2%) 240                  | 256                          | (13.8%) 78                   |
|                                | (98.9%)                     | (10.3%)                     | (48.3%)                     | (44.2%)                     | (41.4%)                     | (10.3%)                     | (99.6%)                      | (18.0%)                      | (43.3%)                      | (44.9%)                      | (47.9%)                      | (14.6%)                      |

Key:VTd=bortezomib(VELCADE)+thalidomide+dexamethasone;DVTd=daratumumab+bortezomib(VELCADE)+thalidomide+dexamethasone.

Key:WBC=WhiteBlood Cell;AST=Aspartate Aminotransferase;ALT=AlanineAminotransferase.

Note:The laboratory toxicitygrades arederivedbased on theNCI CTCAE(NationalCancerInstitute CommonTerminology Criteria forAdverseEvents)Version 4.03.Grade 0 means normal.Subjects reported as Grade O are subjects with normal values or a value in the opposite direction (for laboratory tests with bidirectional toxicities defined). Note:For eachparameter,thetotal column includes all subjects with available data at bothbaseline andpost-baseline,including thosewhose toxicitygrade didnotworsen during treatment;percentagesin the totalcolumn are calculatedwith thenumber of treatedsubjectsineachgroup as denominator.Percentagesfor toxicitygradecolumns arecalculatedwith the number of subjects in the total column as denominator.For each subject and each parameter,the worst toxicitygrade is selected.

Grade 3 or 4 haematology values of low white blood cells (WBC), low platelets, and low neutrophils were reported at a higher incidence in subjects from the DVTd treatment group compared with the VTd treatment group.

<div style=\"page-break-after: always\"></div>

## Chemistry

Overall,  there  were  no  clinically  relevant  trends  observed  for  any  chemistry  parameter.  Grade  3  or  4 biochemistry laboratory abnormalities during the study were low (&lt;5%) in both tre atment groups, with the exception of Grade 4 events of hypercalcemia (DVTd: 7.7%; VTd: 10.1%).

Table 42 Summary of Worst toxicity grade during treatment in Heamatology and Biochemistry; Safety Analysis Set (Study MMY3006)

|                                  | PLA Toxicity Grade, n (%)   | PLA Toxicity Grade, n (%)   | PLA Toxicity Grade, n (%)   | PLA Toxicity Grade, n (%)   | PLA Toxicity Grade, n (%)   | PLA Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   | DVTd Toxicity Grade, n (%)   |
|----------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                  | Total                       | 0                           | 1                           | 2                           | 3                           | 4                           | Total                        | 0                            | 1                            | 2                            | 3                            | 4                            |
| Analysis set: safety             | 538                         |                             |                             |                             |                             |                             | 536                          |                              |                              |                              |                              |                              |
| Hematology                       |                             |                             |                             |                             |                             |                             |                              |                              |                              |                              |                              |                              |
| WBC low (Leukopenia)             | 538 (100.0%)                | 324 (60.2%)                 | 241 (44.8%)                 | 123 (22.9%)                 | 34 (6.3%)                   | 52 (9.7%)                   | 535 (99.8%)                  | 339 (63.4%)                  | 230 (43.0%)                  | 190 (35.5%)                  | 80 (15.0%)                   | 54 (10.1%)                   |
| Hemoglobin low (Anemia)          | 538 (100.0%)                | 194 (36.1%)                 | 423 (78.6%)                 | 157 (29.2%)                 | 29 (5.4%)                   | 0                           | 536 (100.0%)                 | 225 (42.0%)                  | 416 (77.6%)                  | 182 (34.0%)                  | 27 (5.0%)                    | 0                            |
| Platelets low (Thrombocytopenia) | 538 (100.0%)                | 366 (68.0%)                 | 276 (51.3%)                 | 59 (11.0%)                  | 44 (8.2%)                   | 17 (3.2%)                   | 535 (99.8%)                  | 342 (63.9%)                  | 356 (66.5%)                  | 97 (18.1%)                   | 47 (8.8%)                    | 26 (4.9%)                    |
| Neutrophils low (Neutropenia)    | 536 (99.6%)                 | 450 (84.0%)                 | 63 (11.8%)                  | 110 (20.5%)                 | 58 (10.8%)                  | 49 (9.1%)                   | 535 (99.8%)                  | 439 (82.1%)                  | 51 (9.5%)                    | 151 (28.2%)                  | 108 (20.2%)                  | 74 (13.8%)                   |
| Lymphocytes low (Lymphopenia)    | 532 (98.9%)                 | 55 (10.3%)                  | 257 (48.3%)                 | 235 (44.2%)                 | 220 (41.4%)                 | 55 (10.3%)                  | 534 (99.6%)                  | 96 (18.0%)                   | 231 (43.3%)                  | 240 (44.9%)                  | 256 (47.9%)                  | 78 (14.6%)                   |
| Biochemistry                     |                             |                             |                             |                             |                             |                             |                              |                              |                              |                              |                              |                              |
| ALT high                         | 535 (99.4%)                 | 421 (78.7%)                 | 230 (43.0%)                 | 21 (3.9%)                   | 14 (2.6%)                   | 0                           | 534 (99.6%)                  | 435 (81.5%)                  | 226 (42.3%)                  | 13 (2.4%)                    |                              | 0                            |
| AST high                         | 535 (99.4%)                 | 501 (93.6%)                 | 91 (17.0%)                  |                             |                             | 0                           | 534 (99.6%)                  | 506 (94.8%)                  | 84 (15.7%)                   | 5 (0.9%)                     | 6 (1.1%) 4 (0.7%)            | 0                            |
| Creatinine high                  | 535 (99.4%)                 | 482                         | 90                          | 5 (0.9%) 13 (2.4%)          | 4 (0.7%)                    | 0                           | 535                          | 495                          | 72 (13.5%)                   |                              |                              | 0                            |
| Bilirubin high                   | 533                         | (90.1%) 524                 | (16.8%) 20                  | 12                          | 3 (0.6%)                    |                             | (99.8%) 533                  | (92.5%) 522                  | 24                           | 9 (1.7%) 14                  | 2 (0.4%)                     |                              |
| Alkaline phosphatase high        | (99.1%) 532                 | (98.3%) 386                 | (3.8%) 141                  | (2.3%)                      | 1 (0.2%)                    | 0                           | (99.4%) 533                  | (97.9%) 373                  | (4.5%) 146                   | (2.6%) 14                    | 3 (0.6%)                     | 0                            |
| Uric acid high (Hyperuricemia)   | (98.9%) 512                 | (72.6%) 454                 | (26.5%) 54                  | 5 (0.9%)                    | 2 (0.4%)                    | 0                           | (99.4%) 513                  | (70.0%) 465                  | (27.4%) 42                   | (2.6%)                       | 1 (0.2%)                     | 0                            |
| Corrected calcium high           | (95.2%) 533                 | (88.7%) 484                 | (10.5%) 74                  | 0                           | 0                           | 5 (1.0%) 54                 | (95.7%) 534                  | (90.6%) 486                  | (8.2%) 85                    | 0                            | 0                            | 6 (1.2%) 41                  |
| (Hypercalcemia)                  | (99.1%)                     | (90.8%)                     | (13.9%)                     | 3 (0.6%)                    | 0                           | (10.1%)                     | (99.6%)                      | (91.0%)                      | (15.9%)                      | 0                            | 1 (0.2%)                     | (7.7%)                       |
| Corrected calcium low            | 533                         | 432                         | 218                         | 20                          |                             | 1 (0.2%)                    | 534                          | 416                          | 244                          | 26                           |                              |                              |
| (Hypocalcemia)                   | (99.1%)                     | (81.1%)                     | (40.9%)                     | (3.8%)                      | 2 (0.4%)                    |                             | (99.6%)                      | (77.9%)                      | (45.7%)                      | (4.9%)                       | 2 (0.4%)                     | 4 (0.7%)                     |
| Albumin low(Hypoalbuminemia)     | 536 (99.6%)                 | 436 (81.3%)                 | 251 (46.8%)                 | 98 (18.3%)                  | 0                           | 0                           | 536 (100.0%)                 | 434 (81.0%)                  | 245 (45.7%)                  | 135 (25.2%)                  | 8 (1.5%)                     | 0                            |
| Glucose high (Hyperglycemia)     | 510 (94.8%)                 | 487 (95.5%)                 | 0                           | 0                           | 22 (4.3%)                   |                             | 497 (92.7%)                  | 485 (97.6%)                  | 0                            | 0                            | 12 (2.4%)                    | 0                            |
| Glucose low (Hypoglycemia)       | 510                         | 462                         | 44                          |                             |                             | 1 (0.2%)                    | 497                          | 438                          | 57                           |                              |                              |                              |
|                                  | (94.8%)                     | (90.6%)                     | (8.6%)                      | 1 (0.2%)                    | 1 (0.2%)                    | 2 (0.4%)                    | (92.7%)                      | (88.1%)                      | (11.5%)                      | 0                            | 0                            | 2 (0.4%)                     |
|                                  | Total                       | 0                           | 1                           | 2                           | 3                           | 4                           | Total                        | 0                            | 1                            | 2                            | 3                            | 4                            |

Key:VTd=bortezomib(VELCADE)+ thalidomide + dexamethasone;DVTd=daratumumab +bortezomib (VELCADE)+ thalidomide+ dexamethasone.

Note: The laboratory toxicity grades are derived based on the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Version 4.03. Grade 0

Key: WBC = White Blood Cell; AST = Aspartate Aminotransferase; ALT = Alanine Aminotransferase.

means normal. Subjects reported as Grade O are subjects with normal values or a value in the opposite direction (for laboratory tests with bidirectional toxicities defined). Note: For each parameter, the total column includes all subjects with available data at both baseline and post-baseline, including those whose toxicity grade did not worsen during treatment; percentages in the total column are calculated with the number of treated subjects in each group as denominator.Percentages for toxicity grade columns are calculated with the number of subjects in the total column as denominator. For each subject and each parameter, the worst toxicity grade is selected.

A summary of biochemistry laboratory values over time is provided in Table 43.

Table 43 Chemistry: values and changes from pre-induction baseline over time during Induction/ASCT/Consolidation Phase Safety Analysis Set (Study MMY3006)

TSFLAB01B\\_EMA\\_3006: Calcium and Urate: Values and Changes from Pre-induction Baseline Over Time During Induction/ASCT/Consolidation Phase; Safety Analysis Set (Study 54767414MMY3006)

|                                | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                |                                |                                |                                |                                |                                |                                |                                | Change from Baseline           | Change from Baseline           | Change from Baseline           | Change from Baseline           | Change from Baseline           | Change from Baseline           | Change from Baseline           |
|                                | N                              | Mean                           | SD                             | Median                         | Min                            | Max                            | Base Mean                      | N                              | Mean                           | SD                             | SE                             | Median                         | Min                            | Max                            |
| Calcium Corrected (mmol/L) VTd |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Pre- induction baseline        | 537                            | 2.39                           | 0.171                          | 2.38                           | 1.7                            | 3.5                            | 2.39                           |                                |                                |                                |                                |                                |                                |                                |
| Cycle 2 Day 1                  | 485                            | 2.32                           | 0.122                          | 2.31                           | 1.9                            | 2.9                            | 2.39                           | 484                            | - 0.08                         | 0.177                          | 0.008                          | - 0.06                         | - 1.1                          | 0.7                            |

<div style=\"page-break-after: always\"></div>

TSFLAB01B\\_EMA\\_3006: Calcium and Urate: Values and Changes from Pre-induction Baseline Over Time During Induction/ASCT/Consolidation Phase; Safety Analysis Set (Study 54767414MMY3006)

|                | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|----------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                |                                |                                |                                |                                |                                |                                |                                | Change from Baseline           | Change from Baseline           | Change from Baseline           | Change from Baseline           | Change from Baseline           | Change from Baseline           | Change from Baseline           |
|                | N                              | Mean                           | SD                             | Median                         | Min                            | Max                            | Mean                           | N                              | Mean                           | SD                             | SE                             | Median                         | Min                            | Max                            |
| Cycle 3 Day 1  | 482                            | 2.30                           | 0.109                          | 2.30                           | 1.9                            | 2.7                            | 2.39                           | 481                            | - 0.09                         | 0.184                          | 0.008                          | - 0.07                         | - 1.1                          | 0.7                            |
| Cycle 4 Day 1  | 474                            | 2.29                           | 0.108                          | 2.29                           | 2.0                            | 2.6                            | 2.39                           | 474                            | - 0.11                         | 0.180                          | 0.008                          | - 0.10                         | - 1.1                          | 0.6                            |
| Cycle 5 Day 1  | 396                            | 2.30                           | 0.111                          | 2.30                           | 1.8                            | 2.7                            | 2.39                           | 396                            | - 0.09                         | 0.193                          | 0.010                          | - 0.07                         | - 1.1                          | 0.6                            |
| Cycle 6 Day 1  | 404                            | 2.29                           | 0.117                          | 2.29                           | 1.3                            | 2.6                            | 2.39                           | 404                            | - 0.10                         | 0.189                          | 0.009                          | - 0.10                         | - 1.2                          | 0.5                            |
| DVTd           |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Pre- induction |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| baseline       | 536                            | 2.38                           | 0.178                          | 2.37                           | 1.2                            | 3.3                            | 2.38                           |                                |                                |                                |                                |                                |                                |                                |
| Cycle 2 Day 1  | 490                            | 2.29                           | 0.114                          | 2.29                           | 1.9                            | 2.8                            | 2.38                           | 490                            | - 0.08                         | 0.175                          | 0.008                          | - 0.09                         | - 0.7                          | 1.2                            |
| Cycle 3 Day 1  | 475                            | 2.29                           | 0.116                          | 2.28                           | 1.8                            | 2.7                            | 2.38                           | 475                            | - 0.09                         | 0.181                          | 0.008                          | - 0.08                         | - 0.7                          | 1.3                            |
| Cycle 4 Day 1  | 479                            | 2.28                           | 0.118                          | 2.28                           | 1.9                            | 3.0                            | 2.38                           | 479                            | - 0.09                         | 0.181                          | 0.008                          | - 0.08                         | - 0.7                          | 1.2                            |
| Cycle 5 Day 1  | 410                            | 2.31                           | 0.102                          | 2.30                           | 2.1                            | 2.7                            | 2.39                           | 410                            | - 0.08                         | 0.160                          | 0.008                          | - 0.07                         | - 0.7                          | 0.5                            |
| Cycle 6 Day 1  | 430                            | 2.29                           | 0.108                          | 2.29                           | 1.9                            | 2.7                            | 2.38                           | 430                            | - 0.09                         | 0.177                          | 0.009                          | - 0.08                         | - 0.8                          | 1.1                            |
| Total          |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Pre- induction |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| baseline       | 1073                           | 2.39                           | 0.174                          | 2.38                           | 1.2                            | 3.5                            | 2.39                           |                                |                                |                                |                                |                                |                                |                                |
| Cycle 2 Day 1  | 975                            | 2.31                           | 0.118                          | 2.30                           | 1.9                            | 2.9                            | 2.39                           | 974                            | - 0.08                         | 0.176                          | 0.006                          | - 0.07                         | - 1.1                          | 1.2                            |
| Cycle 3 Day 1  | 957                            | 2.30                           | 0.112                          | 2.29                           | 1.8                            | 2.7                            | 2.38                           | 956                            | - 0.09                         | 0.182                          | 0.006                          | - 0.08                         | - 1.1                          | 1.3                            |
| Cycle 4 Day 1  | 953                            | 2.29                           | 0.113                          | 2.29                           | 1.9                            | 3.0                            | 2.38                           | 953                            | - 0.10                         | 0.181                          | 0.006                          | - 0.09                         | - 1.1                          | 1.2                            |
| Cycle 5 Day 1  | 806                            | 2.31                           | 0.106                          | 2.30                           | 1.8                            | 2.7                            | 2.39                           | 806                            | - 0.08                         | 0.177                          | 0.006                          | - 0.07                         | - 1.1                          | 0.6                            |
| Cycle 6 Day 1  | 834                            | 2.29                           | 0.112                          | 2.29                           | 1.3                            | 2.7                            | 2.38                           | 834                            | - 0.10                         | 0.183                          | 0.006                          | - 0.09                         | - 1.2                          | 1.1                            |

<div style=\"page-break-after: always\"></div>

TSFLAB01B\\_EMA\\_3006: Calcium and Urate: Values and Changes from Pre-induction Baseline Over Time During Induction/ASCT/Consolidation Phase; Safety Analysis Set (Study 54767414MMY3006)

|                                       | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|---------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                       |                                |                                |                                |                                |                                |                                | Base                           |                                |                                |                                |                                |                                |                                |                                |
|                                       | N                              | Mean                           | SD                             | Median                         | Min                            | Max                            | Mean                           | N                              | Mean                           | SD                             | SE                             | Median                         | Min                            | Max                            |
| Urate (umol/L) VTd                    |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Pre- induction baseline               | 525                            | 337.44                         | 95.067                         | 333.00                         | 60.0                           | 826.8                          | 337.44                         |                                |                                |                                |                                |                                |                                |                                |
| Cycle 2 Day 1                         | 456                            | 250.92                         | 73.272                         | 242.50                         | 22.0                           | 512.0                          | 339.30                         | 453                            | - 88.05                        | 72.530                         | 3.408                          | - 83.00                        | - 523.4                        | 89.2                           |
| Cycle 3 Day 1                         | 443                            | 240.28                         | 73.411                         | 231.97                         | 28.0                           | 560.0                          | 339.13                         | 438                            | - 98.83                        | 75.606                         | 3.613                          | - 97.50                        | - 523.4                        | 154.1                          |
| Cycle 4 Day 1                         | 448                            | 249.02                         | 73.753                         | 239.50                         | 89.0                           | 529.4                          | 338.62                         | 444                            | - 89.31                        | 70.505                         | 3.346                          | - 83.27                        | - 529.4                        | 90.0                           |
| Cycle 5 Day 1                         | 360                            | 286.71                         | 75.666                         | 286.00                         | 0.3                            | 516.3                          | 338.03                         | 354                            | - 51.27                        | 77.838                         | 4.137                          | - 45.00                        | - 409.8                        | 154.0                          |
| Cycle 6 Day 1                         | 369                            | 253.90                         | 68.795                         | 248.00                         | 60.0                           | 498.0                          | 336.80                         | 363                            | - 82.73                        | 75.121                         | 3.943                          | - 77.32                        | - 446.1                        | 189.0                          |
| DVTd                                  |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| Pre- induction baseline Cycle 2 Day 1 | 523                            | 337.19                         | 98.112                         | 328.00                         | 1.0                            | 672.0                          | 337.19                         |                                | -                              |                                |                                |                                |                                |                                |
|                                       | 451                            | 236.13                         | 69.887                         | 231.00                         | 0.2                            | 462.0                          | 336.80                         | 447                            | 100.92 -                       | 77.215                         | 3.652                          | - 95.00 -                      | - 398.0                        | 242.0                          |
| Cycle 3 Day 1                         | 451                            | 231.37                         | 69.370                         | 226.02                         | 0.2                            | 547.2                          | 337.93                         | 447                            | 106.58                         | 80.905                         | 3.827                          | 102.00                         | - 388.0                        | 265.3                          |
| Cycle 4 Day 1                         | 442                            | 244.10                         | 72.916                         | 237.96                         | 0.2                            | 570.0                          | 335.89                         | 438                            | - 91.52                        | 82.445                         | 3.939                          | - 89.61                        | - 392.6                        | 271.2                          |
| Cycle 5 Day 1                         | 386                            | 283.50                         | 74.024                         | 280.00                         | 31.5                           | 640.0                          | 334.84                         | 382                            | - 50.80                        | 78.627                         | 4.023                          | - 47.79                        | - 309.3                        | 241.5                          |
| Cycle 6 Day 1                         | 396                            | 253.83                         | 72.080                         | 249.82                         | 0.2                            | 460.0                          | 336.16                         | 390                            | - 81.81                        | 77.264                         | 3.912                          | - 80.00                        | - 380.7                        | 283.1                          |
| Total                                 |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |                                |
| baseline                              | 1048                           | 337.31                         | 96.552                         | 329.50                         | 1.0                            | 826.8                          | 337.31                         |                                |                                |                                |                                |                                |                                |                                |
| Cycle 2 Day 1 Cycle 3 Day 1           | 907                            | 243.56                         | 71.951                         | 237.92                         | 0.2                            | 512.0                          | 338.06                         | 900                            | - 94.44 -                      | 75.128                         | 2.504                          | - 89.25 -                      | - 523.4                        | 242.0                          |
|                                       | 894                            | 235.78                         | 71.500                         | 230.00                         | 0.2                            | 560.0                          | 338.52                         | 885                            | 102.74                         | 78.379                         | 2.635                          | 101.00                         | - 523.4                        | 265.3                          |
| Cycle 4 Day 1                         | 890                            | 246.58                         | 73.339                         | 239.00                         | 0.2                            | 570.0                          | 337.27                         | 882                            | - 90.41                        | 76.631                         | 2.580                          | - 88.31                        | - 529.4                        | 271.2                          |
| Cycle 5 Day 1                         | 746                            | 285.05                         | 74.788                         | 282.00                         | 0.3                            | 640.0                          | 336.37                         | 736                            | - 51.03                        | 78.195                         | 2.882                          | - 47.00                        | - 409.8                        | 241.5                          |
| Cycle 6 Day 1                         | 765                            | 253.87                         | 70.468                         | 249.82                         | 0.2                            | 498.0                          | 336.47                         | 753                            | - 82.25                        | 76.189                         | 2.776                          | - 79.00                        | - 446.1                        | 283.1                          |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

[TSFLAB01B\\_EMA\\_3006.RTF] [JNJ -54767414 \\ MMY3006 \\ DBR\\_EMA\\_UPDATE \\ RE\\_EMA\\_UPDATE \\ PROD \\ TSFLAB01B\\_EMA\\_3006.SAS] 29JUL2019, 21:33

<div style=\"page-break-after: always\"></div>

## Vital signs

A summary of vital signs collected at baseline is provided in Table 44. There were no clinically meaningful differences between the treatment groups.

Table 44 Summary of Vital Signs Values at Pre-induction Baseline; Intent-to-treat Analysis Set (Study 54767414MMY3006)

|                                 | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|---------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                 | VTd                            | DVTd                           | Total                          |
| Analysis set: intent-to-treat   | 542                            | 543                            | 1085                           |
| Height (cm)                     |                                |                                |                                |
| N                               | 542                            | 543                            | 1085                           |
| Mean (SD)                       | 170.2 (9.66)                   | 169.9 (10.02)                  | 170.0 (9.84)                   |
| Median                          | 170.0                          | 170.0                          | 170.0                          |
| Range                           | (146; 201)                     | (143; 201)                     | (143; 201)                     |
| Weight (kg)                     |                                |                                |                                |
| N                               | 542                            | 543                            | 1085                           |
| Mean (SD)                       | 75.83 (15.605)                 | 75.52 (15.632)                 | 75.67 (15.612)                 |
| Median                          | 75.00                          | 74.00                          | 74.50                          |
| Range                           | (44.0; 142.5)                  | (46.0; 135.0)                  | (44.0; 142.5)                  |
| Temperature (C)                 |                                |                                |                                |
| N                               | 532                            | 541                            | 1073                           |
| Mean (SD)                       | 36.79 (0.492)                  | 36.79 (0.498)                  | 36.79 (0.495)                  |
| Median                          | 36.80                          | 36.80                          | 36.80                          |
| Range                           | (34.9; 38.5)                   | (34.6; 38.3)                   | (34.6; 38.5)                   |
| Diastolic Blood Pressure (mmHg) |                                |                                |                                |
| N                               | 539                            | 543                            | 1082                           |
| Mean (SD)                       | 78.2 (11.51)                   | 74.6 (12.07)                   | 76.4 (11.92)                   |
| Median                          | 80.0                           | 74.0                           | 77.0                           |
| Range                           | (44; 115)                      | (40; 110)                      | (40; 115)                      |
| Systolic Blood Pressure (mmHg)  |                                |                                |                                |
| N                               | 539                            | 543                            | 1082                           |
| Mean (SD)                       | 132.5 (17.62)                  | 128.8 (17.59)                  | 130.7 (17.70)                  |
| Median                          | 130.0                          | 128.0                          | 130.0                          |
| Range                           | (84; 193)                      | (90; 186)                      | (84; 193)                      |
| Pulse Rate (BEATS/MIN)          |                                |                                |                                |
| N                               | 539                            | 543                            | 1082                           |
| Mean (SD)                       | 80.2 (13.54)                   | 76.4 (12.88)                   | 78.3 (13.35)                   |
| Median                          | 79.0                           | 75.0                           | 77.0                           |
| Range                           | (50; 120)                      | (47; 133)                      | (47; 133)                      |
| Body Surface Area (m?)          |                                |                                |                                |
| N                               | 542                            | 543                            | 1085                           |
| Mean (SD)                       | 1.886 (0.2298)                 | 1.880 (0.2258)                 | 1.883 (0.2277)                 |
| Median                          | 1.880                          | 1.870                          | 1.870                          |
| Range                           | (1.39; 2.71)                   | (1.40; 2.61)                   | (1.39; 2.71)                   |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide +dexamethasone.

17:13

## Safety in special populations

Subgroup  analyses  of  adverse  events  (TEAEs,  serious  TEAEs,  Grade  3  or  higher  TEAEs,  treatment discontinuations due to TEAEs, and drug related TEAEs) demonstrated that the safety profile of DVTd and

<div style=\"page-break-after: always\"></div>

VTd was consistent across pre-specified, clinically relevant subgroups. Race was not collected in accordance with the study protocol.

Table 45 Subgroup Analyses on Overview of Treatment-Emergent Adverse Events During Induction/ASCT/Consolidation Phase;Safety Analysis Set (Study 54767414MMY3006)

|                                                                                                        | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   | Induction/ASCT/Consolidation VTd   |
|--------------------------------------------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                                                                                        |                                    |                                    |                                    |                                    |                                    | DVTd n (%)                         | DVTd n (%)                         | DVTd n (%)                         | DVTd n (%)                         | DVTd n (%)                         |
|                                                                                                        |                                    | TEAE /DR a                         | Serious TEAE /DR a                 | Grade 3 or Higher TEAE /DR a       | TD due to TEAE b /DRa              | N                                  | TEAE /DR a                         | Serious TEAE /DR a                 | Grade 3 or Higher TEAE /DR a       | TD due to TEAE b /DR a             |
| Analysis set: safety                                                                                   | N 538                              | 536(99.6%) /518(96.3%)             | 255(47.4%) /114(21.2%)             | 409(76.0%) /243(45.2%)             | 105(19.5%) /96(17.8%)              | 536                                | 535(99.8%) /523(97.6%)             | 251(46.8%) /148(27.6%)             | 432(80.6%) /306(57.1%)             | 124(23.1%) /106(19.8%)             |
| sex: male                                                                                              | 317                                | 316(99.7%) /302(95.3%)             | 147(46.4%) /61(19.2%)              | 233(73.5%) /138(43.5%)             | 70(22.1%) /62(19.6%)               | 313                                | 312(99.7%) /307(98.1%)             | 145(46.3%) /83(26.5%)              | 246(78.6%) /175(55.9%)             | 74(23.6%) /65(20.8%)               |
| sex: female                                                                                            | 221                                | 220(99.5%) /216(97.7%)             | 108(48.9%) /53(24.0%)              | 176(79.6%) /105(47.5%)             | 35(15.8%) /34(15.4%)               | 223                                | 223(100.0%) /216(96.9%)            | 106(47.5%) /65(29.1%)              | 186(83.4%) /131(58.7%)             | 50(22.4%) /41(18.4%)               |
| age: <50 year                                                                                          | 90                                 | 90(100.0%) /85(94.4%)              | 37(41.1%) /14(15.6%)               | 66(73.3%) /37(41.1%)               | 18(20.0%) /17(18.9%)               | 80                                 | 80(100.0%) /77(96.3%)              | 29(36.3%) /12(15.0%)               | 56(70.0%) /34(42.5%)               | 15(18.8%) /14(17.5%)               |
| age: ≥50 year                                                                                          | 448                                | 446(99.6%) /433(96.7%)             | 218(48.7%) /100(22.3%)             | 343(76.6%) /206(46.0%)             | 87(19.4%) /79(17.6%)               | 456                                | 455(99.8%) /446(97.8%)             | 222(48.7%) /136(29.8%)             | 376(82.5%) /272(59.6%)             | 109(23.9%) /92(20.2%)              |
| site: IFM                                                                                              | 453                                | 451(99.6%) /434(95.8%)             | 212(46.8%) /89(19.6%)              | 346(76.4%) /199(43.9%)             | 74(16.3%) /66(14.6%)               | 445                                | 444(99.8%) /434(97.5%)             | 212(47.6%) /120(27.0%)             | 361(81.1%) /248(55.7%)             | 93(20.9%) /80(18.0%)               |
| site: Hovon                                                                                            | 85                                 | 85(100.0%) /84(98.8%)              | 43(50.6%) /25(29.4%)               | 63(74.1%) /44(51.8%)               | 31(36.5%) /30(35.3%)               | 91                                 | 91(100.0%) /89(97.8%)              | 39(42.9%) /28(30.8%)               | 71(78.0%) /58(63.7%)               | 31(34.1%) /26(28.6%)               |
| Baseline renal function (CrCI): <60 mL/min                                                             | 41                                 | 40(97.6%) /38(92.7%)               | 21(51.2%) /11(26.8%)               | 33(80.5%) /19(46.3%)               | 6(14.6%) /5(12.2%)                 | 38                                 | 38(100.0%) /36(94.7%)              | 21(55.3%) /13(34.2%)               | 35(92.1%) /22(57.9%)               | 7(18.4%) /7(18.4%)                 |
| Baseline renal function (CrCl): 60 to <90 mL/min                                                       | 182                                | 182(100.0%) /177(97.3%)            | 98(53.8%) /44(24.2%)               | 146(80.2%) /89(48.9%)              | 37(20.3%) /34(18.7%)               | 169                                | 169(100.0%) /165(97.6%)            | 76(45.0%) /48(28.4%)               | 138(81.7%) /98(58.0%)              | 40(23.7%) /29(17.2%)               |
| Baseline renal function (CrCI): ≥90 mL/min                                                             | 315                                | 314(99.7%) /303(96.2%)             | 136(43.2%) /59(18.7%)              | 230(73.0%) /135(42.9%)             | 62(19.7%) /57(18.1%)               | 329                                | 328(99.7%) /322(97.9%)             | 154(46.8%) /87(26.4%)              | 259(78.7%) /186(56.5%)             | 77(23.4%) /70(21.3%)               |
| Baseline renal function (CrCl) with adjustment for overweight subjects (BMI>30kg/m2): <60 mL/min       |                                    | 3(100.0%) /2(66.7%)                | 1(33.3%) /1(33.3%)                 | 2(66.7%) /0                        | 1(33.3%) /1(33.3%)                 |                                    | 7(100.0%) /7(100.0%)               | 6(85.7%) /3(42.9%)                 | 7(100.0%) /5(71.4%)                | 1(14.3%) /1(14.3%)                 |
| Baseline renal function (CrCl) with adjustment for overweight subjects (BMI>30kg/m2): 60 to <90 mL/min | 29                                 | 29(100.0%) /28(96.6%)              | 21(72.4%) /10(34.5%)               | 23(79.3%) /13(44.8%)               | 7(24.1%) /6(20.7%)                 | 31                                 | 31(100.0%) /31(100.0%)             | 18(58.1%) /12(38.7%)               | 24(77.4%) /18(58.1%)               | 8(25.8%) /7(22.6%)                 |
| Baseline renal function (CrCl) with adjustment for overweight subjects (BMI>30kg/m2): ≥90 mL/min       | 56                                 | 56(100.0%) /55(98.2%)              | 31(55.4%) /21(37.5%)               | 45(80.4%) /35(62.5%)               | 12(21.4%) /12(21.4%)               | 63                                 | 62(98.4%) /61(96.8%)               | 37(58.7%) /16(25.4%)               | 50(79.4%) /42(66.7%)               | 20(31.7%) /18(28.6%)               |
| Baseline hepatic function: Normal                                                                      | 497                                | 495(99.6%) /477(96.0%)             | 236(47.5%) /105(21.1%)             | 372(74.8%) /220(44.3%)             | 99(19.9%) /90(18.1%)               | 474                                | 473(99.8%) /463(97.7%)             | 218(46.0%) /126(26.6%)             | 379(80.0%) /267(56.3%)             | 112(23.6%) /94(19.8%)              |
| Baseline hepatic function: Impaired                                                                    | 41                                 | 41(100.0%) /41(100.0%)             | 19(46.3%) /9(22.0%)                | 37(90.2%) /23(56.1%)               | 6(14.6%) /6(14.6%)                 | 62                                 | 62(100.0%) /60(96.8%)              | 33(53.2%) /22(35.5%)               | 53(85.5%) /39(62.9%)               | 12(19.4%) /12(19.4%)               |

Key:VTd =bortezomib (VELCADE)+ thalidomide + dexamethasone;DVTd =daratumumab+bortezomib (VELCADE)+ thalidomide+ dexamethasone.

Key:TEAE = treatment-emergent adverse event;DR = drug-related; TD = treatment discontinuation of study regimen. aRelated to anystudy drug.

Includes subjects with none of the study drugs ended with normal course of the protocol and in the last cycle of study treatments, at least one of the study drugs stopped due toAE.

Note: Impaired baseline hepatic function include mild (total bilirubin ≤ ULN and AST &gt; ULN) or (ULN &lt; total bilirubin ≤ 1.5xULN); moderate (1.5xULN &lt; total bilirubin ≤3xULN); and severe(totalbilirubin&gt;3xULN).

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

During the transplant period, according to protocol, only limited AE were collected.

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

No dedicated  drug-drug  interaction  studies  were  performed.  Since  there  is  no  overlapping  pathway  of elimination,  no  pharmacokinetic  interactions  are  expected  between  daratumumab  and  co-administered small-molecule drugs such as bortezomib, thalidomide, and dexamethasone. As reported in a previous submission, analysis of daratumumab and bortezomib concentrations from Study MMY1001 indicated a lack of clinically relevant drug-drug interaction between these molecules.

## Discontinuation due to adverse events

The frequency of AEs leading to treatment discontinuation in induction/ASCT/consolidation was similar in DVTd group (7.5%) compared with VTd group (8.4%). The most common reported AE leading to treatment discontinuation was peripheral sensory neuropathy (DVTd: 1.9%; VTd: 4.3%) (Table 26).

Table 46Most Common (at least 1%) Treatment-Emergent Adverse Events Leading to Discontinuation of Study Treatment During Induction/ASCT/Consolidation Phase by MedDRA System Organ Class, Preferred Term and Maximum Toxicity Grade; Safety Analysis Set (Study 54767414MMY3006)

|                                                                                   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   | Induction/ASCT/Consolidation   |
|-----------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                                                   | VTd                            | VTd                            | VTd                            | DVTd                           | DVTd                           | DVTd                           |
|                                                                                   | All Grades n (%)               | Grade 3 or 4 n (%)             | Grade 5 n (%)                  | All Grades n (%) 536           | Grade 3 or 4 n (%)             | Grade 5 n (%)                  |
| Analysis set: safety                                                              | 538                            |                                |                                |                                |                                |                                |
| Total number of subjects with TEAE leading to discontinuation of study treatmenta | 45 (8.4%)                      | 34 (6.3%)                      | 0                              | 40 (7.5%)                      | 30 (5.6%)                      | 1 (0.2%)                       |
| MedDRA system organ class / preferred term Nervous system disorders               | 33 (6.1%)                      | 25 (4.6%)                      | 0                              | 15 (2.8%)                      | 11 (2.1%)                      | 0                              |
| Peripheral sensory neuropathy                                                     | 23 (4.3%)                      | 18 (3.3%)                      | 0                              | 10 (1.9%)                      | 7 (1.3%)                       | 0                              |

Key: VTd = bortezomib (VELCADE) + thalidomide + dexamethasone; DVTd = daratumumab + bortezomib (VELCADE) + thalidomide + dexamethasone.

Key: TEAE = treatment-emergent adverse event.

a Includes those subjects indicated as having discontinued treatment due to an adverse event or treatment delay for toxicity for more than 6 weeks on the end of treatment CRF page.

Note: Adverse events are reported using MedDRA version 20.0.

During the transplant period, according to protocol, only limited AE were collected.

Note: Percentages are calculated with the number of subjects in each group as denominator.

## Adverse Events Leading to Dose Modifications of Daratumumab

TEAEs  leading  to  daratumumab  infusion  interruptions  were  reported  in  31.9%  of  subjects.  The  most commonly reported ( ≥ 2%) TEAEs leading to daratumumab infusion interruptions were consistent with IRRs and include:

- Chills (4.1%)
- Dyspnoea (2.6%)
- Pyrexia (2.4%)
- Cough (2.2%)
- Vomiting (2.2%)
- Nausea (2.1%)

Grade 3 or 4 TEAEs leading to daratumumab infusion interruptions were infrequent, occurring in 3.2% of subjects.

<div style=\"page-break-after: always\"></div>

## 2.6. Discussion on clinical safety

There are no new safety signals from this study: Neutropenia and infections, in particular respiratory but with no particular pattern of infectious agent, were more frequently observed in the DVTd arm as was nausea, thrombocytopenia, lymphopenia, and cough. The TEAEs that occurred more frequently in the DVTd arm are all well-known AEs (Very Common) for daratumumab as listed in the SmPC.

The results for IRRs in study 3006 are in line with the previous studies as listed in the SmPC.

According to the RMP Hepatitis B virus reactivation has been added to the list of Important identified risks;. In study 3006 10 subjects in the DVTd group and 11 in the VTd group reported a medical history of HBV infection. Half of the patients in each arm received Hepatitis B prophylaxis. No subjects were reported with HBV reactivation in either treatment group.

## 2.6.1. Conclusions on clinical safety

Overall,  the  addition  of  daratumumab  to  the  combination  of  VTd  does  not  seem  to  increase  toxicity significantly and it appears to be relatively well tolerated. The safety profile of daratumumab is unchanged. The toxicity reflects the well-known safety profile as described in the SmPC. The majority of adverse events are manageable in the clinical setting and well-known to haematologists (cytopenias and infections). No new safety signals from study MMMY3006 were observed.

## 2.6.2. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Risk management plan

The CHMP endorsed the Risk Management Plan version 6.4 with the following content:

## Safety concerns

Table 47: Summary of the safety concerns:

| Important identified risks   | Interference for blood typing (minor antigen) (positive indirect Coombs' test) Hepatitis B virus reactivation   |
|------------------------------|-----------------------------------------------------------------------------------------------------------------|
| Important potential risk     | Immunogenicity                                                                                                  |
| Missing information          | Use in pregnancy and lactation                                                                                  |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

Table 48 Ongoing and Planned Additional Pharmacovigilance Activities

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due Dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| Not applicable                                                                                                                                                                                                             |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| Not applicable                                                                                                                                                                                                             |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Investigate new method for detecting antidrug antibodies Ongoing                                                                                                                                                           | Improve the immunogenicity method's ability to detect anti-daratumumab antibodies in the presence of high trough levels of daratumumab.                                                                                    | Immunogenicity                                                                                                                                                                                                             | Final report                                                                                                                                                                                                               | 1 st Quarter 2020                                                                                                                                                                                                          |

## Risk minimisation measures

Table 49: Summary Table of Risk Minimization Activities and Pharmacovigilance Activities by Safety Concern

| Safety Concern                                                                 | Risk Minimization Measures                                                                                                                                                                                                                          | Pharmacovigilance Activities                                                                                                                                                                                                                                  |
|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Interference for blood typing (minor antigen) (positive indirect Coombs' test) | Routine risk minimization measures: • SmPC Section 4.4; 4.5. • PL Section 2. Additional risk minimization measures: • Distribution of educational materials and Patient Alert Cards to HCPs and blood banks as described in the PL, in Annex II, D. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • A guided targeted follow-up questionnaire to collect additional information concerning adverse events associated with interference and transfusion reactions. |

<div style=\"page-break-after: always\"></div>

| Safety Concern                          | Risk Minimization Measures                                                                                                                                                                                                         | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                      |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hepatitis B virus reactivation          | Routine risk minimization measures: • SmPC Section 4.4; 4.8. • PL Section 2; 4. Additional risk minimization measures: • Distribution of a DHPC to HCPs who prescribe daratumumab was issued in the EU member states in June 2019. | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None. Additional pharmacovigilance activities: • None.                                                                                                                                                                                                            |
| Immunogenicity                          | Routine risk minimization measures: • SmPC Section 5.1. Additional risk minimization measures: • None.                                                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None. Additional pharmacovigilance activities: • Investigation of a new method for detecting antidrug antibodies to improve the immunogenicity method's ability to detect anti-daratumumab antibodies in the presence of high trough levels of daratumumab. Final |
| Use in pregnancy and lactation          | Routine risk minimization measures: • SmPC Section 4.6 and PL Section 2. Additional risk minimization measures: • None.                                                                                                            | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None. Additional pharmacovigilance activities: • None.                                                                                                                                                                                                            |
| Reproductive and developmental toxicity | Routine risk communication: • SmPC Section 5.3. Additional risk minimization measures: • None.                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None. Additional pharmacovigilance activities: • None.                                                                                                                                                                                                            |

The CHMP, having considered the data submitted in the application was of the opinion that the risk management plan is acceptable.

## 2.8. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

<div style=\"page-break-after: always\"></div>

The changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

Darzalex is indicated in combination with bortezomib, thalidomide and dexamethasone for the treatment of  adult  patients  with  newly  diagnosed  multiple  myeloma  who  are  eligible  for  autologous  stem  cell transplant.

## 3.2. Disease or condition

Multiple myeloma, a malignant disorder of plasma cells, is characterised by uncontrolled and progressive proliferation of plasma cell clones. The proliferation of myeloma cells causes displacement of the normal bone  marrow  hematopoietic  precursors,  an  overproduction  of  M-proteins,  anemia  and  an  increased susceptibility to infections. Other characteristics to multiple myeloma  include  osteolytic lesions, hypercalcemia, renal insufficiency and neurological complications, resulting in progressive morbidity and eventual mortality.

## 3.2.1. Available therapies and unmet medical need

Patients with newly diagnosed multiple myeloma are typically categorised into 2 subpopulations defined by their age, comorbidity and suitability for intensive treatment. For patients who are less than 65 years of age and considered fit, an induction regimen followed by high dose chemotherapy (HDT) and ASCT is considered the standard of care according to European Society for Medical Oncology [ESMO]; Moreau 2017 guidelines. Patient up to 70 years who are considered fit will usually also be treated in a similar way.

For induction, a triplet regimen such as VTd, bortezomib + cyclophosphamide + dexamethasone (VCd), bortezomib + doxorubicin + dexamethasone (PAD) or VRd are the current standard of care for induction therapy. In Europe, VTd and VCd are the more commonly used regimens with 4 to 6 courses typically given before transplant.

## 3.2.2. Main clinical studies

The MAH has provided a randomised phase 3, open label multicentre study, MMY3006 in patients 18-65 years newly diagnosed with multiple myeloma and eligible for HDT and ASCT randomized in a 1:1 ratio to receive either D-VTd or VTd (4 cycles of induction therapy before ASCT and 2 cycles of consolidation therapy after ASCT).

## 3.3. Favourable effects

The study met its primary endpoint, a statistically significant improvement in the sCR rate 100 days postASCT was demonstrated in favour of D-VTd, 28.9% vs. 20.3%.

Additional data from an exploratory analysis, corresponding to an updated clinical data cut-off of 1 May 2019, i.e. 10 months after the original cut-off date was provided as well. The updated data confirmed a statistically significant improvement in the sCR rate in favour of D-VTd, 54.3% vs. 42.1%. The results were consistent in the pre-specified subgroups.

Secondary endpoints: MRD negativity, CR or better and PFS were consistent and confirmed the primary analysis.

<div style=\"page-break-after: always\"></div>

The effect on MRD negativity was significant 63.7% vs. 43.5% and consistent throughout all subgroups, also the high-risk and ISS Stage III subgroups.

The CR or better rates were significantly higher for the DVTd compared with VTd alone, 62.1% vs. 47.6%.

Results of a PFS analysis by censoring patients who were randomized to daratumumab maintenance in the second randomization, at the date of the second randomization showed HR=0.50; 95% CI: 0.34, 0.75; p=0.0005.

## 3.4. Uncertainties and limitations about favourable effects

OS and PFS data are still immature. The MAH has committed (letter of recommendation) to provide postapproval updated part 1 PFS results (including the analysis censoring patients in each arm who were randomised to daratumumab maintenance in the second randomisation) and updated part 1 OS data in 2021 based on the data cut of the planned interim analysis.

## 3.5. Unfavourable effects

Neutropenia and infections, in particular respiratory but with no particular pattern of infectious agent, were more frequently observed in the DVTd arm as was nausea, thrombocytopenia, lymphopenia, and cough. The TEAEs that occurred more frequently in the DVTd arm are all well-known AEs (Very Common) for daratumumab as listed in the SmPC. The results for IRRs in study 3006 are in line with the previous studies as listed in the SmPC with only 3.6% being Grade 3-4 (no Grade 5).

## 3.6. Uncertainties and limitations about unfavourable effects

NA

## 3.7. Effects Table

Table 50: Effects Table for Darzalex in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (data cut-off: 19 June 2018):

| Effect               | Short description                                      | Unit                 | Treatment            | Control              | Uncertainties / Strength of evidence   | References           |
|----------------------|--------------------------------------------------------|----------------------|----------------------|----------------------|----------------------------------------|----------------------|
| Favourable Effects   | Favourable Effects                                     | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                     | Favourable Effects   |
| sCR                  | Stringent CR                                           | %                    | 28.9                 | 20.3                 | Odds ratio = 1.60, p<0.0010            |                      |
| MRD                  | MRD negativity                                         | %                    | 63.7%                | 43.5%                | Odds ratio = 2.27, p<0.0001            |                      |
| CR or better         |                                                        | %                    | 38.9%                | 26.0%                | Odds ratio =1.82, p<0.0001             |                      |
| PFS *                | Censored at 2 nd randomization (cut-off 1 st May 2019) |                      |                      |                      | HR=0.50; 95% CI: 0.34, 0.75; p=0.0005  |                      |
| Unfavourable Effects | Unfavourable Effects                                   | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                   | Unfavourable Effects |
| Grade 3 or 4 AEs     |                                                        | %                    | 80.6%                | 75.8%                |                                        |                      |
| infections           |                                                        | %                    | 65.5%                | 56.9%                |                                        |                      |
| neutrope nia         |                                                        | %                    | 34.9%                | 24.5%                |                                        |                      |

Abbreviations: sCR=stringent complete response MRD=minimal residual disease CR= complete response PFS progression free survival

<div style=\"page-break-after: always\"></div>

*  Requested during the assessment

During the assessment several analyses with updated cut-off date were requested which confirmed the initial analysis as table below shows

## 3.8. Benefit-risk assessment and discussion

## 3.8.1. Importance of favourable and unfavourable effects

Daratumumab has shown significant and clinically relevant efficacy in the relapse/refractory setting and in patients ineligible to HDT and ASCT. In this study, daratumumab in combination with a standard induction regime VTd resulted in deeper responses at day 100 post-ASCT, in terms of sCR, MRD negativity and achieving CR or better, in the frontline setting for patients eligible to ASCT. This higher proportion of patients achieving deeper responses post-transplant, is of high clinical relevance. The MAH presented an analysis for PFS where patients who received maintenance therapy at the second randomization were censored. The results are in line with those presented in the primary analysis. The effect on secondary endpoints PFS and OS appeared favourable despite relatively immature data. OS and PFS data are still immature. The MAH has committed (letter of recommendation) to provide post-approval updated part 1 PFS results (including the analysis censoring patients in each arm who were randomised to daratumumab maintenance in the second randomisation) and updated part 1 OS data in 2021 based on the data cut of the planned interim analysis.

## 3.8.2. Balance of benefits and risks

The Benefit-risk balance of daratumumab in combination with D-VTd in patients with newly diagnosed MM, who are eligible for ASCT is considered positive.

## 3.8.3. Additional considerations on the benefit-risk balance

## 3.9. Conclusions

The overall B/R of Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT) is currently positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIA         |

Extension of indication in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT) for Darzalex; as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC

<div style=\"page-break-after: always\"></div>

are updated. The Package Leaflet is updated in accordance. The RMP (version 6.4) has also been agreed.

The variation leads to amendments to the Summary of Product Characteristics and Labelling and to the Risk Management Plan (RMP).

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Darzalex is not similar to Imnovid (pomalidomide), Farydak (panabinostat), Kyprolis (carfilzomib) and Ninlaro (ixazomib) within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of indication in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT) for Darzalex; as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP (version 6.4) has also been agreed.

## Summary

Please refer to the Scientific Discussion Darzalex-H-C-4077-II-0030.